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Abstract 
 
 
Proton Transfer Reaction Mass Spectrometry (PTR-MS) was applied to determine which 
volatile organic compounds in breath are associated with cirrhosis and hence 
diagnostically useful. A two-stage biomarker procedure was used. In the first-stage, 
alveolar breath samples of 31 cirrhotic patients and 30 controls were analysed and 
compared. In the second-stage, 12 of the patients had their breath analysed after liver 
transplant. 
The first-stage study showed that seven volatiles were elevated in patients’ breath 
compared to controls. Of these, limonene, methanol, 2-pentanone showed a statistically 
significant decrease post-transplant and hence can unequivocally be used as biomarkers 
for chronic liver disease. Limonene which is not produced in the body showed washout 
characteristics and the best diagnostic capability. These findings suggest that limonene, 
methanol and 2-pentanone are potential biomarkers for early-stage liver disease. 
Limonene was detected in higher levels in patients with symptoms of hepatic 
encephalopathy (HE) in comparison to those with no symptoms. Limonene discriminates 
patients suffering from HE, but not methanol or 2-pentanone.  
The elimination characteristics of post-operative isoflurane levels in breath of 5 
patients were investigated. High concentrations of isoflurane remained in their breath for 
several weeks. This study raises the question about the effect of isoflurane in the 
neurocognitive function of patients after major surgery. 
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 1 
 
1 INTRODUCTION 
 
The majority of clinical diagnosis focuses on the analysis of biological fluids such as 
serum and urine to collect information for disease prognosis or monitoring, allowing 
physicians to decide the best treatment for a patient. In recent years, with the fast 
improvement of new analytical techniques, such as Proton-Transfer-Reaction-Mass-
Spectrometry (PTR-MS) there is a potential of non-invasive procedures to provide 
information about medical conditions. These have the benefit of reducing the 
inconvenience and stress caused on the patients by the invasive techniques and long 
periods of delays for a prognosis. Recently, the study of volatile organic compounds 
(VOCs) in breath has shown an increased clinical interest within the medical community. 
Breath contains VOCs that can be correlated with concentration levels of these 
compounds present in the human blood which are consequences of normal activity or due 
to pathological disorder [1] [2] [3] [4] [5]. Therefore, VOCs excreted via exhalation are 
representative of monitoring metabolic and pathological processes.  
An analytical technology which has been used widely for the analysis of VOCs in 
breath as a fast, real-time and non-invasive diagnostic tool is Proton-Transfer-Reaction 
Mass-Spectrometry (PTR-MS) [6]. The collection of breath samples is painless for the 
patient and the method chosen can be easily replicate. Breath analysis is exclusive in the 
sense that it can provide continuous information about metabolic pathways and 
physiological processes that occur in the human body. Despite all these advantages, 
analysis of breath VOCs (and for that matter headspace analysis of serum, sputum, urine, 
and faeces) is still not used in the clinical practice [7]. One handicap is that there is a lack 
of a standardized [8] methodology for breath sampling and as a consequence there is a 
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huge variety of results with a very low confidence level. Another reason is that exhaled 
breath contains a diversity of volatiles with a large range of concentrations. Furthermore, 
despite over a decade of research, only few studies of volatiles compounds in breath have 
correlated a biomarker to a specific disease or habit [5] [9]. 
Arguably, too much reliance has been placed on multivariate statistics looking for 
correlations, which can lead to voodoo statistics, i.e. finding correlations when there are 
none. In addition to this, many compounds that have been put forward as biomarkers for a 
disease have either been incorrectly assigned or are not specific enough to be of use.  
It is relevant to mention that although PTR-MS has rapidly stablished as an analytical tool 
for the analysis of VOCs in breath [10] [11], the technique is still used only for 
fundamental research at Universities, Technological Centres and University Hospitals. 
The huge amount of data generated for analysis and the expensive cost and maintenance 
of the instrument limit the technique, which is a main drawback for the development of 
the technique. The major outcome of the work presented in this thesis is to show for the 
first time how key volatiles in the complex chemical profile of breath have the potential 
for use as non-invasive probes in the diagnosis and monitoring of liver disease. 
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1.1 Thesis Outline 
This thesis consists of seven chapters, each of them included in three main sections 
detailing (1) PTR-MS (2) methodology including breath samplings techniques and patient 
recruitment and (3) results and discussion. Included with the details of PTR-MS in 
Chapter 2 is an explanation of the theoretical aspects of the ion chemistry reactions 
involved. The section dealing with the methodology of breath sampling provided in 
Chapter 3, also briefly explains the theory of gas exchange and explains the different 
methods of sampling collection and drawbacks. Chapter 3 describes and explain the 
sampling protocol developed in this study for alveolar breath collection and the off-line 
measurements by PTR-MS. In this chapter is also involves the details and protocol of the 
patient recruitment.  
In the third major section (Chapters 4-6), the results are presented. Chapters 4 and 
5 deal with the liver disease studies. In these chapters, details of the two stages of the 
clinical trial procedure are explained. Comparisons are made between the concentrations 
of VOCs in exhaled breaths from patients versus controls and then the patients are used 
as their own controls. Biomarkers are detected in the alveolar breath of patients which are 
associated to the disease, although are not coming from the diseased liver. The chapter 
concludes with a discussion of the experimental results.  
Chapter 6 describes the elimination characteristics of post-operative isoflurane 
levels in alveolar breath. Isoflurane anaesthetic agent was detected during the analysis of 
the breath profiles in patients who underwent liver transplantation, therefore taken the 
advantage of this fact, the washout characteristics of isoflurane anaesthetic were 
investigated.  
A previous study found that isoflurane, which is hardly metabolised by the liver, is 
quickly eliminated from the body through breath, urine and sweat within days [12]. 
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However, that study used healthy young males and isoflurane was administrated only for 
30 minutes. 
This thesis concludes with chapter 7 in which is included a further discussion with 
key conclusions and summary of findings, discussions on the limitations of the study, and 
proposals for future direction in breath analysis for the detection of liver disease.  
1.2 Aims and Objectives 
As mentioned above, one of the most crucial drawbacks in breath analysis is the lack of a 
standard protocol procedure to collect breath samples [13]. Unfortunately, the PTR-MS 
instrument used for this study was not placed at the Queen Elizabeth hospital where the 
patient recruitment takes place. Therefore, a main goal was to develop a reliable method 
to collect breath samples and to establish reproducible breath sampling protocol for the 
collection of breath samples for off-line measurements by PTR-MS. A standardized 
protocol will not avoid the intra-individual variations in breath. For this reason, and to 
avoid uncertainty in the measurements, four alveolar breath sample replicates were 
collected for each patient. 
A major aim of research summarised in this thesis is to investigate the potential of 
PTR-MS for detecting and monitoring liver disease using non- invasive and real time 
breath sampling analysis techniques. The goal is to evaluate short and midterm changes 
of VOCs in the exhaled breath of patient after liver transplant and to raise the valuable 
diagnostic potential of breath analysis for clinical diagnose discuss the implications of the 
use of breath analysis for assessing liver function after liver transplant. The goal is to 
examine changes in the same volatiles during long periods of time and pre and after liver 
transplant.  
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Another aim of the work presented in this thesis is to measure VOCs in the breath of 
patients suffering with acute encephalopathy and examine which VOCs are elevated in 
the case of hepatic encephalopathy (HE) and which change over time in association with 
the severity of symptoms. 
Finally, an investigation is presented which seeks to study the elimination profile of 
anaesthetics in the exhaled breath of patient’s weeks after a major surgery and their 
implication to the cognitive function recovery of patients. Details are provided of which 
ions are diagnostically useful for the monitoring of isoflurane anaesthetic in alveolar 
exhaled breath. The goal of this investigation is to follow- up the changes in anaesthetic 
concentration following an operation. 
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2 PROTON TRANSFER REACTION MASS SPECTROMETRY 
This chapter summaries the technique of proton transfer reaction mass spectrometry and 
the basic chemical processes involved.  
2.1 The PTR-MS 
Proton transfer reaction mass spectrometry is a sensitive analytical technique for on-line 
real-time monitoring of volatile organic compounds (VOCs) in air with a minimal sample 
preparation. Physicists at the Institute for Ionic Physics at the Leopold-Frances University 
in Innsbruck first developed the technology in the mid-90s. The proton transfer reaction 
mass spectrometer uses gas phase hydronium ions as the reagent agents with limits of 
detections down to concentrations of part per billion (ppbv). New models of PTR-MS 
have detection limits down to part per trillion (pptv) [14]. This uses a quadrupole mass 
spectrometer for m/z selection. Figure 2.1 shows a photograph of the instrument used in 
this study, which is a first generation PTR-MS built by IONICON Analytik GmbH.  
 
Figure 2.1 PTR-QUAD-MS Ionicon Analytik GmbH apparatus. 
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The spin-out company that resulted from their work, IONICON Analytik GmbH has 
become one of the leading manufacturers and suppliers of PTR-MS instruments. Figure 
2.2 displays a top view photograph of the PTR-MS instrument.  
 
Figure 2.2 Photograph of the top view of a PTR-QUAD-MS Ionicon 
Analytik GmbH apparatus. 
The origin of the proton transfer reaction mass spectrometry comes from the investigation 
of the flowing afterglow technique for the study of ion-molecule reactions [15]. Chemical 
Ionization (CI) is a soft ionization technique developed by Munson and Field in the 
middle 1960s for the identification of trace organic compounds in complex chemical 
environments [16]. CI is a method based on gas phase ion/molecule chemistry and 
requires a transfer of charge, such as an electron or proton, between the reactants and the 
formation of the ions by chemical reactions. Owing to the low energies involved with CI 
fragmentation is often limited. This leads to a mass spectrum which is easier to interpret, 
than that obtained from conventional 70 eV electron impact mass spectrometry.  
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There are several types of ion/molecule chemistry. Some of the key ones are shown 
below:  
 Proton transfer   M + BH+ → MH+ + B   
 Anion abstraction   M + X+ → [M–A]+ + AX  
 Charge transfer    M + X+ → M+ + X  
 
CI methods implied the use of reagent ions that undergo exothermic ion molecule 
reactions with the neutral reactants. The reagent ion is chosen so that the ionisation 
reaction has a low exotermicity and therefore there is a low energy transferred to the 
product ion reducing the ion fragmentation.  
For example, in the PTR-MS the chemical ionization mainly depends of the 
transfer of a proton from the protonated form to the neutral species. In PTR-MS the 
hydronium ion (protonated water H3O
+
) is used as a proton donor. The proton affinity 
(PA) of a neutral molecule is a determinant parameter in the proton transfer reactions.  
In a protonation reaction defined at 298 K, PA is the negative of the enthalpy change for 
the addition of a proton (H
+
). For example for a molecule M: 
                           M + H
+
 → MH+                                            Equation 2.1 
In PTR-MS, hydronium cations (H3O
+
) only transfer the proton when the gas 
molecule has a proton affinity higher than the water proton affinity (691 kJ mol
-1
 or      
7.22 eV, where 96.5 kJ mol 
-1
 = 1 eV) [17]. The proton transfer reaction involving H3O
+ 
is defined by the reaction: 
       M + H3O
+  → MH+ + H2O             Equation 2.2 
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In the gas phase, for exoergic reactions the process is spontaneous and fast with reaction 
rate coefficients being at the collisional limiting values. Importantly, for breath analysis 
(and many other applications), the common gases in air (N2, O2, CO2, argon, etc.) have 
proton affinities (PAs) less than water. Table 2.1 shows the proton affinities of some 
volatile organic compounds including common constituents in air. Hence air (and breath) 
is functioning as carrier gas in the reaction chamber of the PTR-MS. Most volatile 
organic compounds have proton affinities in the range between 7 and 9 eV. Therefore, the 
proton transfer involving H3O
+ 
results in small enthalpy changes so that generally little 
fragmentation is involved.  
Table 2.1 Proton affinities of some volatile organic compounds including common 
constituents in air. Taken from the compilation given is reference [18]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molecule 
Proton 
affinity 
(kJ/mol) 
Oxygen 95 
Nitrogen 118 
Carbon monoxide 594 
Carbon dioxide 540 
Propane 626 
Water 691 
Methanol 754 
Acetaldehyde 770 
Ammonia 853 
Pyridine 948 
Limonene 875 
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The PTR-MS used in this study was a first generation Ionicon PTR-MS instrument with a 
serial number 01-13. Figure 2.3 shows a schematic representation of a PTR-MS apparatus 
used in the study [19] showing the different parts of the instrument in more detail. 
 
 
Figure 2.3 Schematic diagram of a PTR-MS apparatus [19]. Reprinted from International 
Journal of Mass Spectrometry and Ion Processes with the permission of Elsevier. 
 
1. A reagent ion source - a hollow cathode discharge (HC) and a source drift 
region (SDR) 
2. A drift tube - the reaction region (DT) 
3. Detection - involving a mass to charge selection using a quadrupole  
mass spectrometer and secondary electron multiplier (QMS and SEM) 
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2.1.1 The ion source and source drift region  
A detailed explanation of the ion source used in a PTR-MS instrument has been reported 
by Hansel et al. [19]. Researchers at the Institute of Ion Physics in Innsbruck have also 
published studies on comparable ion sources used in PTR-MS [20]. In PTR-MS 
instruments, the ion source is a DC hollow cathode discharge. H3O
+
 ions are produced 
from a plasma discharge in a region of water vapour. The hollow cathode operates at 
typically pressure of 1 millibar. The ion source is divided into two parts, a hollow cathode 
(HC) and a source ion drift region (SDR). The description of the ion source can be 
followed from the picture shown in figure 2.3.   
The hollow cathode consists in three main regions, cathode, cathode fall and 
negative glow. A plasma is produced by ionisation of water vapour between the anode 
and cathode. The discharge is a “negative glow” key region axial inside region of the 
hollow cathode. This region is a free-field cylindrical region, with a potential close to the 
anode potential. Between the negative flow and the cathode, a potential difference of 
hundreds of volts is created. This region is called cathode fall. In the cathode fall, 
electrons are accelerated up to several electron volts and collide with neutral molecules 
which are ionised by collisions with high-energy electrons to produce ions. In the 
negative glow region, neutral molecules undergo further collisions with the primary ions 
to form secondary and tertiary ions. These will be accelerated up to several electron volts 
and further ions collision occurs. This continuous effect produces a high-density plasma 
which is retained in the hollow cathode region. Two anode plates limit at either end the 
negative glow region in the HC. There is a small central orifice of 1.0 mm diameter in 
one these endplates [19]. 
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The ions produced in the hollow cathode pass into the adjacent source drift region 
through the central orifice. The discharge current is maintained in the hollow cathode by 
a potentiometer set typically at 5 mA while the hollow cathode is in operational mode. In 
the PTR-MS the potentiometer can be regulated from 1-10 mA. The higher the discharge 
current is the higher the intensity ion current is produced and the more stable is the 
discharge and therefore the reagent ion signal. It is important to note that at higher 
discharge currents settings and with the continued use, the internal surface of the HC can 
become contaminated with compounds deposits affecting the production and stability of 
the reagent ions. Therefore, the HC ion source must be cleaned every 1-2 month to 
maintain a good instrument performance.  
During operating conditions, a flow of high purity water vapour is introduced into 
the ion source and an electrical discharge will lead to the production of hydronium ions 
through a number of reactions. A mass flow controller maintains the water vapour flow 
rate. The flow rate can be set from 0 to 10 sccm (standard cubic centimetres per minute). 
In this study the flow rate was kept at 5 sccm. Electron impact ionization of water 
molecules lead to H2O
+
 or fragment ions such as O
+
, H
+
, H2
+
 and OH
+
.  
Parent and fragment ions produced in the glow discharge that have recombination 
energies greater that the ionisation potential of water will react with water, ultimately 
leading to H3O
+
, equations 2.3-2.8.  
H2O
+ 
+ H2O → H3O
+ 
+ OH
+  
   k=1.8 x10
-9 
cm
3 
s
-1
               Equation 2.3 
H2O + O
+ → H2O
+ 
+ O     k=2.6 x10
-9 
cm
3 
s
-1
                  Equation 2.4 
H2O + H
+ → H2O
+ 
+ H                k=8.2 x10
-9 
cm
3 
s
-1
                  Equation 2.5 
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H2O + H2
+
 → H3O
+ 
+ H            k = 3.4 x10
-9 
cm
3 
s
-1
                  Equation 2.6  
                    → H2O
+ 
+ H2         k = 3.7 x10
-9 
cm
3 
s
-1
    
           H2O + OH
+ → H3O
+ 
+ O        k = 2.8 x10
-9 
cm
3 
s
-1
      Equation 2.7 
              → H2O
+ 
+ OH      k = 1.8 x10
-9 
cm
3 
s
-1
 
where the k are the experimental reaction rate coefficients at 300 K. All the 
reactions are fast with the reaction rate coefficients being close to or at the collision 
value. The data above has been taken from the compilation from Ikezoe et al. published 
in 1987 [21].  
The source drift region is a region placed between hollow cathode and the drift tube. Its 
purpose is to allow more time for the above reactions to take place and hence to maximise 
the reagent ion signal. It also serves to reduce protonated water clusters.               
N2
+
 + H2O → H2O
+
 + N2                  k = 2.8 × 10
-9 
cm
3 
s
-1 
                  Equation 2.8 
It is unpreventable that some gas from the drift tube flows back into the discharge 
region of a PTR-MS. This results in other types of reagent ions which do not react with 
water, such as O2
+ 
, N2
+
, NO
+
, being produced. N2
+ 
is eliminated by charge exchange with 
water (Equation 2.8). N2
+
 lead to H3O
+
 formation via reaction of H2O
+
 with water. 
 
The mechanism of O2
+ 
elimination is more complicated. The ionization energy of 
the H2O (12.6 eV) is higher than the recombination energy of O2
 
which has a 
recombination energy of 12.1 eV compared with water which has an ionization energy of 
12.6 eV. Therefore O2
+
 cannot exchange charge with neutral water. Hence O2
+
 is seen as 
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a low-level contaminant from the ion source and a low concentration of O2
+
 is always 
present in the DT.  
NO
+
 is another contaminant ion in PTR-MS that is generated by the reaction 
specified below: 
    N
+ 
+ O2 → NO
+ 
+ O           k= 2.6 x10
-9 
cm
3 
s
-1
           Equation 2.9 
The recombination energy of NO
+
 (9.3 eV) is too low for it to be able to charge 
transfer with water.  
Although present in the drift tube, it is possible to reduce their intensities by 
adjusting the PTR-MS operational parameters (gas flow, hollow cathode voltages) to 
minimise their concentrations. In this study, the abundance of NO
+ 
and O2
+
 was kept 
below 2% of the H3O
+ 
ions. Consequently, a clean signal of reagent ion with a purity 
greater than 98% was produced [19]. 
 
2.1.1.1 Gas inlet air flow 
In the PTR-MS the sample gas to analyse enters into the system via a needle valve. The 
needle valve controls the inlet flow going into the drift tube (DT). The pressure in the 
system is maintained by the pressure controller that can be set from 0- to 800 mbar using 
a specific software. Generally, the pressure controller is set to maintain a pressure of 2 
mbar in the drift tube. In the back panel of the PTR-MS close to the inlet flow valve, 
there is an inlet called the ballast inlet. The goal of the ballast inlet is to supply a constant 
flow of dry air to the diaphragm vacuum pump. It is necessary to use this inlet ballast to 
avoid water condensation inside the diaphragm vacuum pump. The flow in the inlet 
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ballast is set at the specific value recommended in Ionicon´s specifications manual for the 
instrument. 
 
2.1.2 Drift tube 
The drift tube is a cylindrical tube that contains a series of electrodes (stainless steel 
rings) equally spaced and separated by electrically insulated spacers (Teflon O-rings) to 
control the voltage to each electrode. A series of high impedance resistors are connected 
between the adjacent electrodes. These generate a homogeneous electric field that move 
ions along the drift tube when a voltage is set across the drift tube. The drift tube has a 
diameter of 3 cm and approximately 10 cm length. The drift tube can be heated up at to 
100°C. Figure 2.4 shows a photograph of a drift tube in a PTR-instrument. 
 
Figure 2.4 Photograph of a drift tube in a PTR-MS instrument. 
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The analyte is introduced through an inlet valve with air as the carrier gas into the drift 
tube. The reagent ions are guided into the drift tube and react with the analyte present in 
the air.  
Given the presence of the H2O in the air sample and from the hollow cathode, 
H3O
+
 ions can associate with H2O molecules through a three body process, forming 
hydrate clusters ions:  
   H3O
+
 + H2O + M → (H3O
+
 ∙ H2O) + M             Equation 2.10 
 
When monohydrate cluster ions are formed (H3O
+
 ∙ H2O), the abundance of H3O
+
 
is reduced [17] [19]. Table 2.2 gives information on the proton affinities of neutral water 
and water clusters. 
Table 2.2 Proton affinities of water and water clusters [21, 22]. 
 
Neutral Molecule Proton Affinity (KJ/mol)  Protonated Molecule m/z 
H2O 691 H3O
+ 
19 
(H2O)2 833 H3O
+ ∙ H2O 37 
(H2O)3 889 H3O
+∙ (H2O)2 55 
(H2O)4 920 H3O
+
 ∙ (H2O)3 73 
 
 
The electric field applied through the drift tube controls the energy delivered to ion-
molecule collisions to reduce excessive water clusters and encourage the breakup of 
water cluster ions.  
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The operational conditions in the drift must be optimised to provide a balance between 
the amount of protonated water cluster ions formed and the energy for a soft ionisation to 
reduce the fragmentation of volatile organic compounds. The energy in an ion-molecule 
reaction depends on the electric field, E, and the total number density of gas, N, in the 
drift tube. E/N is a measure of the ions kinetic energy in the drift tube.  
The reduced electric field (E/N) is referred to as the ratio of the electric field 
strength and the total number density of gas, N, in the drift tube, units of V cm
2
. The 
reduced electric field is more frequently defined in Townsend (Td), by the relation 1 Td= 
10
-17
 V cm
2
. For example, a voltage of 600 V applied across the drift tube provides an 
electric field of 
  
                                       𝐸 =
𝑉
𝑑
=
600
9.6
= 62.5 𝑉𝑐𝑚−1                                          Equation 2. 11 
        
The gas number density is the number of gas molecules per unit volume. Using 
the following equation, from the ideal gas equation [23]: 
 
                                
   𝑁𝐴
   𝑉𝑀
 
273.15 𝐾
𝑇𝑑
 
𝑃𝑑
101.325 𝑘𝑃𝑎
                                                  Equation 2.12 
     
 
NA is Avogadro’s number (6.022 x10
23
 mol
-1
) and the molar volume is VM (22414 
cm
3
mol
-1
) is the volume occupied by one mole of ideal gas at standard temperature 
(273.15 K) standard pressure, 1 atmosphere of pressure (101.325 kPa). Pd is the gas 
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pressure in the drift tube (kPa) and Td is the operational temperature of the drift tube 
(Kelvin).  
When operating the drift tube at a pressure of 2.06 mbar at a temperature of 318 K the 
total number of density is 4.69 x 10
16
 cm
-3
. Together this provides an E/N of 138 Td. 
 
2.1.2.1 Determination of trace gas concentrations  
 One of the applications of PTR-MS is to determine without calibration absolute 
concentrations of a species M providing the reaction time td and the rate coefficient are 
known [10].  
The reaction is a second-order reaction following this rate equation: 
 
                                 −
𝑑[H3O
+]
dt
= 𝑘[H3O
+][M]                                              Equation 2. 13 
 
[M] is a neutral gas and assuming that [M] ≫ [ H3O
+], then [M] is constant. The 
equation 2.13 can be integrated and the reaction follows a pseudo first order kinetics.   
                                      [H3O
+]𝑡 = [H3O
+]0 𝑒
−𝑘[𝑀]𝑡,                                     Equation 2. 14 
 
where t is the reaction time, the time it takes for the hydronium ion to travel to the 
end of the drift tube.  The concentration of [H3O
+] can be related to the concentration of 
[MH
+
] by  
                                         [MH+]𝑡 = [H3O
+]0 − [H3O
+]𝑡                             Equation 2. 15 
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Rearranging both equations a and b the [MH
+
]t is given by 
                     [MH+]𝑡 = [H3O
+]0 (1 − 𝑒
−𝑘[𝑀]𝑡)                                 Equation 2. 16 
Firstly, the condition can be simplified assuming that only a low concentration of [H3O
+] 
is consumed by the reaction then [H3O
+]0 ≈ [H3O
+]𝑡 that is [MH
+
] ≪ [H3O
+] therefore, 
the product ion density [MH
+
] can be described: 
                              
[MH+]𝑡
[H3O+]𝑡
= (1 − 𝑒−𝑘[𝑀]𝑡)                                                Equation 2. 17      
Secondly,    k[M]t ≪ 1 assuming that VOC are not greater than part per million level.  
The concentration of the gas M can be calculated from the ratio of the product ion density 
and the hydronium ion density by: 
 
                                   
[MH+]
[H3O+]
  =  𝑘[𝑀]𝑡                                                       Equation 2. 18            
 
 
The concentration of the gas M can be calculated from the ratio of the product ion density 
and the hydronium ion density 
2.1.2.2 Determination of the reaction time in the drift tube. 
In the drift tube the reaction time (td) can be determined by calculating the drift velocity 
from the ion mobility. The ion drift velocity ( 𝑣𝑑) is given by: 
 
                               vd=μ E                                                              Equation 2.19 
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Where 𝜇 is the ion mobility ( 𝑐𝑚2 𝑉−1𝑠−1). Often a reduced mobility is used, 𝜇0, which 
is given by: 
                                      μ0=
N
N0
 μ                                                            Equation 2.20 
N is defined as the number of density of the carrier gas at experimental condition and 𝑁0 
is the carrier gas number density at standard temperature and pressure (STP). 
The drift velocity is expressed in terms of the reduced mobility, carrier gas density at STP 
and the electric reduced field by: 
                                                    vd=N0 μ0
E
N
                                                   Equation 2.21 
The value for the reduced mobility coefficient for H3O
+ 
is 2.76 cm
2
 V
-1
s
-1 
[24]
. 
Under operating conditions the velocity of the ions in the drift tube is
 
vd = 1.02 × 10
5cm s
-1
  
The drift tube length is 9.6 cm and gives a value of drift time of reaction of 
reaction time td= 0.09 ms. The reaction time in the drift tube can be calculated by: 
                                                     td =
𝐿
μ0N0 
N
𝐸
                                                Equation 2. 22           
 
 
2.1.2.3 Collisional Reaction Rate Coefficient 
The reaction rate coefficient is an important parameter of ion-molecule reaction and is 
defined in terms of reactants (consumed) and products (formed). The reaction rate 
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measures the speed at which a reaction takes place. Chemical reactions have to be 
efficien 
t in order to obtain adequate products. An efficient reaction takes place at or close to the 
collisional rate. Exoergic proton transfer reactions are close to the collisional limiting 
values. For example, for the reaction: 
R
+
 + M → P++ X 
The reaction rate coefficient is defined by 
                                              
𝑑 [𝑅+]
𝑑𝑡
=  −𝑘 [𝑅+][𝑀] ,                                            Equation 2. 23 
 
where 𝑘 is the rate of reaction (cm3s-1). The collisional rate coefficient is the upper limit 
to the reaction rate coefficient. In the literature are calculated many of the reactions rate 
coefficients [21] for proton transfer reactions. 
Different theoretical studies have been proposed to determine the rate coefficient 
of exothermic ion-molecule reactions. One of the models developed for non-polar 
molecules, was proposed by Langevin over a century ago. The Langevin rate coefficient 
is classically calculated assuming that the reaction occurs upon every collision [24]. The 
principle is based on the idea that the ion induces a dipole in the non-polar neutral 
molecule.   
The Langevin rate constant is independent of the relative velocity and the 
temperature. The collisional rate constant or the Langevin non-polar constant (kL) is 
described by: 
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                 𝑘𝐿 = √
𝜋𝛼𝑞2
𝜇𝜀0
                               Equation 2.24 
Here α is the polarizability, µ is the reduced mass and 𝜀0 the free space permittivity.  
This method has been used as a standard for the calculation of ion molecule and ion-atom 
collisions. This approach does not work well for the interaction of polar molecule and ion 
because it omits interactions between permanent electric dipole moment and positive 
charge and of an underestimation of the reaction rate coefficient.   
The locked dipole approximation takes into account the effect of the reaction between an 
ion and a polar molecule. However, this model tends to overestimate rate coefficients by 
deleting a range of dipole orientations.   
A more accurate calculation is that by Su and Bowers who developed an average dipole 
orientation (ADO) theory. The ADO rate coefficient is described by: 
 
                       𝑘𝐴𝐷𝑂 = √
𝜋𝛼𝑞2
𝜇𝜀0
+
𝐶𝜇𝐷 𝑞
𝜀0
√
𝐴
2𝜋𝜇 𝑘𝐵𝑇
                                    Equation 2.25 
                           
 𝑘𝐵  is the Boltzman constant and 𝜇𝐷 is the dipole moment. The first part of the 
equation is the Langevin contribution shown in equation 2.24 whereas the second part of 
the equation takes into account the ion-permanent dipole. A comparison of the rate 
coefficient calculated by ADO theory and experimental values of rates coefficients, the 
result is that ADO calculations tend to underestimate the rate coefficients by 10-20% 
[25]. The reason is because 𝑘𝐴𝐷𝑂 does not take into account the dipole moment of a 
charged reagent. 
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2.1.3 Detection system 
The detection system in the PTR-MS used in this study consist of a quadrupole mass 
spectrometer (QMS) which filters the ions according to their m/z (mass/charge ratio), 
coupled to a secondary electron multiplier (SEM) which has the task of detecting the 
presence of the ions passed by the mass filter. The SEM multiplier operated in pulse 
counting detection. 
The quadrupole consists of a set of four metal horizontal, cylindrical parallel rods 
positioned equidistant from a central axis. They are arranged as shown in figure 2.5. 
Adjacent rods are electrically connected together and a radio frequency voltage (RF) with 
a DC offset voltage is applied so that a quadrupole electric field can be created [26].  
 
 
 
Figure 2.5 Schematic diagram of a quadrupole mass spectrometer [26]. Figure used with 
permission from Dr Paul Gates, University of Bristol, United Kingdom. 
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A sequence of DC and RF voltages applied to the rods determine the pathway of the ions 
passing through the quadrupole field. The geometry of the quadrupole and the X, Y 
directions are defined in the figure 2.6 [27]. 
 
Figure 2.6 Schematic diagram of the geometry of a quadrupole mass filter defined in the 
x, y directions. Reprinted from Journal of Vacuum Science & Technology with the 
permission of AIP Publishing [27]. 
 
For given values of DC and RF voltage applied to the rods is defined an 
oscillating electric field that only ions of a specific m/z ratio are transmitted and recorded 
leading to a mass spectrum. The other ions with different m/z will be lost on the rods of 
the quadrupole. 
The model of the quadrupole in the PTR-MS is a Balzers QMS-422. This model 
of quadrupole spectrometer has limited mass range, typically unit mass resolution (a low 
mass resolving power), and with at operating mass range up to 500 m/z.  
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One of the drawbacks of the Balzers QMS-422 is that unambiguous identification of 
compounds is difficult based only on m/z values. However, additional analytical 
techniques, such as gas chromatography can be used to for pre-separation. 
The SEM provides an electrical pulse for each incident ion. As the SEM ages, it loses 
sensitivity, and this has to be periodically checked. The operating voltage is determined 
by gradually increasing the voltage and observing the point at which the instrument 
response counts per second (cps) plateaus. The value of plateau has to be chosen to 
operate at the shoulder of the sigmoid. If the voltage is set too low than the sensitivity 
will be reduced whereas for a voltage too high the signal to noise ratio deteriorates owing 
to dark currents causing a poor quality signal. Figure 2.7 shows a picture of a secondary 
electron multiplier used in a PTR-MS instrument.  
 
 
 
Figure 2.7 Photograph of a new secondary electron multiplier. The dynodes are visible 
between the white ceramic layers. 
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Furthermore operating at high voltage leads to a reduction in the lifetime of the SEM. It is 
recommended by the supplier to operate the instrument at a voltage that gives for every 
100 V increase in the SEM potential a 10% increase at m/z 21.  
If the cps incident on the SEM are more that million, the output signal loses linearity. 
Furthermore, high number of ions will accelerate the damage to the detector 
At m/z 19 the hydronium signal saturates the detector. As an alternative, the count 
rate of the 
18
O isotope of H3O
+ 
is measured and indirectly calculated the m/z 19 signal. 
The relative abundant of the 
16
O is 99.8% and for 
18
O is 0.2%. The m/z 19 count rate is 
calculated by multiplying by 500 the count rate signal at m/z 21. Changes in the operating 
conditions resulting in changes in the H3O
+
 signal intensity. Furthermore, the signal 
intensity is dependent on E/N. Therefore, it is common to normalise the intensity of the 
signal to the number of the reagent ion H3O
+
.  
 
2.1.3.1 Reagent ion and normalization 
To ensure that data acquired during measurements is comparable, normalisation of the 
product ion intensity signals to reagent ion signal is required. In this way it is possible to 
make comparisons of the measurements under different modes or conditions. In the PTR-
MS instrument, 𝐻3𝑂
+ signal can be different from one day to another day or it can also 
change over the course of a day. 
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The following equation was used for the normalization:  
                                  𝑛𝑐𝑝𝑠 = 50 × 106  
(𝑀𝐻+)
(𝐻3𝑂+)
                                                   Equation 2.26      
                                               
 
 
The data acquired during this study was normalised to the H3O
+ signal of 50 million 
counts. In the equation 2.26, 
(𝑀𝐻+)
(𝐻3𝑂+)
  is the ratio of the product ion density and the hydronium ion density. 
In the DT, the hydronium ion is the dominant reagent ion. When the analyte gas is 
humid, there are significant concentrations of the monohydrate water cluster in the 
sample gas which may also react by proton transfer with the analyte. When proton 
transfer from the protonated water cluster can occur then the intensity of the product ion 
signal should be normalized to the hydronium H3O
+
 and monohydrate water cluster 
H3O
+∙H2O.  
Several studies have shown that the VOCs concentration using PTR-MS has a 
dependency on the water vapour content in the samples gas [28]. De Gouw and Warneke 
reported that the normalization has to be considered for water clustering, the signal H3O
+
 
and H3O
+∙H2O may not be constant and varies with the humidity [29]. The intensity of 
the signal H3O
+
 changes in the HC and the water content in the samples often is different. 
Therefore the impact of the humidity has to take into account during proton transfer 
reaction [29].  
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The following equation was suggested [29] where X is a factor which is specific for each 
compound and account for the reaction rate of the VOC with the monohydrate cluster ion 
and the transmission efficiency of the monohydrate water cluster ion.  
                        
𝑀𝐻+ 
𝐻3𝑂+
  →    
𝑀𝐻+
𝐻3𝑂+ + X ×  (𝐻3𝑂+  (𝐻2𝑂))
                                  Equation 2. 27  
 
The factor X depends of the compound measured and reproduce the difference in 
efficiency for the detection of H3O
+
 and H3O
+∙H2O ions in the QMS and the rate 
coefficient different for H3O
+
 and H3O
+∙H2O in the proton transfer reactions [29]. Values 
of X ≈1 imply H3O
+
 normalized signals independent of the humidity. Aromatics 
compounds do not react at all with the H3O
+∙H2O their X values are approximately to 
zero. For other VOCs X ≈ 0.5 [29]. 
2.1.4 Advantages of PTR-MS 
The application of PTR-MS technology has several advantages compared to other types 
of mass spectrometers. These are the major ones 
(i) Detection of low concentrations of volatiles due to the high sensitivity (down to 
part per billion by volume (ppbv)) with no gas sample pre-concentration.  
(ii) Minimal fragmentation of the volatiles compounds analysed; during soft 
ionization process a small amount of energy is transferred as a result very little 
fragmentation are obtained. The advantage is that the spectra are easier to interpret 
compared to other ionization methods.  
(iii) Provide real-time measurements and quantification of volatile organic compounds 
with low response times.  
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(iv) Minimal sample preparation, headspace of volatiles are measured. 
(v) The sensitivity of the measurements is similar for detection of volatiles with 
different m/z. 
(vi) No reaction with the main constituents in air (N2, O2, Ar, CO2, etc.) due to the 
lower proton affinity compared to water. 
(vii) PTR-MS is a transportable instrument. The device can be used in different places 
or locations. 
 
2.2 PTR-MS Data Analysis 
 
2.2.1 PTR-MS and the recording of data  
The quadrupole is controlled using the software for data acquisition supplied by Balzers 
QMS-422. The software consists of different controller programs for the control of the 
PTR-MS system. The software allows the use of different settings controlling water flows 
and gas inlet flows, voltages in the drift tube and data recording and visualisation as well.  
The PTR-MS can be used in two different ways for ion detection; Mass Scan and 
Multiple Ion Detection mode (MID). A mass scan, is generally used when the ion 
products of the reactions are unknown. When the PTR-MS instrument is run in the MID 
mode, the user can monitor individual peaks of selected m/z values as a function of time 
so that rapid changes (time resolution 100 ms) in concentrations can be recorded.  
An important parameter for mass scan and MID modes is the dwell time. The 
dwell time characterizes the time spent for the quadrupole for the data acquisition on a 
particular m/z. In mass scan mode the dwell time can be chosen from 0.5 ms up to 60 s 
per channel. The setting used for the data acquisition in this study was found for an 
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optimal data acquisition of 0.5 s. The dwell time can be used to improve signal to noise. 
For instance, volatiles at high concentrations (e.g. greater than 100s of ppbv) do not need 
a long integration time whereas volatiles at low concentrations (several ppbv) need longer 
integration times (seconds). When measuring low concentrations and the product ions are 
known for a given compound the dwell time can be increased significantly over that 
possible with mass scan mode by using a MID mode, thereby improving the counting 
statistics. 
In the PTR-MS instrument used in this investigation, data extraction and analysis of the 
spectra (mass scans and MID) was not an automatized procedure. Every cycle generated 
was converted to an ascii file through the Balzers Quadstar 422 software package and 
then copied to an excel spreadsheet. 
 
2.2.1.1 Mass scan mode 
In this selected mode the mass scan generates a complete spectrum showing ion counts 
per second versus m/z. In the mass scan mode the instrument records all the intensities 
between two selected m/z values in the software. Figure 2.8 shows an example of a 
typical mass spectrum generated in the mass scan mode of a breath sample over the mass 
range from m/z 30-75.  
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Figure 2.8 Mass scan spectrum of an alveolar exhaled breath sample from a healthy 
volunteer. Key volatiles present in the breath are identified. 
 
In the software settings, the mass scan mode does not allow the user to choose individual 
mass dwell times instead a specific dwell time is required for the complete cycle. A scan 
cycle is finished when the whole range of m/z values chosen has been scanned over a 
specified dwell time for each point. 
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2.2.1.2 Multiple ion detection (MID) 
By way of illustration, figure 2.9 shows a typical MID spectrum for an on-line real-time 
breath sampling for which ions at m/z 33 (protonated methanol), m/z 59 (protonated 
acetone) and m/z 69 (protonated isoprene) were monitored. MID generates a file with the 
specific masses measured. This mode is often used to measure concentration of specific 
ions compounds as well as monitoring changes on VOCs over time.  
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Figure 2.9 MID spectrum of alveolar breath sample. 
 
2.2.2 Statistical analysis  
For each measurement three scans were averaged and added to one sum spectrum. The 
following approach was applied to all data presented in this study. For the comparison 
study between patients and healthy volunteers, the appropriate analysis tool was selected.  
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Choosing the statistical test is essential depending on the data generated. IBM SPSS 
version 22 software was used for all statistical analysis. The distribution of the data was 
assessed using Shapiro-Wilks test which found that the data was not normally distributed. 
A non-parametric statistical test based on the result obtained was chosen with Shapiro-
Wilks test. Mann–Whitney U-tests determined which m/z values differed between the 
patients and controls. A Wilcoxon signed rank test was used to determine which volatile 
concentrations differed between pre- and post-transplant breath samples. To compare 
blood chemistry values with breath volatiles Kendall's tau-b correlation coefficients were 
measured.  
             Finally, in order to know how reliable is the study for diagnostic test evaluation 
of volatiles Receiver Operating Characteristic (ROC) curves were used to graphically plot 
the true positive rate (TP), sensitivity in function of the false positive rate (FP) (100-
Specificity) [30]. The area under the ROC curve measures how well the volatiles can 
distinguish between two diagnostic groups (in this case patients versus healthy 
volunteers). 
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2.2.3 Calibration 
 
The PTR-MS instrument was regularly checked to measure the sensitivity using limonene 
as the calibration gas standard. The calibrations were performed at the same pressure and 
at a constant temperature set during the breath samples measurements from patients and 
controls described in chapter 4 and 5. During the calibration the DT voltage was 600 V, 
the pressure in the DT was 2.07 ± 0.01 mbar at a temperature of 45 ± 1C. The PTR-MS 
was calibrated using a KINTEK gas standard generator and permeation tubes. The 
emission rate of the permeation tube was calculated by measuring the rate of weight loss. 
The permeation tube was placed inside the KINTEK unit and limonene vapour was 
emitted through the tube wall when the gas standard generator was at constant 
temperature. The sensitivity obtained was 700 cps/ppb. In general, a good agreement was 
found between the gravimetrically method and the calculated method using the collisional 
reaction rate coefficients.  
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3 BREATH ANALYSIS FOR CLINICAL DIAGNOSIS AND 
MONOTORING 
 
3.1 Introduction 
The potential of breath as a diagnostic medium for prognosis of a disease has been 
reported since the time of Hippocrates (460–370 BC). He described a fecal smell, which 
is a sign of a liver failure called fetor hepaticus, in his studies on volatile organic 
compounds in breath. Modern breath analysis took place many centuries later when in the 
early 70s, Linus Pauling analysed an extensive number of volatiles in exhaled breath and 
in urine vapour by using gas chromatography (GC) [31].  
In recent years, the analysis of blood, urine and other body fluids have been 
established as routine analysis in clinical settings. However, breath analysis is now 
attracting great interest clinically owing to its potential as non-invasive and faster 
diagnostic method for disease monitoring and diagnosis [23]. Breath analysis can also be 
used as a technique to provide information about the metabolic processes occurring in 
organs or places in the body. Alterations in the metabolic pathways due to abnormal 
metabolism or a disease can lead to changes of concentrations in the breath VOCs or new 
ones being produced related to a disease. 
The analysis of exhaled breath has many advantages [32]. For example, breath 
analysis has a low risk of infection and breath is a biological sample that does not need to 
be stored and there is no need to be concerned about safe disposal compared with the 
blood and urine analysis samples. A technology that has been applied in the medical 
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setting in the last 20 years for breath analysis is Proton Transfer Reaction Mass 
Spectrometry.  
This technique has been used in research for the on-line monitoring of VOCs in 
variety of areas from the analysis and the detection of anaesthetics in exhaled breath [4, 
33] [34], to skin volatiles [35] and the monitoring of microbial volatile metabolites [36].  
However, it is important to highlight that breath sampling and data analysis are 
not trivial. There are many pitfalls such a confounding variables that can lead to 
erroneous results and conclusions [37].  
 
3.2 Human Respiratory System Physiology 
The main function of the human respiratory system is to provide the cells of the human 
body with a continuous flow of oxygen and to remove carbon dioxide. The respiratory 
system consists of two sections, the upper respiratory tract or upper airway and the lower 
airways. 
The upper respiratory tract includes the parts of the respiratory system above the 
glottis or vocal cords. The upper respiratory tract (upper airways) consists of nasal and 
oral cavities, pharynx and larynx (voice box). The lower respiratory tract (lower airways) 
consists of the trachea (wind pipe). The trachea divides into the two primary bronchi, 
bronchioles and the lungs. Figure 3.1 shows schematically the structure of the human 
respiratory system and the alveoli in the lungs [38]. The bronchial tree includes the 
bronchi, terminal bronchioles, alveolar sac and alveoli. The bronchial tree allows the air 
pass from the trachea to the lungs.  
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Figure 3.1 Human respiratory system and the structure of the alveoli in the lungs [38]. 
Reprinted from Computational Fluid and Particle Dynamics in the Human Respiratory 
System with the permission of Springer International Publishing. 
 
 
3.2.1 Gas exchange 
The primarily function of the human respiratory system is the gas exchange. Gas 
exchange takes place in the capillaries of each alveolus in the lungs and occurs through 
diffusion by a concentration gradient. The oxygen is taken from the air and diffuses in the 
alveoli into the bloodstream and waste carbon dioxide is removed in the lungs via air sacs 
(alveoli) at the end of the bronchial tubes.  
The composition of O2 and CO2 contained in the breath changes during the process of 
breathing due to gas exchange, for instance inhaled air contains 21% oxygen and 0.04% 
CO2 in contrast exhaled breath contains 16% and approximately 4% CO2. 
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3.2.2 Lung capacities and volumes 
An adult male has a lung capacity of approximately 6 litres; the actual lung capacity is 
determined by factors such as age, gender, weight, height and ethnicity. During normal 
and relaxed breathing, only a small volume of this capacity is used and is on average 500 
ml of air. This volume of air breathed during normal inhalation and exhalation is the tilde 
volume. Figure 3.2 shows a schematic diagram of the different lung volumes and 
capacities [38]. 
 
Figure 3.2 Lung volumes and capacities. Reprinted from Computational Fluid and 
Particle Dynamics in the Human Respiratory System with the permission of Springer 
International Publishing [38]. 
 
The respiratory lung capacities can be define into four different volumes: 
 Tidal volume (TV) (previously described) 
 Expiratory reserve volume (ERV) 
 Residual volume (RV) 
 Inspiratory reserve volume (IRV)  
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The inspiratory capacity (IC) is the maximum volume of air that can be held in the lungs 
and inspired in a full inhalation. The vital capacity (VC) is described as the maximum 
volume of air that is forcibly expired from the lungs after a fully inhalation. The VC can 
be calculated by the sum of the expiratory reserve volume (ERV), inspiratory reserve 
volume (IRV) and tidal volume (TV) [39].  
The expiratory reserve volume (ERV) is the additional volume of air that can be 
exhaled after a normal exhalation of a tidal volume of air. The additional volume of extra 
air that can be inhaled in a normal expiration of a tidal volume of air is called the 
inspiratory reserve volume (IRV).  
The residual volume is describes as the volume of air that still remains in the lungs 
after a maximal exhalation. The maximum volume of air that can hold in the lungs is 
defined as the functional residual capacity (FRC). Total lung capacity (TLC) is the total 
volume of air that can hold in the lungs which is approximately 6000 ml of air in healthy 
adult males. 
 
3.3 The Origin and Composition of Breath 
According to the origin of the volatile organic compound exhaled in the breath can be 
divided into two well differentiated groups, exogenous or endogenous [40]. Endogenous 
compounds are produced in the human body and provide information about metabolic 
pathways and different pathologies and diseases. Endogenous compounds can contain 
inorganic gases such as nitric oxide and carbon monoxide, or volatile organic compounds 
such, methanol, isoprene and acetone [41].  
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If the origin of the VOCs is due to an exposure of pollutants from the environment, diet 
intake, drugs or absorbed through the skin, then they are referred to as exogenous 
compounds. 
Exhaled breath contains a variety of gases such as oxygen, nitrogen, carbon 
dioxide, inert gases, water vapour and small concentration of gas traces in variable 
concentrations [42]. These volatile compounds are detected in human breath at typically 
parts per billion (ppbv) and part per million (ppmv) by volume. For example, a previous 
research has measured breath acetone and isoprene levels ranging from 515–2335 ppbv 
and 308–702, respectively [3]. Compounds such as isoprene and acetone can be 
correlated with metabolic processes in the human body. Table 3.1 shows a list of typical 
molecules measured in human exhaled breath, adapted from references [7] [43] and [44]. 
Ketones bodies, such acetone is associated to lipolysis and glucose metabolism. Isoprene 
in exhaled breath is a by-product of cholesterol biosynthesis. High levels of volatile 
sulphur compounds have been detected in patients with chronic liver disease with respect 
to healthy volunteers [5, 42, 45].  
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Table 3.1 Details of volatiles in breath, concentration range and metabolic process 
involved [7] [43] [44]. 
Compound Range Metabolic process 
Acetaldehyde ppb Lipid peroxidation/ Ethanol metabolism 
Acetone    ppb-ppm Fat catabolism 
Dimethyl sulphide ppb 
 
Liver dysfunction/ Oral bacteria 
 
2- butanone 
3- butanone 
ppb 
Liver dysfunction/ Fatty acid oxidation 
Methanol     ppb   
Liver dysfunction/ Pectin degradation/ Gut flora 
Ammonia ppb Protein metabolism 
Isoprene ppb Cholesterol biosynthesis 
1-pentane ppb Lipid peroxidation 
Hydrogen sulphide ppb Liver function/ Protein metabolism of bacteria 
Ethanol ppb Gut bacteria/ Drinking 
 
 
3.3.1 Breath volatiles for medical diagnosis 
To date, the use of breath volatiles for medical diagnosis has been met with limited 
success. Confounding factors, such as volatiles present in the environment, contamination 
in the sampling procedures, poor sampling methods and influence of food intake, have 
meant that there is a great deal of uncertainty in volatile discovery [46] [47]. Problems of 
bias and false findings in biomarker discovery research have been widely reviewed [48, 
49]. 
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Most of the studies in breath analysis have been mainly focused on the determination of 
concentration of volatile organic compounds such as isoprene, acetone, ethanol, methanol 
since they are contained in a significant range in the human breath [3, 50]. The 
production of acetone in breath is related to the insulin and blood sugar and fat 
metabolism. When the glucose levels are low in the blood, the body produces ketones 
(acetone) from adipose tissue as a source of energy. The triglycerides (TG) are major 
constituents in the body fat, which can be break down into one glycerol molecule and 3 
fatty acid molecules by the hormone lipase (HSL). If the glucose levels are low, the fatty 
acid levels in the blood increase and the catabolic process called beta-oxidation takes 
places. In the process the TG are broken down and generate Acetyl-CoA. When the 
concentration of Acetyl-CoA rises, it triggers ketogenesis. During the ketogenesis 
acetoacetate is formed first and the converted into two types of ketones: beta-
hydroxybutyrate and acetone [51]. 
 Acetone levels rise in patients suffering from diabetes because of the influence of 
glucose metabolism. Previous studies have shown that the concentration of acetone rise 
when the volunteer is on a low-carbohydrate diet or are fasting [52] and in adults with 
alcoholism. The concentration of acetone in breath has been proposed to predict ketosis 
and can be used as a tool to understand metabolic pathways of the diet, fat loss or to 
predict diabetes. However, due to the large variability in acetone levels in exhaled breath 
through the day in individuals and other caused that can influence acetone levels such as 
health status, diet, and age, the monitored acetone level cannot be used with confidence.  
Another common endogenous breath volatile which has been the focus of 
attention is isoprene. Isoprene is linked to be part of the cholesterol biosynthesis, 
although its biological pathway of biosynthesis and origin is still unclear. Therefore, 
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analysis of isoprene levels in exhaled breath proves to be particularly valuable as a 
method to detect lipid digestion, diagnose cholesterol or lipid disorders. It is important to 
mention that due to its variability with movement, isoprene can only be used as non-
invasive marker under cardiac output controlled conditions and only if heart rate is 
maintained constant during the breath sampling.  
For instance, isoprene concentration increases during exercise in part because the 
heart rate has a direct impact on its concentration increased the blood flow. Isoprene is 
excreted from the muscles and exhaled in the breath during exercise due to pulmonary 
gas exchange process occurring in the body tissues. It is known from previous studies that 
isoprene concentration can increase by a factor of ~3-4 within about one minute during 
exercise [53].  
A number of recent studies on breath analysis for the diagnosis of lung cancer 
have been based on the analysis of breath samples by GC-MS techniques. A large 
combination of VOCS that either increase or decrease in concentration if cancer is 
present has been identified [54]. Feinberg and co-workers investigated the volatile profile 
before and after an oral glucose test in patients suffering from lung cancer. The findings 
suggested that the oral glucose tolerance test has low effect on the tumour cells 
metabolism [55]. A cross-sectional study, carried out by Phillips et al. proposed that 22 
VOCs are found in patients with lung cancer [2].  
In order to support the study of volatiles in breath and understand better the 
metabolism and their physiological processes involved, several studies have focus on the 
investigation of volatiles emission from growth medium [55]. Feinberg and co-workers 
investigate the volatile profile of lung cancer cells by PTR-MS. They found that lung 
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cells had a distinct sub-population depending on the activity of the mitochondrial cells 
which can be discriminated by a different volatile profile [56]. 
In particular, O’Hara et. al investigated the profile of volatiles of bacterial cultures. The 
finding suggested that there were unique molecular marker for the bacterial culture which 
was independent of the culture growth [36].  
 
3.4 Methods of Alveolar Breath Sampling collection  
Lack of standardization and sampling procedures has led to differing results and 
conclusions. Although a number of groups have suggested a standardized practise in 
breath analysis, it is still not being commonly used and so it has not been established in 
the breath community [57]. A problem is in part associated with the fact that no one 
method may be suitable, depending on the disease and volatiles. 
Following an established method for collecting breath samples is crucial to have 
reproducible results. The difficulty in breath collection is that exhaled breath is not an 
homogenous sample. For this reason, breath should be sampled under specific protocol 
and controlled sampling procedures [58]. The challenge in breath sampling is the 
separation and collection of the alveolar breath from the dead space (volume of breath 
contained in the upper airways). The aim in breath analysis for biomarker discovery is to 
be able to determine when the alveolar phase is reached. For this CO2 levels could be 
monitored during breath sampling. 
For PTR-MS, and especially where breath to breath analysis is being done in real-
time it is possible to monitor for instance acetone levels to ascertain when the alveolar 
Chapter 3. Breath analysis for clinical diagnosis 
45 
 
phase has been reached. However, this is limited because the PTR-MS can not be brought 
to a patient. 
The sampling of VOCs in breath can be undertaken following two different methods. In 
the off-line analysis, the sample is collected in bags, canisters, syringes or using pre-
concentration methods such as needle traps. In contrast, for on-line breath gas sampling, 
patients are able to breath directly into the instrument and the sample is analysed in real 
time [59]. In this way, certain problems due to sample decomposition and contamination 
are avoided. 
 
3.4.1 Use of capnography for alveolar breath sampling 
Capnography is a technique that gives us an excellent picture of the respiratory process 
and can be used to improve gas-sampling methods. Capnography provides a wave display 
of the carbon dioxide CO2 during the respiratory cycle. In medicine is used during 
anaesthesia and intensive care as a non-invasive analysis providing and recording CO2 
partial pressure measurements in exhaled breath over time.  
It is important to note that a capnograph will display an erratic waveform when 
there are air leaks in the airways system, tubing obstructions, disconnections and CO2 
recording apparatus fails to function normally [60]. For instance, the shape of CO2 
waveform is monitored in order to detect any malfunction in the system. The capnogram 
displays a uniform and stable shape when CO2 measurements are acceptable. Whereas a 
capnograph shows an irregular and anomalous shape of CO2 waveform when there is a 
dilution of expired CO2 in the system. 
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The end of exhalation, called end-tidal CO2, (Et-CO2), is correlated with the alveolar 
phase in exhaled breath. Et- CO2 represents the maximum concentration of CO2 or partial 
pressure expressed as a percentage or in units of mmHg. The Et- CO2 is measured by a 
sensor located between the patient airway and the capnograph.  
The technology is based on infrared spectroscopy (IR). CO2 absorbs in the IR part 
of the electromagnetic spectrum at very specific wavenumbers (usually the line at 2350 
cm
-1
 is used) [61]. Detecting these energy absorptions, using an appropriate photo 
detector sensitive in this spectral region, allows CO2 concentrations in a gas sample to be 
easily determined.  
The capnograph monitor displays the CO2 waveform which is called capnogram, 
showing the relationship of CO2 concentration versus time. The normal values are 5% to 
6% CO2 and 35-45 mmHg [62].  
Figure 3.3 shows a normal capnogram and the phases in the expiratory and 
inspiratory cycle. The first phase point A to B, represents the end of inspiration. The 
phase from B to C represents the beginning of expiration, exhalation of CO2 free gas from 
the anatomical and apparatus dead space. This is the first step in exhalation. From point C 
to D the volunteer begins to exhale additional CO2 from the connecting airways and 
alveoli of the lungs. This phase represents air from the alveoli and CO2 remains relatively 
constant because mainly alveolar gas is exhaled and is defined as the alveolar plateau. 
The Et-CO2 is measured at the end of the plateau (D) correspond with the highest 
concentration of CO2. Once the majority of air is exhaled from the airways, the inhalation 
begins and the increasing slope of the waveform will begin to slow down (D-E). Oxygen 
fills the airways and CO2 levels decreases back to zero. 
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Uncontrolled breath sampling has been shown to be unreliable. For the correct analysis of 
exhaled breath it is crucial to monitor and collect only the alveolar phase of the volunteer 
breath. Previous investigations have determined the impact of sampling methods on the 
analysis of VOCs in exhaled breath. A higher concentration of volatile organic 
compounds in alveolar breath samples is found compared to mixed exhaled breath 
samples [63]. 
 
  
 
 
 
 
 
 
 
Figure 3.3 Phases in the expiratory and inspiratory cycle. 
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Figure 3.4 shows a picture of the capnometer used in this study to control the expiratory 
and inspiratory phases. It is a mainstream capnogard model 1265 from Novametrix 
Medical Systems, INC (Wallingford, USA).  
 
 
Figure 3.4 Capnogard 1265 from Novametrix. 
 
 
In figure 3.5 a screen close-up is shown in which the phases in the expiratory cycle can be 
clearly identified.  
 
 
 
Figure 3.5 Photograph of a screen display on a capnograph. 
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This capnograph is a small and light portable instrument that completes a self-testing and 
auto-calibration within minutes. The capnogard provides a screen display with 
information of the end tidal CO2 with an alarm set event.  
 
3.5 Optimization of a Breath Sampling Protocol 
The first aim was to improve breath-sampling techniques for off-line analysis. The main 
goal of this study was to establish the most suitable method for breath sampling collection 
and the optimal cleaning protocol for this investigation. There is no adopted breath 
collection method for the analysis of volatile analysis and uncontrolled breath sampling is 
not acceptable due to the high variability in the VOCs concentrations [64].  
It was necessary to test and compared the suitability of flexFoil bags and glass 
syringes in order to establish the protocol for the collection of exhaled breath. The 
investigation was focused mainly on the issues of background effects. 
 
3.5.1 Testing SKC flexFoil bags 
The figure 3.6 shows a photograph of a SKC FlexFoil PLUS bag. The manufacturer of 
SKC bags state that they are ideal for collecting and storing human breath samples for 
short period of time and can store low-level (ppb) VOCs in addition to sulphur 
compounds and low molecular weight gases. The bag (SKC FlexFoil PLUS) has PTFE 
fittings attached. This fitting has a syringe port with PTFE-lined septum for taking 
samples for using in gas chromatography mass spectrometry analysis (GC-MS).  
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Figure 3.6 Photograph of a SKC FlexFoil PLUS bag and fitting. 
 
For the collection of the breath samples in this investigation, SKC FlexFoil PLUS (SKC, 
USA) bags were tested. Prior to testing, the SKC bags were flushed three to four times 
with nitrogen to remove any remains of background contaminants and stored in an oven 
at a temperature of 45°C overnight. 
Before the analysis, the bags were flushed again with nitrogen. The content of the bag 
was analysed after cleaning and compared with the analysis of the laboratory air to 
monitor contaminations. Figure 3.7 shows a mass scan spectrum of a SKC bag 
background versus lab air background. In the figure 3.7 the mass spectrum clearly 
indicates a high background coming from the SKC bags. The SKC bags were not suitable 
for this study and therefore were not chosen for the breath collection. Thus, glass syringes 
are preferred over bags and for breath sampling. 
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Figure 3.7 Mass scan spectrum of a SKC bag background versus laboratory air 
background. 
 
 
3.5.2 Testing glass syringes 
Glass syringes (Sigma-Aldrich) were tested and compared to SKC bags in order to probe 
their suitability to collect exhaled breath. The glass syringes were tested after a 
sterilization cycle. Glass syringes were flushed with N2 several times and filled with lab 
air for the subsequent analysis. The content of the glass syringe was analysed 
immediately after the sterilization. Tests carried out showed that glass syringes were 
more suitable to use to collect breath in comparison to bags. The figure 3.8 shows a mass 
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scan spectrum of a glass syringe background compared to a mass scan spectrum of lab 
air. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Mass scan spectrum of a glass syringe background versus laboratory air 
background. 
 
For the collection of the breath samples, glass syringes (Sigma-Aldrich) with a capacity 
100 ml (graduation line) and metal luer lock tip were required. Figure 3.9 shows a 
photograph of the type of glass syringe used in this investigation. Glass syringes have 
many advantages in comparison with Tedlar bags. For instance, the fortuna optima glass 
syringes are easy to clean and sterilize using autoclave systems avoiding the inconvenient 
of high backgrounds.  
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Figure 3.9 Photograph of a Fortuna® Optima glass syringe. 
 
Glass syringes are considered more suitable for collecting and storing gases compared to 
bags [65]. They have a luer lock attachment that can be used to connect the glass syringe 
to the male or female luer or to small tubing of a respiratory system. The glass syringe 
has a plunger seal that creates a leak-free seal. Using the luer lock fittings the breath 
samples can be sealed reducing sample dilutions or contaminations with clinic or lab air. 
The cleaning method is essential factor for the reusability of the glass syringes. Glass 
syringes were tested after use and cleaning sterilization procedures. The results found that 
breath volatiles did not adsorb onto the glass. It also could not be found above the limit of 
detection any volatiles that could affect the analysis. All the concentrations measured 
during the study described in chapter 4, 5,6 were above the limit of detection of the PTR-
MS instrument. The results of this investigation showed that glass syringes can be reused 
after a cleaning sterilization protocol.  
Cleaning glass syringes in comparison to bags is quicker, safer for the material 
and more convenient. The cleaning procedure time for glass syringes sterilization takes 
only 3 minutes and the autoclave has the capability of sterilising up to 5 glass syringes in 
one cycle.  
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3.6 Breath Sampling Protocol 
A 100 ml glass syringe (Sigma-Aldrich) was coupled to the respiratory sampling device 
tubing using a 3-way luer-lock stopcock (Braun Medical Limited) to seal the respiratory 
collection system. Figure 3.10 schematically shows the sampling system used for 
collecting the breath samples for this study. 
 
 
Figure 3.10 Schematic diagram of the breath sampling device. Breath samples are only 
drawn into the glass syringes once the capnograph shows that the alveolar phase of the 
exhaled breath has been reached. Typically 3-4 breaths are needed to fill a syringe to 
100ml. 
 
 
The figure 3.11 shows a photograph of a volunteer sitting down in a relaxed state. The 
subject was asked to breathe normally into a gas tight respiratory system containing an in-
line CO2 mainstream sensor connected to a fast-time response capnometer (Capnogard 
1265 Novametrix Medical Systems Inc.).  
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Figure 3.11 Photograph showing a healthy volunteer giving a breath sample. In the right, 
the photograph shows a close up of the capnostat sensor with the airways adapter coupled 
to the respiratory breath tubing.  
 
A capnometer was used to ensure that only the end-tidal breath was collected for each 
volunteer. When the alveolar plateau of CO2 was displayed on the screen of the 
capnograph, the breath sample was manually drawn from the subject’s breath stream into 
the glass syringe. Three to four alveolar breaths samples were sampled for each 100 ml 
syringe in order to increase the precision and to reduce the statistical error. Four 
replicates were collected to examine the repeatability of the samples, in cases of 
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instrument failure or due to inappropriate handling during the measurements or in cases 
of issues in transportation.  
The breath samples collected were sealed using a 3-way stopcock connector (2 female 
luer locks) and stored in an incubator at 40°C to reduce condensation effects during the 
measurements. Following this, the content of the glass syringes were analysed by PTR-
MS. Figure 3.12 shows how the glass syringe is coupled to the PTR-MS inlet using a 
Swagelok connection. 
 
 
 
Figure 3.12 Photograph of a glass syringe attached to the PTR-MS 
 
During the measurements, in order to minimize possible condensation of breath in the 
glass syringes, the glass syringes were covered with a plastic sheet and placed inside a 
heating blanket that was maintained at 45°C. Figure 3.13 shows the heating bag and 
plastic cover. 
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Figure 3.13 Heating blanket and plastic cover. 
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4 ANALYSIS OF VOLATILE ORGANIC COMPOUNDS IN BREATH 
FROM PATIENTS SUFFERING CIRRHOSIS AND THEIR 
COMPARISON PRE AND POST-TRANSPLANT 
 
This chapter consists of a description of the analysis of breath volatiles for biomarker 
discovery and medical diagnosis relating to liver disease. The study involved patient 
recruitment, collection of the breath samples, mass spectral analysis of the breath samples 
using PTR-MS and analysis of the measurements. It is important to highlight that clinical 
research studies are challenging because of the need to recruit patients in clinical trials, to 
coordinate staff in the clinic and laboratory, liaise with physicians and patients, handle 
biological samples, manage and analyse large data sets and maintain secure database for 
the patient recruited.  
 
4.1 Introduction 
Liver disease is a major global health issue and the third most common cause of mortality 
and morbidity in the United kingdom (UK), with cirrhosis accounting for 83% of liver 
related deaths [66], this rate is increasing every year being higher in the UK than in other 
European countries [67]. The publication of the 2014 Lancet Commission on liver disease 
has highlighted how the burden of liver disease in the UK has risen sharply over the past 
few decades and is the third biggest cause of premature mortality [68]. Liver disease has a 
widespread effect not only for the patient, encompassing physical and psychological 
morbidity and mortality, but also incurring significant societal costs. 
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Figure 4.1 shows the trend in mortality from liver disease in relation to the trend in 
mortality from other causes of death in the UK [69]. It is clearly shown that only liver 
disease has been increasing since 1970.  
 
 
 
Figure 4.1 Standardized mortality rate data for common diseases in the UK. Data taken 
from the World Health Organization regional office for Europe. European health for all 
databases. WHO-HFA. Analysed by Nick Sheron [70]. 
 
It is relevant to mention that in Europe, the main causes of death among diseases of the 
digestive system are chronic liver disease and cirrhosis followed by stomach and 
intestinal ulcers [71]. Among the ten key recommendations detailed in the Lancet report 
is one to strengthen the detection of early-stage liver disease, which is essential to reduce 
disease progression. Analysis of volatiles in the breath has the potential of delivering this, 
but, only if chemical compounds can be found that are unambiguously associated with a 
diseased liver. 
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One of the main difficulties in the diagnosis of liver disease is that often patients 
suffering chronic liver disease do not present symptoms or a sign until the disease is 
advanced. Even then diagnosis is difficult and the symptoms and signs are often general 
and can be mistaken for other pathologies [70]. Unfortunately, end-stage liver cirrhosis is 
irreversible and to date patients suffering the disease can only survive with a liver 
transplant.  
Liver evaluation methods can be categorised as between those that are non-
invasive and the invasive methods. The non- invasive diagnostic techniques currently 
used are serum biomarkers, genetic tests and imaging techniques as fibroscan (FS) or 
transient elastography (TE). These techniques are not ideal and have limitations. Serum 
biomarkers are not liver specific and in case of inflammation, tend to be elevated.  
TE results require an expert clinician for interpretation [72]. Liver biopsy is 
classified as an invasive method and remains to date as the “gold standard” to grade the 
staging of chronic liver disease and fibrosis. 
One advantage of a liver biopsy is that a Consultant Hepatologist can obtain 
useful diagnostic information. Not only on cirrhosis but also on different pathologies 
related to the liver such as, liver necrosis, steatosis, liver cancer, hepatic deposits, 
cryptogenic and inflammation [73]. However, a liver biopsy has disadvantages such as, in 
sampling error, which can underestimate the grade of liver damage, and there is a risk of 
injury to the patient. Another disadvantage is that a liver biopsy is not suitable for follow 
up the disease. Cirrhosis can be missed on a single biopsy in 10%-30% of cases, 
increasing the percentage of a reliable diagnosis from 80% to 100% when several liver 
samples are analysed [74] [75].  
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Liver disease is an attractive target for breath analysis and hence has captivated the 
attention of the breath research community. A reason for this is that the liver plays a vital 
role in metabolism and performs critical functions in the human body. The liver is 
connected to two large blood vessels; the portal vein and the hepatic artery. 
The portal vein is a vessel that delivers 70-75% of the total blood flow to the liver 
and the remainder coming from the hepatic arteries. The portal vein is different in 
comparison among other organs of the human body. It is unique due to the blood supply 
to the liver. The portal vein collects the blood which comes from the capillaries of the 
gastrointestinal track such as stomach, pancreas, intestines and spleens and delivers the 
blood to the liver tissues [76].  
The hepatic portal vein does not carry blood into the heart. The function of the 
portal vein is to drain blood nutrients from the digestive track to the liver. The liver 
metabolizes and processes the metabolites in the blood before reaching the general 
circulation. Whereas the hepatic artery transports oxygenated blood to the liver. 
Blood-based VOCs produced by impaired liver metabolism will undergo gas-
exchange in the patient’s lung and are exhaled in their breath and hence may provide a 
novel method to diagnose chronic liver disease. In the case of liver disease, previous 
studies investigating breath volatiles in patients suffering with chronic liver diseases have 
proposed a large number of possible biomarkers, but generally different studies report 
different volatiles [44, 45] [77]. 
Many of the biomarkers found are volatile sulphur compounds such as hydrogen 
sulphide, dimethylsulfide (DMS) or mercaptans [77]. The compound dimethyl sulfide has 
been reported to cause the distinctive odour found in the breath of patients suffering 
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chronic liver disease known as fetor hepaticus [78]. Van den Velde et al. proposed that 
the odour exhaled in the breath discriminated patients with liver disease and was mainly 
attributed to dimethyl sulphide [43]. Various GC-MS studies reported elevated levels of 
many volatiles in the breath of patients with liver disease, including dimethyl sulfide, 
acetone, 2-butanone, 2-pentanone, β-pinene, α-pinene, and limonene [79-82]. Studies 
using soft chemical ionization mass spectrometric techniques have reported volatiles such 
as acetaldehyde, ethanol, isoprene, benzene, methanol, 2-butanone, 2- or 3-pentanone, 
heptadienol, and a monoterpene (limonene) [44]. Friedman et al. reported levels of breath 
limonene in patients suffering chronic liver disease. However the authors did not 
conclude whether the elevated concentration found and the origin of limonene were a 
consequence of the chronic liver disease or coming from the diet intake [79]. 
Ammonia is another volatile compound that is present in breath as consequence of 
a hepatic disease [82] [83]. The concentration of blood ammonia is frequently measured 
to access the severity and grade of hepatic encephalopathy (HC). HC occurs in patients 
suffering chronic liver disease. It is caused by the accumulation certain toxins and 
chemicals such as ammonia in the patient’s blood stream. The liver is impaired and not 
able to convert the ammonia into urea that is excreted from the body in the urine. Patients 
with HC become drowsy and confused. 
Spacek et al. reported differences in ammonia concentration between the breath 
ammonia and the venous blood ammonia in chronic cirrhotic patients. Concentration of 
ammonia in blood increases as a consequence of the disease, for instance, the presence of 
oral ammonia-producing bacteria, gamma-glutamyl transferase (GGT) and alanine 
aminotransferase activity (ALT) may be the reason as to why ammonia in blood is often 
over-estimated in cirrhotic patients [83].  
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Some volatiles, which have been proposed as biomarkers for liver disease, such as 
isoprene, acetone and ethanol, are not specific enough because they also result from other 
diseases or arise from numerous normal metabolic processes as previously mentioned.  
In summary, although the results of previous studies are extremely encouraging, 
only several volatile organic compounds (VOCs) are common to more than two or three 
studies and it is not useful to have hundreds of putative markers. 
If breath analysis is to progress to clinical utility, then markers must be 
definitively associated with the disease in question. This approach will provide a non-
invasive method and tool to screen large populations, allowing the follow-up of patients 
suffering with chronic liver disease. All previous studies can be regarded as hypothesis-
generating, in that they do not follow up in a second group to confirm the putative 
biomarkers.  
The study presented here investigates the VOCs related to liver disease and 
demonstrates the diagnostic potential of breath analysis and its possibilities in the 
detection of chronic liver disease. This investigation directly connects biomarkers to a 
disease. Also, this work includes an independent study to confirm that the biomarker is 
linked to the disease.  
A two-stage biomarker discovery process is reported:  
(i) Breath samples from a group of patients suffering from liver disease are first 
compared to breath samples from healthy controls.  
(ii) Post-transplant breath samples are then compared with a sub-cohort of these 
patients who went on to have a liver transplant.  
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A set of putative volatile markers is first determined by comparing patients with controls, 
and then pre- and post-transplant breath samples are examined to look for intra-individual 
differences in these volatiles. In this way, this study is hypothesis-led and uses patients as 
their own controls, thereby reducing the risk of false discovery.  
 Furthermore, the use of patients’ companions as controls and of room air samples 
minimizes the influence of any exogenous volatiles present in the home and hospital as 
confounding factors. The findings and results from this study presented in this chapter 4 
have been published in the biomedical journal of EBiomedicine supported by The Lancet 
[5].  
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4.2 Methods 
 
4.2.1 Ethical approval 
This study was established and conducted in collaboration with Dr. Andrew Holt and Dr. 
Tahir Shah, both consultant physicians employed at the liver transplant unit at the Queen 
Elizabeth Hospital Birmingham and Dr. Tony Whitehouse, Consultant Anaesthetist in the 
Intensive Care Unit (ICU) in the Department of Anaesthesia at the University Hospitals 
Birmingham NHS Foundation Trust.  
The study was approved by the regional ethics committee of Camden and 
Islington (REC reference: 13/LO/0952). Provided in the appendix of this thesis are the 
protocol documents for the permission of the study and the ethical approval application. 
The study protocol was a crucial document providing all the requirements and design for 
the proposed research study.  
The protocol consists of different details about the proposed project, such as goal 
of the study, participant selection and recruitment, actions, people and investigators 
involved in the study, locations, inclusion and exclusion criteria, and a record of consent 
and patient information forms. 
This study was conducted in agreement of the ethical principles of Good Clinical 
Practice. The study was performed according to the ethics documents reviewed by the 
research ethics committee and any amendments made were submitted to and then 
approved by the research ethics committee.  
 
 
Chapter 4. VOCs related to liver disease 
66 
 
4.2.2 Patient selection and recruitment 
Patient and control recruitment is one of the most challenging, time-consuming and 
unpredictable phases of clinical trials. A successful recruitment involves a well-
coordinated research team and plan that can be assessed. It is important to identify 
specific subjects with the right characteristic and profile, which is difficult sometimes. 
However, in the study presented, the patients recruited were well characterized by 
following the main inclusion criteria. Consultant physicians in liver medicine and 
hepatology were responsible for the edification and selection of potential participants in 
this clinical study. For this study, patients were recruited according to the approved 
protocol at the University Hospital Birmingham either from the transplant assessment 
clinic or in wards after being admitted with hepatic encephalopathy.  
In the case of follow-up clinical trial of subjects, carefully planning and patient 
tracking is needed to enhance the follow-up and avoid data lost. A deficient follow-up 
restricts the suitability of the longitudinal data. 
Once a right candidate was selected, a meeting was arranged during which it was 
discussed the goal of the study and provided all the necessary information about the 
research and all the details in clinic. In this way patients and healthy controls could make 
an informed consent. 
It is important to highlight that in this study companions of patients were asked to 
act as healthy controls as they have been breathing the same air in the recent past as the 
patient. Confounding factors such as VOCs in the clinic air were therefore better 
controlled and minimized. More importantly, patients and companions often share a diet 
and home environment with the patients, therefore long-lived VOCs that can be stored in 
fat tissues or other body compartments were also controlled. 
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The candidates were also provided with either a patient or a volunteer information 
document regarding the aim, risks of the study, number of samples required (information 
documents are attached in the appendix of this thesis). Before patient recruitment, written 
informed consent was obtained from each volunteer. Volunteers had time to agree to take 
part in the study or not. 
Candidates were asked to fill out an information sheet to provide details on their home 
environment, diet, smoking status, health and medications. During the collection of the 
breath samples a research nurse was present at the liver transplant assessment unit and 
was responsible for the collection of the consent forms and completing the patient case 
support forms, collecting patient data and ensuring the anonymity of the patients. 
Enrolled patients and controls were assigned with a unique alphanumerical code. All the 
personal data related to the patients and volunteers were held on the confidential 
password-protected databases and the master lists were not accessible outside the clinic.  
 
4.2.3 Conditioning and cleaning of the sampling system 
The glass syringes used to collect the breath samples were cleaned and sterilized in an 
autoclave prior to and after their use, following the autoclave standard operation 
procedure (SOP) to ensure that all infectious material and biological waste is inactive 
before re-used. Following the SOP cross-contaminations was prevented. 
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The procedure for autoclaving is described below: 
All the material to be autoclaved was placed inside the autoclave for a period of 20 
minutes at a temperature of 121°C. 3-way stopcocks, adult airways adapters attached to 
the capnostat CO2 sensor gas sampling ports are not reusable. Sterilization will likely 
compromise system performance and they are designed for single use. Tubing 
connections were not reusable and were disposed of after use. Figure 4.2 shows a 
photograph of the connectors and adapters used for the breath collection system in this 
study. 
 
 
 
 
 
Figure 4.2 Photograph of connector and adapters. A. 3-way-stopcock (B. Braun Medical 
Limited, UK), B. airways adapter and C. Elbow 22M/15F-15M gas sampling port 
(Intersurgical, UK). 
 
4.2.4 Breath sampling protocol  
Prior to the collection of the breath samples, patients and companions spent 
approximately 10-15 minutes sitting quietly on a chair filling out the corresponding 
questionnaire. In such a way, it was ensured that the subjects were in a relaxed state 
throughout the collection of the breath sample. For improving breath analysis, CO2 
A B C 
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controlled sampling is recommended. Therefore, the protocol for breath collection 
previously described in chapter 3 was followed. In brief, the breath of the subjects was 
only drawn into the glass syringe once the capnograph showed that the alveolar phase of 
the exhaled breath had been reached.  
During the collection of the breath samples in the case of mechanical ventilated 
patients in the intensive care unit (ICUs), an anaesthetist was responsible for attaching the 
capnometer sensor to the breathing circuit of the mechanical ventilator. Figure 4.3 shows 
a picture of an anonymous patient with mechanical ventilation during the collection of the 
breath samples after liver transplant in the ICU. The photograph shows the capnometer 
sensor coupled onto a breathing circuit tube of the ventilator. 
 
 
Figure 4.3 Photograph of a capnometer sensor attached to the breathing circuit tube. 
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After the collection, the syringes were sealed using a luer lock fitting. Each glass syringe 
was individually placed in an opaque bubble bag suitable for their transportation and 
storage. The samples were brought from the hospital to the laboratory of the Molecular 
Physics Group in a basket secured on a trolley. The time distance from hospital to the lab 
was a fifteen minutes outdoor walk. Once at the laboratory, the syringes were placed 
inside an incubator set at 40
o
C to reduce condensation of the samples. All samples were 
mass spectrometrically analysed within two hours of collection and the syringes were 
sterilized after used.  
During the measurements, syringes were placed into a purpose designed heating bag to 
control the temperature at 45
o
C in order to limit condensation, which could otherwise 
cause volatile loss in water-soluble organic compounds [3]. 
The luer stopcock was coupled to a Swagelok fitting and connected directly to the inlet of 
the PTR-MS. The inlet flow was set at 10-15 ml/min and the drift tube and inlet lines 
were maintained at 45
o
C.  
The syringes were gas tight and have minimal friction such that once the syringes 
are connected to the PTR-MS and the valve opened atmospheric pressure is sufficient to 
push the plunger in smoothly so that a breath sample was being drawn into the instrument 
at a constant flow during the measurements. 
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4.2.5  Analytical measurements and PTR-MS settings 
The instrument used for the analysis of the samples was a first generation PTR-Quad-MS 
(IONICON Analytik GmbH). In chapter 2, the instrument has been described in detail. In 
this study, the voltage across the drift-tube was set at 600 V, to provide an E/N value of 
136 ±1 Td, which is sufficiently high to reduce water clustering to reagent and product 
ions by collision induced dissociation. The drift tube was controlled and maintained at a 
pressure of 2.07 ± 0.01 mbar and temperature of 45 ± 1 C. The sequence followed to 
measure the breath samples in the lab was set following the collection time at the 
hospital, that is, from the earliest time of collection to the latest time of collection. 
Before using the samples, background measurements were taken to obtain mass 
spectra under lab air conditions to check the performance of the instrument. By providing 
the instrumental background of the PTR-MS, it was ensured that the conditions of the 
PTR-MS were adequate for the analysis. After the background analysis, a glass syringe 
containing a breath sample was attached to the PTR-MS and subsequently measured. A 
mass scan spectrum was selected using the software to control the instrument and 
generally scanned a m/z range from 20 to 200 amu with a dwell time of 0.5 seconds per 
atomic mass unit. Mass spectra of the breath samples were recorded from the average of 
three cycles for each glass syringe measured, for every participant. As mentioned before, 
4 glass syringes were used to collect breath samples for each participant. The resulting 12 
mass spectra were averaged to provide one data set for each subject with the uncertainty 
in the intensity of each spectral peak expressed as the standard error of the mean for the 
four syringes. 
The intensities of the product ion(s) associated with a given volatile were 
converted to volume mixing ratios (VMR) in units of nmol/mol by use of a standard 
procedure that relies on a calculated, compound-specific, collisional reaction rate 
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coefficient, determined using the effective translational temperature of the reagent ions 
[23]. The VMR was calculated by 
     
                          VMR =
i (MH+)
i (H3O+)
1
k t
 
109
Nd
                   Equation 4.1 
 
Nd is the number of density of the gas in the drift tube and it is determined from the 
pressure and the temperature of the measurements. The VMR is expressed in ppb and the 
Nd is given in unit of cm-3. The VMR was calculated taking into account the protonated 
water dimer. 
In this work, in order to identify and further understand the product ions of 
volatiles, pure samples of key volatiles were individually measured and analysed using 
PTR-MS to establish the m/z values of the product ions. 
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4.2.6 Details of the patients participating in the study 
In this study, 31 patients suffering from liver disease were recruited in the pre-transplant 
assessment clinic (TAC) and participated in the pre-transplant measurements. The 
following notation was used in tables and figures to name the male volunteers M and 
female volunteers F subjects. (F/M 8/23, mean age 55 years, min-max 27-71 years).  
Patients recruited were selected from the different types of liver stages. There 
were a number of aetiologies and some patients had more than one condition. Conditions 
include: alcoholic liver disease (ALD), hepatocellular cancer (HCC), cryptogenic, 
hepatitis C (CD), primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), 
autoimmune liver disease (AID), hepatitis B (HBV), non-alcoholic steatohepatitis 
(NASH), and non-alcoholic fatty liver disease (NAFLD). A summary providing the 
details of the 31 patients, including the different aetiologies, and the number of patients 
recruited with the same condition is given below in the table 4.1. 
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Table 4.1 Volunteer aetiology and number of patients recruited. 
            Aetiology Patients recruited 
Alcoholic liver disease  13 
Hepatocellular cancer 
Cryptogenic 
10 
4 
Hepatitis C 5 
Primary sclerosing cholangitis 4 
Primary biliary cirrhosis 
Autoimmune liver disease 
2 
1 
Hepatitis B 3 
Non-alcoholic steatohepatitis 1 
Non-alcoholic fatty liver disease 1 
  
 
In the second stage, 5 female and 8 male patients from the first group of 31 subjects had a 
liver transplant operation and had their breath collected and analysed after liver 
transplant. Table 4.2 shows the liver transplant patient details, including sex, age, initial 
diagnosis, histopathological results, the locations of the breath sampling pre and post-
transplant, and the number of days pre and after transplant when breath samples were 
taken. 
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Table 4.2 Liver transplant patients’ details. Including gender (female F, male M), age, 
initial diagnosis, histopathological results, location of pre-transplant and post-transplant 
breath sampling, and the number of days prior to and after transplant when breath 
samples were collected. 
P
a
ti
e
n
t 
ID
 
Age (yr) Initial Diagnosis 
Histopathological 
Results 
Location 
of pre-
transplant 
breath 
sample 
Pre-
transplant 
breath 
sample: 
days 
before 
transplant 
Location 
of post-
transplant 
breath 
sample 
Post-
transplant 
breath 
samples: 
days after 
transplant 
F1 27 AID 
Severe steatohepatitis 
(PSC) 
TAC 54 OPC 65 
F2 49 Liver Failure 
Severe hepatitis with 
multiacinar necrosis, 
seronegative hepatitis 
ITU 01 OPC 
3, 5, 
130 
F3 53 PBC Cirrhosis (PBC) TAC 74 OPC 45 
F4 58 PSC Cirrhosis (PSC) TAC 83 Ward 
5-8, 11-
15, 18, 
58 
F5 53 ALD 
Hepatocellular 
carcinoma, liver 
cirrhosis.(ALD, HCV) 
- - Ward 
2-6, 9-
12 
M1 54 ALD Severe steatohepatitis Ward 47 OPC 33 
M2 45 ALD Cirrhosis (ALD) TAC 97 OPC 22 
M3 53 ALD 
Cirrhosis ( ALD/HCV) 
Hepatocellular 
carcinoma (grade2) 
TAC 179 Ward 4, 7, 48 
M4 53 
ALD, HBV, 
HCV 
Cirrhosis (ALD, HCV, 
HBV) 
TAC 21 OPC 126 
M5 56 
ALD, HCV, 
HCC 
Cirrhosis (ALD, HCV, 
HCC) 
TAC 125 OPC 61 
M6 53 CD 
Cirrhosis with mild 
steatohepatitis 
(etiology possibly 
NASH but uncertain) 
TAC 154 OPC 22 
M7 36 CD 
Cirrhosis of uncertain 
etiology 
TAC 180 Ward 
2, 3, 6-
8, 55 
M8 67 ALD Cirrhosis (ALD) ITU 14 Ward 6 
1. The pre-transplant breath sample for patient F2 was taken approximately 10 minutes before the patient 
went into surgery. This patient was admitted with liver failure and hepatic encephalopathy. 
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In the table 4.2 diseases include autoimmune liver disease (AID), alcoholic liver disease 
(ALD), cryptogenic disease (CD), hepatitis B (HBV), hepatitis C (HCV), hepatocellular 
cancer (HCC), primary biliary cirrhosis, (PBC) and primary sclerosing cholangitis (PSC). 
Breath samples were taken at various locations including the Intensive Treatment Unit 
(ITU), Out-Patient Clinic (OPC), Transplant Assessment Clinic (TAC), and in wards.  
 
4.2.7 Data Analysis and Statistical Evaluation 
In breath analysis, the concentration of exhaled breath dramatically changes from 
exposure to indoor spaces and pollution, which is a confounding factor, and which has 
been the subject of much discussion [84]. For instance in the case of e-cigarettes and 
cigarette smoke, certain harmful substances and toxic chemicals found in tobacco or in 
the smoke can also be detected in the exhaled breath of smokers and passive smokers [9] 
[85].  
If the intensity of a product ion has a significant contribution coming from room 
air, then care must be taken when using it as a biomarker. There is no simple correction 
which can be applied to account for inhaled volatile concentrations, and it has been 
shown that simply subtracting the room air concentration is too simplistic [40] [63]. 
For this study, only the ion signal intensities in the breath sample that were at least twice 
that in the room air samples in at least half of the patients were retained for analysis. This 
resulted in a set of 40 product ions for analysis.  
Table 4.3 shows m/z values and normalised counts per second, many of which are well 
known including m/z 33 (methanol), m/z 45 (acetaldehyde), m/z 47 (ethanol), m/z 59 
(acetone) and m/z 69 (isoprene).  
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Table 4.3 m/z values and normalised counts per second, many of which are well known, 
including m/z 33 (methanol), m/z 45 (acetaldehyde), m/z 47 (ethanol), m/z 59 (acetone) and m/z 69 
(isoprene). Median (lower quartile LQ, upper quartile UQ) and range (minimum – maximum) are 
provided. NCPS refers to normalising to 50 million counts per second for the reagent ions m/z 19 
(hydronium) and m/z 37 (the protonated water dimer).  
  Patients 
(N = 31) 
Controls 
(N = 31) 
Room air 
(N = 21) 
m/z Median (LQ/UQ) Range Median (LQ/UQ) Range Median (LQ/UQ) Range 
33 77200 (64800 / 
144700) 
36600 - 
334700 
56900 (45100 / 
68700) 
32600 - 
92200 
10300 (8800 / 
14600) 
5800 - 
22300 
42 4300 (3950 / 
6290) 
3590 - 78060 4780 (3830 / 37440) 2810 -98400 3030 (2800 / 
5220) 
1550 - 
10050 
43 86200 (75100 / 
91200) 
46700 - 
186300 
86100 (63700 / 
98300) 
45100 - 
330700 
29700 (21300 / 
34400) 
10000 - 
236400 
45 66400 (50000 / 
84800) 
21500 - 
198200 
65700 (39000 / 
103100) 
24400 - 
281700 
30800 (19800 / 
40800) 
8900 - 
257700 
47 34500 (31900 / 
40400) 
15200 - 
64100 
34000 (26800 / 
37000) 
22800 - 
119800 
16800 (12200 / 
18700) 
8300 - 
29000 
49 980 (720 / 1160) 320 - 3920 880 (720 / 1160) 310-1620 450 (220 /630) 80-1310 
51 3870 (2830 / 
5890) 
720 - 12430 2480 (1850 / 3150) 1270 -6000 380 (160 /550) 40-760 
54 860 (580 / 1180) 290 - 2390 1050 (610 / 1570) 240 -30380 260 (140 /410) 40-610 
 
55 85600 (71100 / 
120400) 
37200 - 
208900 
72900 (58200 / 
117500) 
39100 - 
1114900 
5900 (4500 / 
7300) 
2100 - 
81300 
57 12220 (10150 / 
14690) 
5300 - 20300 10530 (9670 / 
12220) 
6720 -25720 4480 (3010 / 
4960) 
1970 - 
9750 
58 2750 (2060 / 
5090) 
990 - 11320 2710 (1890 /4590) 1030 -92120 650 (480 /1130) 270-8640 
59 359400 (268100 / 
719700) 
158200 - 
1119800 
269600 (219700 / 
449200) 
124600 - 
1078500 
31200 (20000 / 
119000) 
9200 - 
1616500 
61 50400 (42100 / 
57300) 
13600 - 
138200 
49500 (36800 / 
61100) 
26200 - 
121200 
13000 (9500 / 
15700) 
5200 - 
23600 
63 8580 (7370 / 
10380) 
3890 - 11780 7650 (5760 /9320) 4760 -13500 660 (510 /1050) 220-1640 
65 2340 (1960 / 
2930) 
820 - 4110 1930 (1660 /2390) 940-29660 370 (230 /520) 50-950 
67 740 (590 / 940) 280 - 3330 660 (490 /850) 280-1940 180 (110 /360) 70 - 510 
68 390 (320 / 470) 150 - 2160 430 (370 /490) 130 -4630 140 (60 /270) 20 - 630 
69 18250 (5800 / 
25890) 
2640 - 73030 11420 (7580 / 
19410) 
1890-43170 830 (550 /970) 370 - 2800 
71 8410 (5530 / 
11200) 
2580 - 16230 6020 (5040 /8130) 2230-13980 780 (660 /1090) 340 - 2460 
72 720 (580 / 920) 430 - 1500 740 (460 /910) 360-5940 230 (190 /400) 40 - 890 
73 11900 (9600 / 
17300) 
7500 - 30800 8900 (7300 /12500) 5800-25600 3300 (2500 / 
5000) 
1900 - 
16800 
74 870 (780 / 1020) 630 - 1800 780 (610 /980) 450-2020 370 (270 /540) 120 -980 
75 4450 (3370 / 
6830) 
1490 - 13400 3060 (2460 /5240) 1630-15240 1210 (890 /1650) 390 -4040 
77 2590 (1840 / 
3790) 
1010 - 7470 1740 (1330 /2920) 830-8660 360 (230 /510) 150 -2260 
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**Note the number of room air samples are less than those for patients and controls because 
some patients were recruited in the same clinic at the same time. 
 
 
All the statistical data analysis was performed using SPSS version 22. In this study the 
data sets for each volatile of interest were assessed using a Shapiro-Wilks test. Shapiro 
Wilks tests were applied to determine the data classification and were found that the data 
set were not normally distributed. In this case, non-parametric tests were used.  
             Patients (N=31)               
 
         Controls (N = 31) 
             
        Room air (N=21) 
m/z Median (LQ/UQ) Range Median (LQ/UQ) Range Median (LQ/UQ) Range 
79 1550 ( 1240 / 1990) 420 - 3150 1300 ( 980 / 2240) 600 - 13060 410 ( 300 / 560) 150 - 830 
81 5000 ( 1700 / 14170) 800 - 61880 980 ( 830 / 1270) 540 - 2270 330 ( 260 / 450) 140 - 1880 
83 1303 ( 1019 / 1905) 530 - 3084 949 ( 787 / 1556) 520 - 2959 479 ( 426 / 571) 224 - 1084 
85 2110 ( 1070 / 3960) 650 - 5070 1800 ( 1140 / 2710) 610 - 6810 400 ( 360 / 620) 230 - 1380 
87 7630 ( 5780 / 11400) 2650 - 33000 4030 ( 3470 / 4620) 2190 - 15410 830 ( 770 / 1360) 540 - 1630 
89 1480 ( 980 / 3370) 540 - 10170 870 ( 690 / 1330) 570 - 12270 480 ( 460 / 630) 240 - 2750 
93 1890 ( 1320 / 3450) 760 - 8300 1090 ( 890 / 2050) 660 - 6350 570 ( 400 / 760) 180 - 990 
95 1810 ( 1200 / 3070) 770 - 10950 1110 ( 860 / 1580) 630 - 3730 450 ( 350 / 500) 280 - 1400 
97 630 ( 550 / 930) 300 - 2010 570 ( 470 / 790) 310 - 1760 330 ( 250 / 410) 110 - 730 
99 870 ( 750 / 1250) 450 - 5640 790 ( 630 / 980) 390 - 1550 440 ( 360 / 630) 80 - 820 
101 2940 ( 2010 / 4420) 1180 - 6370 2140 ( 1820 / 3170) 1380 - 8750 1140 ( 700 / 1640) 500 - 2510 
103 700 ( 620 / 880) 450 - 2690 690 ( 530 / 910) 300 - 3790 340 ( 230 / 430) 130 - 680 
109 610 ( 470 / 860) 190 - 4920 560 ( 480 / 750) 230 - 4570 340 ( 240 / 530) 80 - 1690 
115 610 ( 520 / 860) 410 - 2430 530 ( 460 / 650) 290 - 1520 400 ( 230 / 450) 120 - 630 
135 550 ( 490 / 1100) 270 - 2300 450 ( 310 / 570) 170 - 3750 330 ( 240 / 450) 20 - 1620 
137 3027 ( 830 / 9286) 278 - 40636 409 ( 333 / 506) 97 - 1309 243 ( 72 / 387) 43 - 855 
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Mann-Whitney U-tests determined which m/z values differed between the patients and 
controls. A Wilcoxon signed rank test was used to determine which volatile 
concentrations differed between pre- and post- transplant breath samples. To compare 
blood chemistry values with breath volatiles Kendall’s tau-b correlation coefficients were 
measured. A medical diagnosis test evaluation is crucial in clinical practice to confirm the 
disease in a population and also to exclude the disease in healthy participants. In order to 
determine the performance of the method studied and to be able to achieve the diagnostic 
accuracy of the volatiles analysed, a receiver operating characteristic (ROC) curve was 
plotted using the software IBM SPSS version 22. The plot of the true positive rate (TPR) 
versus the false positive rate (FPR) generate a ROC curve [30]. The true positive rate is 
the sensitivity of the analysis and it is defined as the number of positives correctly 
identified, in this case for patients suffering liver disease.  
The true negative rate is the specificity that measures the number of negatives 
correctly identified in the analysis, in this case volunteers who participated in the study 
and were correctly identified as controls, that is healthy subject with no condition. The 
area under the receiver operating characteristic curve (AUROC) determines the accuracy 
of the study. For instance an area equal to 1 represents that the test performance is 
perfect, whereas and area under the curve equal to 0.5 shows that the method applied is 
worthless. The AUROC is the most frequently chosen method to measure the 
discrimination, it is the capability of the test to categorize participants with and without a 
certain condition. Table 4.4 shows the traditional score and the accuracy of the diagnostic 
method [86] for a ROC analysis. 
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Table 4.4 Guide for classifying the accuracy of the diagnostic method. 
 
 
AUROC 
 
 
Accuracy test 
 
0.90-1 
 
Excellent 
0.80-0.90 good 
0.70-0.80 fair 
0.60-0.70 poor 
0.50-0.60 fail 
 
 
4.3 Limonene 
D-limonene (1-Methyl-4-(1-methylethenyl)-cyclohexene), C10H16, is the most common 
natural cyclic monoterpene found in nature. D-limonene is a flavour component of the 
essential oil extracted from citrus peels such as oranges and lemons, but it is also found in 
a large variety of other fruits a vegetables. Limonene is a chiral molecule with D-
limonene enantiomer having a strong smell of oranges. Essential mint oils contain L-
limonene enantiomer with a characteristic smell of piney. Limonene can be ingested or 
inhaled as it is a common additive in commercial food and drinks. Its citrus fragrance is 
used to give the fruit flavour to foods and is used in cosmetics, perfumes, aromatherapy 
and as a cleaning product solvent [87]. The figure 4.4 shows the chemical structure of 
limonene.  
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Figure 4.4 Chemical structure of limonene  
 
 
 
 
 
 
 
 
In this study, limonene have been found in high concentration in patient’s breath who 
were suffering from chronic cirrhosis in agreement with previous studies [44]. 
 
4.3.1 Limonene headspace analysis 
In addition to this study and to better identify the fragment ions resulting from the 
reaction of limonene with H3O
+ 
in a complex breath profile. A pure commercial sample 
of d-limonene was investigated as a function of the reduced electric field by PTR-MS.  
D-limonene sample was prepared for analysis by adding 1 µl of D-limonene 
(Sigma Aldrich, UK) to a 100 ml glass bottle. A 100 ml glass syringe was coupled to the 
top part of the bottle and using a 3- ways luer lock stopcock and 10 ml of D-limonene 
headspace gas was sampled. The sample was diluted in the glass syringe with 90 ml of 
air.  
C
10
H
16
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For the D-limonene headspace analysis, the voltage across the drift-tube was varied from 
400 V-600 V at intervals of 20 V, with a range of E/N (92-138 Td). Results from the 
PTR-MS analysis of D-limonene headspace are presented in figure 4.5. 
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Figure 4.5 Product ions resulting of the reaction of D-limonene with H3O
+
. 
 
The protonated D-limonene C10H16 H
+
 was observed (m/z 137) for all of the values of the 
reduced electric field. From the results, D-limonene produces a product ion at m/z 81 
(C6H9
+
). In most of the previous studies carried out by PTR-MS, a signal is observed at 
these two masses [88]. Another ion fragment is produced with less intensity at m/z 95 
(C7H11
+
). However, the total contribution is less than 10% of the total ion signal. The ion 
peak at m/z 137 contributed to the total ion signal of 35% whereas the ion peak at m/z 81 
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contributed to the total ion signal of 55% when measured at E/N 136. This results agree 
well with the PTR-MS study carried out by Tani et al. [89]. 
4.4 Results 
For the first stage measurements, a Mann Whitney U-test was used to compare the 40 
product ion signal intensities found from the analysis between patients and controls. 
Of these 40 products ions, eight ions showed significant differences in intensities 
between patients and controls. Their m/z values and significance (p-value in brackets) are 
shown in table 4.5.  
Table 4.5 m/z values and the calculated probability (p-value) for the comparison between 
patients and controls. 
 
 
 
 
 
 
 
 
 
In the second phase, the pre and post-transplant intensities of these eight ions were 
compared using a Wilcoxon Signed Rank Test for paired samples with a significance of 
95%.  
m/z p-value 
33 < 0.001 
73 0.004 
77 0.035 
81 < 0.001 
87 < 0.001 
89 0.03 
135 0.019 
137 < 0.001 
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This eliminated m/z 89 and 135 from the putative marker set. Of the remaining ions, m/z 
33 is assigned to be protonated methanol (CH3OH2
+
) [90]. Based on previous GC and 
GC-MS studies [80, 81, 91], m/z 73 was tentatively identified as protonated 2-butanone 
(C4H8O.H
+
), m/z 77 as protonated carbon disulfide (CS2H
+
) , m/z 87 as protonated 2-
pentanone (C5H10OH
+
). CG- MS analysis confirmed m/z 81 and 137 as limonene (m/z 81 
is a fragment ion (C6H9
+
) resulting from dissociative proton transfer and m/z 137 is 
protonated limonene (C10H17
+
). Alternative, based on previous PTR-MS studies [92], m/z 
77 was tentatively identified as propyl mercaptan. 
Figure 4.6 shows box plots which summarise the results for patients, control and 
clinic air samples (a) methanol and (b) carbon disulfide (c) 2-butanone (d) 2-pentanone 
(e) limonene. For limonene the sum of the intensities of the m/z 81 and m/z 137 product 
ions was used to plot the box and whisker plot. In these plots are shown the median, 
mean, lower quartile (LQ), and upper quartile (UQ) of the VMRs in units of nmol/mol for 
each volatile. 
From the box plots it is clear that the presence of the volatiles in the clinic, in the 
wards and in ITCs has a negligible effect on the concentrations in the breath samples. 
Furthermore, the analysis is based on comparisons and the patients and controls should be 
affected similarly by the room air contaminations.  
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Figure 4.6 Boxplots showing lower quartile (LQ), median, mean and upper quartile (UQ) 
calculated volume mixing ratios (VMR) for (a) methanol, (b) 2-butanone, (c) carbon disulfide, (d) 
2-pentanone, and (e) limonene for 31 patients with liver cirrhosis and 30 controls. Whiskers are 
1.5 times the inter-quartile range and outliers are depicted by a star. 
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The results of the calculated volume mixing ratios (VMRs) are given in table 4.6 
(methanol and 2-butanone) and table 4.7 (carbon disulfide, 2-pentanone and limonene). 
The post-transplant values correspond to those for the last post-transplant sample given in 
table 4.2. Measurement uncertainties are provided in brackets. The ratios of pre- to post- 
transplant concentrations are also provided.  
Table 4.6 VMRs for the pre-transplant and post-transplant samples for methanol and 2-
butanone for all of the participants who underwent liver transplants (4 females (F1-F4) 
and 8 males (M1-M8)).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
P
a
ti
en
t Mean methanol VMRs nmol/mol 
 
     Pre           Post            Pre/Post 
Mean 2-butanone VMRs nmol/mol 
 
   Pre            Post              Pre/Post 
F1 200 (6) 190 (3) 1.1 (0.04) 18 (1.2) 11 (0.2) 1.6 (0.1) 
F2 90 (9) 230 (6) 0.4 (0.04) 16 (1.1) 15 (1.9) 1.1 (0.2) 
F3 530 (2) 78 (5) 6.8 (0.4) 21 (1.7) 12 (2.6) 1.8 (0.4) 
F4 560 (18) 71 (3) 7.9 (0.4) 19 (1.2) 12 (0.4) 1.6 (0.1) 
M1 170 (2) 120 (15) 1.4 (0.2) 26 (1.4) 14 (1.4) 1.9 (0.2) 
M2 430 (36) 81 (1) 5.3 (0.4) 13 (2.2) 15 (1.7) 0.9 (0.2) 
M3 320 (32) 86 (7) 3.7 (0.5) 55 (3.1) 46 (4.2) 1.2 (0.1) 
M4 490 (37) 93 (6) 5.3 (0.5) 38 (5.9) 23 (7.5) 1.7 (0.6) 
M5 190 (3) 320 (1) 0.6 (0.01) 15 (0.5) 17 (1.3) 0.9 (0.1) 
M6 230 (12) 79 (5) 2.9 (0.2) 30 (2.2) 12 (3.3) 2.5 (0.7) 
M7 510 (21) 160 (8) 3.2 (0.2) 19 (0.7) 24 (4.2) 0.8 (0.1) 
M8 180 (5) 86 (2) 2.1 (0.07) 21 (1.0) 12 (0.4) 1.8 (0.1) 
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Table 4.7 VMRs for the pre-transplant and post-transplant samples for carbon disulfide, 
2-pentanone and limonene for all of the participants who underwent liver transplants (4 
females (F1-F4) and 8 males (M1-M8)).  
 
 
 
 
  
 P
a
ti
en
t 
 Mean carbon disulfide VMRs 
(nmol/mol) 
 
    Pre            Post            Pre/Post 
Mean 2-pentanone VMRs 
(nmol/mol) 
 
     Pre              Post           Pre/Post 
Mean limonene VMRs 
(nmol/mol) 
 
    Pre              Post       Pre/Post 
F1 
 
4.7 (0.4) 
2.0 
(0.4) 
2.4 (0.5) 9.0 (0.8) 5.3 (0.6) 1.7 (0.2) 
7.5 
(0.6) 
3.5 
(0.6) 
2.1 
(0.4) 
F2 
 
2.4 (0.5) 
20 
(2.9) 
0.1 
(0.03) 
8.3 (0.8) 7.3 (0.6) 1.1 (0.1) 60 (4.7) 
1.1 
(0.1) 
54 (6) 
F3 
 
11 (1.3) 
2.3 
(0.3) 
4.8 (0.8) 10 (1.2) 5.7 (0.3) 1.8 (0.2) 14 (0.7) 
2.3 
(0.2) 
6.1 
(0.6) 
F4 
 
4.7 (0.2) 
2.3 
(0.4) 
2.0 (0.4) 25 (3.3) 6.1 (0.3) 4.1 (0.6) 11 (0.5) 
2.3 
(0.1) 
4.8 
(0.3) 
M1 
 
9.3 (0.6) 
2.1 
(0.4) 
4.4 (0.9) 10 (0.5) 17 (2) 0.6 (0.1) 32 (0.7) 
3.3 
(0.5) 
9.7 
(1.5) 
M2 
 
3.1 (0.1) 
2.4 
(0.5) 
1.3 (0.3) 23 (0.6) 6.2 (1.5) 3.7 (0.9) 94 (3.4) 
1.6 
(0.2) 
59 (8) 
M3 
 
18 (2.0) 
1.8 
(0.2) 
10 (1.6) 29 (1.0) 13 (1.2) 2.2 (0.2) 170 (1) 
5.7 
(0.2) 
30 (1) 
M4 
 
8.5 (1.0) 
2.6 
(0.5) 
3.3 (0.7) 38 (4.3) 9.9 (0.9) 3.8 (0.6) 110 (6) 55 (4) 
2.0 
(0.2) 
M5 
 
4.0 (0.4) 
3.6 
(0.1) 
1.1 (0.1) 21 (1.3) 6.7 (0.5) 3.1 (0.3) 
9.2 
(0.5) 
4.1 
(0.2) 
2.2 
(0.2) 
M6 
 
13 (1.9) 
2.1 
(0.4) 
6.2 (1.5) 13 (1.3) 5.1 (0.2) 2.5 (0.3) 120 (8) 
4.8 
(0.3) 
25 (2) 
M7 
 
4.9 (0.9) 
4.5 
(0.7) 
1.1 (0.3) 14 (2.6) 7.5 (0.3) 1.9 (0.4) 47 (2) 
2.6 
(0.1) 
18 (1) 
M8 
 
6.8 (0.6) 
1.9 
(0.3) 
3.6 (0.7) 8.8 (0.3) 13 (1.6) 0.7 (0.1) 
7.7 
(0.6) 
3 (0.2) 
2.6 
(0.3) 
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It should be noted that the number of days between collecting the pre-transplant and post-
transplant breath samples is variable, because it is not possible to control when subjects 
are available or when a donor liver would be found. Only for one of the patients, F2, it 
was possible to collect a pre-transplant breath sample just prior to surgery.  
However, and independent of when the pre and post-transplant breath samples were 
taken, the results in table 2 clearly demonstrate that the pre-transplant concentrations of 
these volatiles are, for the majority of patients, higher than the post-transplant levels for 
most patients. Limonene shows the largest average decrease in all patients post-
transplant. Post-transplant concentrations of limonene dropped to within the normal 
control range (median (LQ, UQ) being 2.3 nmol/mol (1.9, 3.0)) within a number of days 
for all but one of the patients, M4, for whom limonene was found to be high even some 
months after transplant.  
 
4.4.1 Longitudinal study 
In order to investigate how the VMRs changed over a period of time and to gain an 
insight of the difference changes in concentration between the key volatiles such as 
methanol, carbon disulfide, 2-butanone, 2-pentanone and limonene, breath samples were 
collected after liver transplant. In the longitudinal study, five patients participated and 
were followed up (F2, F4, F5, M3 and M7). The VMRs changed over a period of time are 
presented in the figure 4.7. The data point at day 0 for F2 was taken just before transplant 
surgery.  
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Figure 4.7 Longitudinal changes in volume mixing ratios (VMRs) in nmol/mol for 
limonene at given days after liver transplant for patients F2, F4, F5, M3 and M7. Error 
bars are smaller than the symbols. 
 
The key result is that limonene VMRs dropped gradually following transplant surgery, as 
illustrated in figure 4.7. The same data for limonene presented as normalised to the 
highest intra-individual value are shown in figure 4.8. No concentration trend with time 
was observed for the case of methanol, carbon disulfide, 2-butanone and 2-pentanone, 
their VMRs were found to have dropped to within the normal range by the time of the 
first post-transplant measurement. Patient F5 showed the highest concentration of 
limonene in breath in relation to the other subjects followed for patient F2, both females. 
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Of note, also patient F2 showed the fastest limonene elimination in breath showing a 
concentration of limonene in breath comparable to healthy volunteers after only 5 days 
after transplant. This result clearly demonstrates that the concentration of limonene in 
breath decreased after liver transplant. 
 
Figure 4.8 Longitudinal changes in volume mixing ratios (VMRs) normalized to the 
highest intra-individual value in nmol/mol for limonene at given days after liver 
transplant for patients F2, F4, F5, M3 and M7. Error bars are smaller than the symbols. 
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4.4.2 Prediction of liver cirrhosis 
 
4.4.2.1 ROC analysis 
In this study the receiver operating characteristic (ROC) curve displays the results of the 
breath study with the data taken together from the first and second study stage. The ROC 
curve is shown in figure 4.9. The ROC curve was obtained with a combination of the data 
from the box plots, the ratio of the pre- and post-transplant VMR values and the 
significance values given above imply that ions at m/z 33, 81, 87 and 137 are the ones 
that were most diagnostically useful.  
The area under the ROC curve was also individually calculated for limonene and 
it was found that limonene provided the most predictive power (AUROC - 0.91 (standard 
error 0.04)). However, the best accuracy is achieved by combining the data from 
methanol, 2-pentanone and limonene.  
The VMRs for limonene, methanol and 2-pentanone were normalised to the 
highest patient value for that volatile. These normalised fractions were simply added with 
no weightings. The model selected for the combination of these 3 volatiles predicted an 
area under the curve AUROC equal 0.95 (standard error 0.03) with a sensitivity of 97% 
and specificity of 70%.  
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Figure 4.9 Receiver operating characteristic curve for a combination of methanol, 2-
pentanone and limonene data in the study groups. 
Often patients suffering from liver disease have liver function test (LFTs) to check 
abnormal results in blood. The LFTs are liver enzyme test that detect the health of the 
liver providing information of the organ such as inflammation and damage. Liver cells 
are destroyed and altered by the disease leaking out into the blood stream. The most 
common LFTS are aspartate aminotransferase (AST) and alanine aminotransferase 
(ALT). Another routine test is measuring bilirubin in blood, which is produced in the 
liver. High level of bilirubin may predict cirrhosis, whereas a low albumin levels in blood 
can be the cause of a liver or kidney disease [93]. The United Kingdom Model for End-
Stage Liver Disease (UKELD) is a clinical scoring model used in the UK to determine 
and predict the best timing to have a liver transplant in cirrhotic patients [94]. It is a 
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calculation based on the clinical chemistry data. If the score is high, the higher the risk of 
death by the disease and the lower the time will be on the waiting list. For the study blood 
samples were routinely taken from patients and analysed in the clinical chemistry 
laboratory to diagnose the degree of injury and to check or monitoring the progression of 
the liver cirrhosis. Clinical chemistry data were available and was investigated for 
evaluation of possible correlations of common clinical chemistry values with the key 
volatiles such as limonene, methanol and 2- pentanone. The following correlations were 
checked, alanine aminotransferase, alkaline phosphatase, aspartate transferase, albumin, 
total bilirubin, creatinine, neutrophils, platelets, potassium, prothrombin/international 
normalized ratio, and UKELD.  
Kendall’s tau-b analysis showed only one correlation with a significance score 
below 0.05. This was for methanol with UKELD which had a Kendall’s tau-b coefficient 
of 0.237 (significance 0.042). Over 33 correlations were tested and no multiple testing 
correction was applied so it is possible that this is a coincidental finding.  
Correlations of key volatiles concentration with disease etiology were also 
examined. Owing to the small sample size and large number of etiologies, this was only 
feasible for the 13 patients with ALD versus the other 18 patients. The results showed 
that limonene was higher (p = 0.020) in the group with ALD than the rest, with median 
(LQ, UQ) of 19.7 nmol/mol (9.2, 63.9) for ALD versus 6.1 nmol/mol (2.9, 16.6) for all 
other etiologies. Methanol, 2-pentanone, 2-butanone and carbon disulfide showed no 
statistically significant difference. 
Correlations between the 7 volatiles of interest in the putative marker set were 
examined both within the patient and the control group using a Kendall’s tau-b test. In the 
patient group, there were 8 correlations with a significance score of < 0.05. Results for all 
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21 correlations are shown in supplementary table 3. In the control group, only two were 
significant, limonene with m/z 135 (p = 0.016) and 2-butanone with carbon disulphide (p 
< 0.001).  
These were also found in the patient group. Limonene correlated significantly 
with 2-butanone (p = 0.004), carbon disulfide (p = 0.034), m/z 89 (p = 0.001) and m/z 135 
(p < 0.001) but not with methanol or 2-pentanone. This suggests that the mechanisms for 
the presence of limonene and that of methanol and 2-pentanone are independent.  
21 correlations were examined with no multiple-testing correction applied; therefore 
some correlations may be coincidental.  
Finally, the data was also checked for correlations between the concentrations of 
volatiles and demographic markers such as age, body mass index (BMI) and sex. The 
results showed that there were no significant correlations. 
 
4.5 Discussion 
The viability of breath analysis as a non-invasive technique for monitoring and 
diagnosing chronic liver disease has been demonstrated. Key volatiles in the patient’s 
breath which are a consequence of the liver disease have been identified. In this 
investigation for the first time, VOCs have been analysed in the breath of patients with 
chronic liver disease pre and post liver transplant. The monitoring of volatiles in breath 
following a dramatic change in the condition of the patient, namely a liver transplant, has 
provided a method to attribute three diagnostically useful volatiles to the cirrhotic organ 
itself. These volatiles were methanol, 2-pentanone, and limonene, with that of limonene 
being the most significant.  
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Limonene has been found in previous breath volatile studies to be elevated in the breath 
of patients with cirrhosis compared with controls. It has also been observed in the breath 
of healthy volunteers; limonene levels found in the control group are comparable to those 
previously observed in healthy human volunteers [95].  
Limonene is an exogenous volatile not produced in the human body and it is a 
common compound naturally found in many foods and drinks; hence it would be difficult 
to avoid ingesting. To note that, previous investigation has found that alveolar breath 
composition showed a lower concentration of exogenous volatiles [63]. This is not true 
for the case of limonene, which was found in high levels in the alveolar exhaled breath of 
patients. 
Within the control and patient groups, it was found no association between breath 
limonene and diet and no correlation between having a self-reported large amount of fruit 
consumption and breath limonene concentrations.  
Once in the blood stream, limonene is metabolized by the P450 enzymes CYP2C9 
and CYP2C19 to the metabolites perillyl alcohol, trans-carveol and trans-isopiperitenol 
[96]. It has been found that levels of the enzyme CYP2C19 are reduced in patients with 
cirrhosis and that levels inversely correlate with severity of cirrhosis. Moreover, of four 
P450 enzymes tested in patients with liver disease, metabolism by CYP2C19 was found 
to decrease at the earliest stage of disease [97]. 
This is suggestive that the observed raised concentrations of limonene in breath 
arise from the inability of a cirrhotic liver to produce the appropriate metabolic enzyme 
[44]. Patient M4 is anomalous in this respect, as his breath limonene concentrations do 
not drop to the normal range post-transplant. Although his graft liver function blood tests 
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were found to be normal, this results suggest that this patient’s new liver is not producing 
sufficient enzyme to metabolise fully limonene.  
Owing to its lipophilic properties, it has been proposed that limonene which is not 
metabolized by the liver accumulates in the fat of patients suffering from liver disease. 
Limonene has a blood/air partition coefficient of 36 and an olive oil/blood partition 
coefficient of 140 [98]. Assuming that the olive oil/blood partition coefficient is close to a 
body fat/blood partition coefficient, a breath concentration of 1 part per billion by volume 
(ppbv) would translate to a fat concentration of approximately 5 parts per million by 
volume (ppmv).  
In the set of data, the highest recorded breath VMR is 170 nmol/mol which 
implies a concentration in fat of the order of 850 ppmv. A study involving women with 
early-stage breast cancer taking a high oral dose of limonene (2 g/daily for 2-6 weeks 
before surgery) found that mean limonene concentration in breast tissue was 41.3 ± 49.9 
µg/g which is much higher than that found in a control group (0.08 ± 0.13 µg/g) [99]. 
Breast tissue is primarily composed of fat [100]. It has been also demonstrated that an 
intake of freshly lemonade which is rich in D-limonene implied a significant build-up of 
D-limonene in adipose tissue in comparison to plasma [101]. 
The longitudinal changes in breath limonene of patients on successive days in the 
3 weeks after liver transplant supports the hypothesis that unmetabolised limonene 
accumulates in fat tissue. Following transplant, the metabolism of limonene increases, but 
it takes time for the limonene to be released from the fat into the blood stream. This 
explains the observed time dependence on limonene VMRs in the breath after transplant 
and its progressive elimination.  
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Of note, a similar wash-out behaviour is not observed for methanol and 2-pentanone 
presumably owing to their low solubilities in fat [102] [103]. 
Some medications are known to be CYP2C9 and CYP2C19 substrates and 
inhibitors. The possibility of the effect of medications in limonene concentrations was 
examined. Twenty patients were taking a CYP2C19 substrate (lansoprazole, omeprazole, 
propanalol, esomeprazole), 2 were taking a CYP2C9 substrate (naproxen, carvedilol), 6 
were taking both a CYP2C9 and CYP2C19 substrate and 1 was taking a CYP2C9 
inhibitor (sulfamethaoxazole). This result showed no associations of any medications 
which are CYP2C9 and CYP2C19 substrates or inhibitors with VMRs of breath 
limonene. Moreover, nine patients who were taking enzyme substrates before transplant 
were still taking them after transplant.  
Of interest is the correlation between limonene and m/z 135, because this product 
ion may come from perillyl alcohol (C10H16O), a metabolite of limonene. Unpublished 
results have shown that the reaction of H3O
+
 with perillyl alcohol leads to a dominant 
product ion C10H15
+
 resulting from dehydration of the protonated parent. Previous studies 
has shown that the elimination of limonene from the body in healthy volunteer is fast and 
it takes 24 hours to be completely cleared from the body [104].  
Dehydration following protonation is a common reaction process observed with 
many alcohols [105]. Morisco et al. also noted an ion at m/z 135 from patients with 
cirrhosis, but they assigned this to a terpene related compound [44]. The fact that a 
correlation of m/z 135 and limonene (p < 0.001) is also significant in the control group 
lends support to this assignment, because one would expect levels of a compound and its 
metabolite to be correlated in a group with well-functioning livers. It is also of interest to 
note that the correlation between limonene and m/z 89 has a very low p-value, but that 
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m/z 89 shows no discrimination between pre- and post- liver transplant. This is suggestive 
that m/z 89 arises from an independent process related to the patient’s illness, but is not 
related to the cirrhosis itself. 
The enhanced levels of methanol and 2-pentanone in pre-transplant patients could 
come from a number of sources, including diet. Elevated levels of methanol have been 
reported following consumption of alcohol or large quantities of fruit [90]. It is a product 
of the degradation of pectin by colonic bacteria, [106] and metabolism of the sweetener 
aspartame [107]. However, and in agreement with Morisco et al. [44]. it was found that 
fruit consumption cannot explain the increased methanol concentrations in the breath of 
liver patients compared to controls. Alcoholic drinks are a source of methanol, but only 
one patient reported that he had drunk alcohol within the 24 hours prior to the breath 
sampling. Methanol is metabolised in humans in the liver, mainly by alcohol 
dehydrogenase, [108] so it is possible that this mechanism is impaired when a liver 
becomes cirrhotic. Morisco et al., also found elevated methanol in cirrhotic patients 
versus healthy controls [44]. The source of 2-pentanone in breath is unknown [109]. It 
has been found in human breath, faeces, skin and urine, [110] and it has been suggested 
that lung cells produce 2-pentanone [111]. 2-pentanone was suggested as a biomarker for 
liver disease by three previous studies [44] [80, 112]. 
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4.6 Concluding Remarks 
Importantly this study provides a set of biomarkers which can be used in a future trial to 
assess the potential of breath analysis for the non-invasive diagnosis of early-stage liver 
disease. A two-stage study was performed which compares volatiles in the breath of pre-
transplant cirrhotic patients with controls followed by pre- and post- transplant breath 
samples. This has resulted in an assignment of methanol, 2-pentanone and limonene as 
markers in exhaled breath for the cirrhotic liver. It has been demonstrated that limonene 
can also be used for assessing liver function following transplant by monitoring wash-out. 
This study links limonene with the diseased organ itself, rather than simply the diseased 
patient as a whole. Breath volatiles have the advantage of the opportunity to assess the 
global function of the liver, rather than a localized test such as a biopsy.  
This work suggests the possibility of a pharmokinetic-based test study for a non-
invasive assessment of liver function which could be used for diagnosing liver disease in 
early stages. For instance, the substrate, limonene could be isotopically labelled (
13
C or 
D) and administrated to the patient suffering different early stages of liver disease. 
13
C is 
a natural, non-radioactive isotope, safe and innocuous for adults and can be safely used in 
children as well [113].  
Since limonene is poorly metabolized in patients with liver disease, it will be seen 
in patients’ breath. This will allow a quantification and monitoring of labelled limonene 
in breath without any background interference from the limonene ingested in the regular 
diet. In this way it should be possible to predict long term liver prognosis, monitoring the 
severity of liver disease pre liver transplant and then monitor the recovery with the 
biomarker disappearing in the breath post liver transplant surgery. 
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It can be also used to predict the best timing for a liver transplant in a patient or to 
followed up if a therapeutic regime is effective or not in a patient.  
Currently, physicians monitor the progression of the liver disease pre and post-
transplant using the current most common invasive liver test (LTs) such the alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST), bilirubin and albumin 
[114]. These are enzymes found in blood and they are biomarker of liver damage. These 
enzymes can be also masked by other diseases or it can take long time to appear in the 
blood. Mass spectrometry would be the fastest and most suitable technology to detect the 
labelled 
13C isotope in patient’s breath [115]. This will bring benefit to the patient and the 
NHS with faster and early diagnosis programs. The handicap is that PTR-MS has a high 
maintenance cost, but this can be solved by developing a new technology, for instance a 
portable device. For example, a device could possibly be developed based on the 
technique infrared spectroscopy (IR) to measure the isotopically labelled volatiles 
proposed in this study at more affordable cost.  
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5 ANALYSIS OF VOLATILE ORGANIC COMPOUNDS IN BREATH 
FROM PATIENTS SUFFERING WITH HEPATIC 
ENCEPHALOPATHY 
 
The aim of this study was to establish the usefulness of PTR-MS for the on-line analysis 
of VOCs in exhaled breath of patients suffering Hepatic Encephalopathy (HE). This case 
study sought to obtain data to determine if there were any differences in the volatile 
breath profiles of patients suffering with liver disease between those with HE and those 
without. In this chapter, data comparison from patients suffering with hepatocellular 
cancer (HCC) and no hepatocellular cancer (no-HCC) are presented. It is also presented 
and examined the intra-individual variation in the key VOC biomarkers discussed in the 
previous chapter, limonene, methanol and 2-pentanone.  
Finally, the results from a longitudinal study for two patients suffering from HE are 
presented which are used to examine changes in the above VOCs concentrations over an 
extended period of time.  
 
5.1 Introduction 
Hepatic encephalopathy (HE) refers to the neurocognitive changes and loss of brain 
function as a result of hepatic dysfunction. Approximately 50% of the patients with 
chronic or acute cirrhosis develop HE in the course of the illness [116]. Once the liver is 
damaged, episodes of loss of brain function may be triggered by the severity of cirrhosis. 
Depending on the severity of the illness, HE symptoms can vary but include confusion, 
disorientation, lethargy, sleep disturbance, severe personality changes, slurred speech and 
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cognitive impairment. Symptoms can begin slow and gradually get worse. Patients 
suffering HC can become unconscious and, in its extreme form, coma or death can result 
[117]. HE is caused by the action of neurotoxic substances, including ammonia and 
manganese, which are usually metabolised by the liver, persisting in elevated 
concentrations in the blood. These toxins can then cause glutamine induced changes in 
astrocytes that lead to the clinical manifestations of HE [118, 119]. HE is classified as 
overt or covert based on symptoms. Overt HE (OHE) is when the illness is clinically 
apparent whereas covert hepatic encephalopathy (CHE) is diagnosed only by cognitive 
test and the symptoms are mild. CHE was previously known as minimal HC (MHC) 
[120]. 
The most often and widely used scoring system to grade HE is the West-Haven 
criteria. This system has scores ranging from 0-4 depending on the severity and 
impairment of autonomy caused by the encephalopathy. Table 5.1 shows the West Haven 
criteria score system to grade a patient’s mental state including a clinical description. 
However, it is very difficult and challenging to diagnose a patient with MHE or grade 1. 
In order to diagnose MHE correctly, psychometric tests and neurophysiological methods 
are required rather than a simple clinical assessment. 
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Table 5.1 West-Haven diagnostic criteria. 
 
Clinical grade (0-4) Diagnostic criteria, clinical symptoms 
0 Normal 
1 Mild impairment, mild intellectual function 
2 Moderate impairment, inappropriate behavior 
3 Severe impairment, disorientation, confusion 
4 Coma, unconsciousness 
 
 
HE can affect the patient’s mental function intermittently, [121] so it is possible for them 
to pass a neurological test on the day of the examination, while still suffering from 
symptoms at other times.  
Minimal HE (MHE) is difficult to diagnose and requires specialized testing. It is 
possible for patients to be suffering from undiagnosed MHE [122] [123]. There is no gold 
standard for the diagnosis of HE and many scoring systems have been criticized for lack 
of objectivity [122]. Current recommendations [124] include using the clinical HE 
staging scale (CHESS) [125], the HE scoring algorithm (HESA) [126] or modified 
orientation log (MO-log) to refine the West-Haven criteria, but their widespread use has 
yet to be adopted. 
Estimates of the incidence of MHE range from 20% to 84% of cirrhotic patients, 
depending on which testing methods are used [121]. Another established method to grade 
the HE is to measure the ammonia levels in plasma. It has been shown that ammonia 
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concentration in arterial or venous blood correlate with the grade of the HE [127] and 
high levels of ammonia in blood indicates the beginning of liver dysfunction [128]. 
Although this is a method currently used to grade the HE the link between ammonia 
levels in plasma and the severity of HE remains questionable. A possible explanation for 
these results may be the fact that ammonia concentration changes during the course of a 
day.  
Differences could also be attributed to the fact that the measurements of ammonia 
levels are strongly affected by the pre-analytical conditions [129]. Patients should be in a 
relaxed state, because difficulties in the blood sampling could increase the ammonia level 
in the plasma. Finally, the blood samples have to be quickly collected (within 15 minutes) 
and kept on ice. This is a crucial step, because it has been demonstrated that ammonia 
concentrations increase spontaneously in blood and plasma owing to the production of 
additional ammonia from the hemolysis of red blood cells [130]. 
Other methods such as imaging techniques are used to help in the diagnosis of 
HE. Brain scans may be used to rule out other conditions such as tumours in the brain. 
However, it is not possible to provide imaging procedures for all patients owing to time 
and costs.  
HE not only degrades the patient quality of life, but it means a poorer prognosis 
for a patient [131]. In cirrhotic patients after the first symptom of HE the survival rate is 
42% and, surprisingly, this rate has not improved in the last decade [132]. An early 
prognosis of HE would help to provide a better diagnosis and consequently a better 
treatment for the patient. There is therefore a need for an alternative method to monitor 
HE. This investigation puts forward the proposal that analysis of breath volatiles could 
aid in this. 
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Breath analysis for HE has been investigated in other pilot studies which used GC-MS 
involving patients with cirrhosis [112] but none of these reported limonene as a marker 
for HE. Khalid T et al. provided a model to distinguish HE in alcoholic cirrhotic patients 
with two volatiles. One volatile found was isothiocyanato-cyclohexane and it was related 
to the presence of HE. However, it is important to note that isothiocyanato-cyclohexane is 
a pollutant widely present in urban and industrial areas. The second volatile was methyl 
vinyl ketone and it was correlated with no symptoms of HE [82]. The study had a small 
number of participants and had no facilities to diagnose whether the patient suffered 
minimal HE or not. Vollnberg et. al performed a GC-MS study based on the analysis of 
breath air and tongue swabs and detected 150 compounds in the breath samples [112]. 
They identified a metabolite acetoine and 2-pentanone in patients with HE.  
 Another pilot study carried out by Arasaradnam et al. investigated HE using 
FAIMS (field asymmetric ion mobility spectrometry, portable e-nose) [133], but this 
technique unlike PTR-MS, was not able to determine precisely which VOCs were the 
cause of the discrimination. The technique is based on the comparison of VOC 
fingerprints with a database, providing an overall fingerprint of VOCs for the 
discrimination. The sample size was small in the study. Therefore, it was not possible to 
confirm whether the study detected limonene or not. Although extensive research on the 
subject has been carried out, it still remains the commitment for the “gold standard” test 
for grade and diagnosis HE because the current test based of the determination of the 
ammonia levels between cirrhotic patients without HE and with HE remains inconclusive 
with a poor prognosis.  
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In this chapter, the work of the study involving breath analysis and HE is presented. The 
findings, results and conclusions have been recently published in the IOPscience Journal 
of Breath Research [134]. 
 
5.2 Methods 
 
5.2.1 Patient and control recruitment 
Patients were recruited at the Queen Elizabeth Hospital Birmingham either from the 
transplant assessment clinic or in wards after being admitted with HE. For this study, 31 
patients suffering from liver disease participated in the pre-transplant measurements (F/M 
8/23, mean age 55 years, min-max 27-71 years). There were a number of etiologies and 
11 patients had more than one condition. Full details of the patients and their diagnoses 
was given in chapter 4 [5]. Additional patient information is presented in the Appendix to 
this thesis. 
 
5.2.2 Longitudinal measurements 
For this investigation, two patients were recruited having been admitted as in-patients 
suffering from HE. Patient M1 was a 54-year-old male with a primary diagnosis of 
alcoholic liver disease (ALD). He gave four breath samples during an admission for HE 
before his liver transplant, then three further samples after transplant.  
Patient M15 was also a 54-year-old male with a primary diagnosis of ALD. He gave 
breath samples on seven different days during an admission for HE. He did not receive a 
transplant so gave no post-transplant samples.  
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5.2.3 Breath sampling protocol 
The breath sampling protocol used to collect the breath has been explained in detail in 
chapter 4. In brief, the subjects were sat down in a calm state and capnography controlled 
sampling was used to collect the alveolar part of the breath. A breath sample was taken 
from the subject using a 100 ml glass syringe. Four replicates were collected for each 
subject.  
 
5.2.4 Proton Transfer Reaction Mass Spectrometry settings 
The analytical measurement settings have been described in chapter 4. In summary, a m/z 
range of 20 to 200 amu was scanned with a dwell time of 0.5 seconds per atomic mass 
unit. The voltage across the drift tube was set at 600 V. The drift tube was maintained at a 
pressure of 2.07 ± 0.01 mbar and a temperature of 45 ± 1 C. It should be noted that PTR-
Quad-MS has a mass resolution of approximately 1 amu so it is possible that other 
compounds or fragments could contribute to observed peaks. 
 
5.2.5 Statistical analysis 
The data sets for each volatile of interest were assessed using the statistical analysis 
explained in chapter 4. In brief, IBM SPSS version 22 was used for all statistical analysis.  
Mann-Whitney U-tests determined were used to determine whether the concentration of 
VOCs from the first stage were significantly different in patients suffering hepatic 
cellular carcinoma (HCC) with non-HCC patients. A Kruskal-Wallis one-way analysis of 
variance was used to compare the HE-now, History-HE and No-HE groups. The tests 
were calculated with a significance level of 0.95. 
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5.3 Results and Discussion 
It has previously been reported in chapter 4 that there are 4 mass spectral peaks with 
statistical differences between patients and controls. The four mass spectral peaks are m/z 
33, m/z 81, m/z 87 and m/z 137.  
Limonene was tentatively identified by comparison with studies recently 
published in the literature on breath research and the assignment based on the results of 
the identification of the limonene key product ions at m/z 81 and 137 [44]. 
In order to confirm the identity of limonene, and in an attempt to determine the 
enantiomeric composition of limonene, 4 cartridges with breath samples were sent to the 
Max Planck Institute in Mainz (Germany) for analysis by GC-MS. The GC-MS only 
provided the confirmation of the findings of limonene presence and it was not possible to 
distinguish the two limonene enantiomers (D-limonene and L-limonene). The 
measurements were not successful due to the high water vapour content in the breath 
samples cartridges and the ensuing water degradation in the GC-MS column during the 
GC-MS measurements. It would be very interesting to know the limonene enantiomer in 
patient’s breath, because previous investigations carried out in humans has indicated that 
limonene is the most abundant monoterpene in breath and blood [95]. 
In order to demonstrate how the key volatiles changed in each subgroup, the patient 
group was further subdivided into those with and without hepatocellular cancer (HCC and 
No-HCC). Figure 5.1 shows the box plots of limonene, methanol (m/z 33) and 2-
pentanone (m/z 87) for patients with and without HCC, controls and room air. Mean 
(lower quartile (LQ)/upper quartile (UQ)) are given in the figure 5.1. It was found that 
there was a difference between patients with and without HCC only for limonene, with a 
Mann-Whitney U score of significance p = 0.015. Patients were categorized in different 
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groups according to the medical status and previous condition. Table 5.2 shows the 
patient classification according to the symptoms and previous history of HE. 
 
Table 5.2 Patients HE classification.  
 
 
Figure 5.1 shows boxplots of volume mixing ratios (VMRs) calculated in units of 
nmol/mol and the comparisons for the different groups categorized by No-HE, History-
HE, HE-now, controls and room air for (a) limonene, (b) methanol and (c) 2-
pentanone.The box-plots were calculated for 21 patients with liver cirrhosis without HCC 
(No-HCC), 10 patients with cirrhosis and HCC (HCC), 30 controls and room air.  
 
 
 
 
 
History-HE No current symptoms of HE but having a history of HE before 
HE-now Having HE symptoms presently 
No-HE No current symptoms of HE and no history of HE before 
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Figure 5.2 shows boxplots of volume mixing ratios (VMRs) calculated in units of 
nmol/mol and the comparisons for the different groups categorized by No-HE, History-
HE, HE-now, controls and room air for (a) limonene, (b) methanol and (c) 2-pentanone 
for 11 patients without HE (No HE), 8 patients who have a history of HE but are not 
showing symptoms on the day of sampling (History HE), 12 patients who were suffering 
symptoms of HE on the day of sampling (HE-now), 30 controls and room air. 
 
The study of the subgroups found that in the comparison of the three patient groups only 
one volatile organic compound limonene, was revealed to successfully differentiate the 
groups with a Kruskall-Wallis score of significance p = 0.001. Figure 5.2 shows a 
noticeable differentiation between HE-now and History-HE. It was observed for the 
subgroup of No-HE that there was an overlap with the HE-now group. 
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Figure 5.1 Box-plots representation showing volume mixing ratios (VMRs) measured for (a) 
limonene, (b) methanol and (c) 2-pentanone.The box-plots were calculated for 21 patients with 
liver cirrhosis without HCC (No-HCC), 10 patients with cirrhosis and HCC (HCC),30 controls 
and room air. (Box represents lower quartile (LQ), median (Med), and upper quartile (UQ) in 
units of nmol/mol). Whiskers are 1.5 times the inter-quartile range and outliers are depicted by a 
star.  
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Figure 5.2 Boxplots representation showing volume mixing ratios (VMRs) measured for (a) 
limonene, (b) methanol and (c) 2-pentanone. 11 patients without HE (No HE), 8 patients who 
have a history of HE but are not showing symptoms on the day of sampling (History HE), 12 
patients who were suffering symptoms of HE on the day of sampling (HE-now), 30 controls and 
room air. (Box represents lower quartile (LQ), median (Med), and upper quartile (UQ) in units of 
nmol/mol).Whiskers are 1.5 times the inter-quartile range and outliers are depicted by a star. 
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From previous results, the assumption of the differences observed in limonene 
concentration in patient’s breath between No-HCC versus HCC groups could be a 
consideration of cirrhosis severity. The most interesting aspect of this assumption is that 
the initial assessment for a liver transplant is often based on the existence of a 
hepatocellular carcinoma (HCC) in the liver while the liver is still able to function 
adequately that is the liver is compensated. The analysis of the UKELD score for the 
different groups is corroborated by this consideration. 
UKELD is an average score test which integrate specific clinical chemistry data to 
predict and access the preference for liver transplantation in patients with a prediction of 
1-year mortality [135]. AUKELD score is > 49 indicates that patients meet the criteria 
and they are considered for liver transplant except for the additional evidence for liver 
transplant such as HCC. In order to demonstrate the differences in the UKELD score in 
the groups and the severity of the liver, the UKELD score was calculated for the No-HCC 
and HCC groups. Table 5.3 shows the results for the calculation of the mean (range) 
UKELD score for the No-HCC and HCC groups. These were significantly different 
(Mann-Whitney p = 0.002).  
 
Table 5.3 UKELD mean (range) score for the No-HCC and HCC groups 
               Patient ethiology UKELD score mean (range) 
No- Hepatic Cellular Cancer (No-HCC) 54 (48 – 63) 
Hepatic Cellular Cancer (HCC) 49 (43 – 56) 
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In order to demonstrate whether the patients in the HE group had a worse outcome, a 
comparable analysis was performed for the HE classifications. Table 5.4 presents the 
results for UKELD mean (range) score for the three different groups (No-HE), history of 
HE and finally HE at the time of the study. 
 
Table 5.4 UKELD mean (range) score for the HE groups.  
Hepatic Encephalopathy history                UKELD score mean (range) 
No- Hepatic Encephalopathy (No-HE) 49 (43 – 57) 
History of HE 53 (46 – 63) 
HE-now 55 (51 – 62) 
 
The data analysis revealed that there was no significant difference between the UKELD 
scores for the History-HE and HE-now groups (Mann-Whitney p = 0.21), whereas there 
was a significant difference when comparing the No-HE groups and the HE-now groups 
(Mann-Whitney p = 0.001). This is evident, in the case of the group of patients who has 
never suffer symptoms of HE has a lower UKELD score in comparison to the group 
which was suffering HE symptoms when the samples were collected. 
However, the considerable difference in limonene concentration between the 
History-HE group and the HE-now group cannot be explained by a difference in severity 
as judged by UKELD score as shown in table 5.4. Finally it should be noted that it was 
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previously reported in chapter 4, [5] that there was no correlation between the 
concentration of breath limonene and UKELD score.  
Cordoba et. al performed a observational study to examine the survival data of 1348 
cirrhotic patients admitted with acute liver decompensation. The data was compared and 
reviewed according the presence or absence of HE to investigate the risk factor for HE 
and to investigate the survival rate in patients with liver disease [136].  
The results of this study determined that one of the most crucial risk aspect for the 
development of new episodes of hepatic encephalopathy in cirrhotic patient was previous 
HE. The study showed that HE was associated to acute chronic liver failure in younger 
cirrhotics, alcoholics, with severe liver failure and systemic inflammatory reaction. 
Whereas HE was not associated to acute chronic liver failure in older cirrhotics and 
inactive drinkers.  
This study has determined that breath limonene is capable to discriminate between 
History-HE and HE-now groups. This outcome envisages the possibility to design 
monitoring tools to screen a high-risk population to improve therapies and treatments.  
In chapter four was also reported that there was no association between self-
reported consumption of fruit/fruit juice and elevated breath limonene [5]. As part of this 
study a pilot investigation was carried out with regards to the possible effect of fruit 
consumption (data not published). Three healthy young volunteers were asked to drink 
half a litre of concentrated orange juice. It was found that consumption of concentrated 
orange juice increases the concentration of limonene in exhaled breath, but this effect is 
due to mouth contamination. The levels of limonene decreased to normal levels 
comparable to the control group within 2-3 hours. In this study, it was not possible to find 
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any food intake in the patient diet or prior 24 hours of the collection of the breath samples 
that demonstrate the high levels of limonene found in their breath. 
Isothiocyanato-cyclohexane was reported by Khalid et al. as indicator for HE in patients 
with symptoms of HE, and methyl vinyl ketone as an indicator to the absence of HE 
within a group of alcoholic cirrhotics [82]. Surprisingly, they used as a method the 
presence-absence analysis in which absolute concentrations were not analysed. The 
analysis was based on the comparison between groups of the signal intensity of 
presence/absence of a volatile compound above three times of the signal to noise ratio. 
Performing this method of analysis, the results would not have differentiated between 
patients and controls due to low concentrations of limonene were also observed in the 
control group, albeit at very low concentrations. Previous investigations have detected 
limonene in the blood and in the emissions from skin of healthy volunteers, and can be 
considered a normal volatile emission from healthy humans [137]. 
Mochalski et al. carried out a study to examine the constituents of human breath 
by GC-MS, limonene was found in the blood and breath of all 28 subjects [95]. The mean 
(range) concentration in breath was 1.46 ppbv (0.27-7.42 ppbv), similar to this present 
study. Up to now, only a small number of studies have investigate the use of volatile 
organic compounds in exhaled breath for the evaluation of markers for the detection of 
HE. 
Vollnberg et al. carried out an investigation using tongue swabs and breath air to 
identify markers of HE [112] by GC-MS. Their work remains a conference abstract 
therefore insufficient details are known to make a comparison and in addition only a low 
number of patients suffering HE was used in the study. They found that acetoin (3-
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hydroxybutanone) and 2-pentanone had a better correlation than blood ammonia for the 
prediction of HE. 
This study presented, 2-pentanone was able to predict the presence of cirrhosis versus 
controls, but was not able to discriminated those with and without HE. During the study, 
volunteers were asked to indicate in the questionnaire when they last had something to eat 
or drink. This results showed that the levels of 2-pentanone were no associated with time 
since last meal. A number of studies has suggested that 3-hydroxybutanone (acetoin) give 
a protonated parent peak at m/z 89 as confirmed by PTR-MS measurements, and GC-MS 
has conclusively assigned this compound [138, 139]. 
In chapter 4, it was shown that in the initial case-control comparison, m/z 89 was 
significantly different between patients and controls. It did not, however, show a 
difference between patients pre- and post-transplant so it was rule out as being a useful 
diagnostic volatile for liver cirrhosis.  
Figure 5.3 shows the box plot for groupings of HE status for m/z 89. The boxplot 
are shown in normalized counts per second. The HE-now group is significantly different 
from the other groups, but the variation in room air is large and it overlaps with all other 
groups. An examination of the 12 patients who had a transplant shows that the 
concentration of m/z 89 in patients with and without HE is not significantly different. It is 
important to note that isomeric and isobaric compounds cannot be distinguished in the 
PTR-MS used in this study and a signal from acetoin may be confounded by the presence 
of another volatile which produced a product ion at the same m/z.  
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Figure 5.3 Boxplots representation showing volume mixing ratios (VMRs) measured for 
m/z 89 for 11 patients without HE (No-HE), 8 patients who have a history of HE but are 
not showing symptoms on the day of sampling (History HCC), 12 patients who were 
suffering symptoms of HE on the day of sampling (HE-now), 30 controls and room air. 
Whiskers are 1.5 times the inter-quartile range and outliers are depicted by a star. Note 
that only 18 room air samples are used as one sample gave a peak which could not be 
distinguished above the instrumental noise. 
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5.3.1 Longitudinal study for HE patients 
In this investigation, the changes in concentration of the key volatiles previously 
identified in chapter 4, namely methanol, 2-pentanone and limonene were observed in the 
exhaled breath of two patients suffering from HE over a period of time. The differences 
were tracked in order to predict HE changes. For this cohort, two male patients 
(identification codes M1 and M15) consented and were enrolled in the study. The patients 
were recruited previously and had been admitted suffering with HE and were followed 
over the course of their stay in hospital. 
Patient M15 had high grade HE, and had a very low mental capacity. M1 had liver 
transplantation during the course of the study so his results show four pre-transplant 
samples and three post-transplant. Figure 5.4 shows the results obtained for the changes 
in VMRs of limonene, methanol and 2-pentanone in breath of patient M15, M1 and room 
air in the longitudinal study. For M1, study days 1, 2, 3 and 4 correspond to 47, 44, 42 
and 40 days prior to transplant, respectively. Study days 5, 6 and 7 correspond to 28, 29 
and 33 days after transplant.  
All the breath samples were taken on the wards, except for study day 7 which was 
taken in the out-patient clinic. For M15, if study day 1 is taken to be on day 1, study days 
1 – 7 correspond to days 1, 2, 6, 7, 8, 9 and 15. The patient was discharged on day 15.  
What is interesting in the data is the high degree of variability from day to day.  
Despite this, from the data in figure 5.4 there is still a measureable decrease in 
breath limonene and methanol following transplant for M1. There is what appears to be 
an anomalous result for 2-pentanone for M1 on study day 6, which is, at present, 
unexplained as it was not present in the room air.  
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It is possible that the patient inhaled an environmental contaminant at high concentration 
some time before the breath test and it was still washing out.  
What can be seen from the data is that the variability for M15 is more pronounced 
than for M1. This is due to the fact that the patient had grade 3 or 4 HE for the first 6 days 
of the study. On study day 7 his acute HE had resolved sufficiently to be discharged later 
that day, although it is likely that he was still suffering from minimal HE as he had a 
recent history of repeated hospital admissions.  
It should be noted that there were difficulties in obtaining samples from M15 on 
some days of the study as his mental incapacity was such that he was unable at times to 
comply with instructions to breathe into the apparatus. It was, therefore, very difficult to 
obtain reliable end-tidal samples and it is possible that some of his samples were 
contaminated with dead-space air. The data presented must be interpreted with caution, 
because of the difficulties of the collection of samples during the course of the HE. From 
this limited evidence, the most important clinically relevant finding was that breath 
limonene cannot predict daily variations in symptoms of HE for an individual patient.  
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Figure 5.4 Scatter plots of volume mixing ratios (VMRs) for (a) limonene, (b) methanol 
and (c) 2-pentanone for patients M15 (left hand panel) and M1 (right hand panel). Breath 
concentrations are represented in black triangles and room air in red triangles. For M1, 
study days 1-4 are pre-transplant and days 5-7 are post-transplant. For patient M15, all 
days are pre-transplant, as he did not receive a transplant. The dashed horizontal line 
drawn in the figure 5.4 indicates the median of the concentration for healthy controls for 
each particular volatile. 
*
The mean is given for M1 2-pentanone as it does not include the 
outlying point. 
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5.4 Conclusion and Final Remarks 
The study has demonstrated the viability of on-line monitoring VOCs in exhaled breath 
by PTR-MS for the assessment of HE in patients with severe liver disease. It is important 
to highlight that for the first time this investigation presents a longitudinal study of VOCs 
in patients suffering HE.  
It has been confirmed from the results that limonene is higher in a patient’s breath 
with HC compared to No-HE patients, which supports the idea that limonene increase in 
breath is dependent on the severity of liver disease. Breath limonene has been reported 
higher in patients with No-HCC than with HCC. This seems to be associated with the 
severity of the cirrhosis and this idea is corroborated by analysis of the UKELD number. 
This investigation could have several applications. It could be useful for estimating 
disease severity and patient survival. It may also be useful as a timing indicator of liver 
transplant.  
Although the current study is based on a small sample of patients, the findings 
suggest that limonene concentration in breath could be used to estimate the grade of liver 
disease since it seems to be related with the severity of hepatic dysfunction. More 
research is needed to investigate this further. Research questions that could be asked 
include the relationship between HE with the key volatiles such as limonene, methanol 
and 2-pentanone.  
It is important to note that there have been reported cases of intoxication caused by tree 
tea essential oil in humans. The major components of the tree oil are terpenes and 
terpinoids and a low percentage of limonene. The symptoms reported in the case study 
were confusion, drowsiness and coma [140]. These are surprisingly similar to the 
symptoms of HE, and suggest that molecules may cross the blood/brain barrier to cause 
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neurological disorders. In all cases, the effects were transient and the patients recovered 
within a matter of hours. While this was not limonene, terpinoid oils consist of similar 
units and due to the lipophilic properties of limonene, it can be deposited in human fat 
tissue.  
Although limonene has demonstrated low toxicity, there is a lack of information 
about chronic exposure for long periods [87]. For instance, if a patient suffering cirrhosis 
has high levels of limonene in plasma for months or years, it is uncertain if it will affect 
their health status.  
These results support the hypothesis that high levels of limonene in breath are 
consequence of liver disease. This study was unable to investigate the intra and inter 
variability on a day-to-day basis. It would be very interesting to monitor changes in 
limonene levels pre liver transplant on a daily basis. This could be the subject of another 
study. This would only be possible for patients not suffering with HE. The main reason 
was due to the low number of participants in the longitudinal study. It is important to note 
that the incapability of one of the patients to follow the instructions at the breath sampling 
collection could have had implications on the high variability of the results.  
This study set out to assess the importance of limonene, methanol and 2-
pentanone to monitor of HE. This could be used to better help clinicians in HE prognosis 
and grading of HE. This study has thrown up many questions in need of further 
investigation such as the use of VOCs in breath to monitor HE. Further research should 
be undertaken with a higher number of participants to investigate the variability of 
exogenous limonene during HE in order to be able to discriminate between HE stages and 
limonene levels.  
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A cross-validation is needed using a new set of subjects from a distinct population and in 
multicentre institutions. Since there is need to have a “Gold standard treatment for HE” 
[122], the results presented provide a new insight into a non-invasive way to grade HE. 
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6 ELIMINATION CHARACTERISTICS OF POST-OPERATIVE 
ISOFLURANE LEVELS IN ALVEOLAR BREATH 
 
The first part of this chapter presents a detailed description of the reaction of H3O
+
 with 
the anaesthetic isoflurane to facilitate the identification of the product ions in the absence 
of the complex breath matrix. The next section reports the first PTR-MS longitudinal 
study investigating isoflurane in the exhaled breath of patients following surgery. Data of 
temporal profiles of isoflurane concentration of 5 patients who had undergone a liver 
transplant are presented. The aim of this study was to investigate isoflurane wash out and 
the implication on the elimination profile based on the age of patients, body index and 
health following major surgery. 
 
6.1 Introduction 
Currently the majority of breath sampling and analysis for the health sciences is research 
based [113], but these studies show there is sufficient potential for the use of breath 
analysis for medical diagnosis and screening. Unlike many other diagnostics tests, the 
major benefit of breath analysis is that it is a non-invasive way of monitoring the patient 
condition. It also offers advantages such as real-time monitoring of VOCs changes in 
expiratory air and the potential of therapeutic monitoring of VOCs of intravenous 
anaesthesia for pharmacokinetic applications during surgery. Clinicians can obtain 
pharmacokinetic parameters of anaesthesia elimination from serum or blood 
measurements [141]. The main disadvantages are that sampling blood for routine analysis 
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requires a nurse or trained personnel and it is not the favoured patient preference option 
to choose. 
Many research studies have focused on the investigation of anaesthesia 
monitoring because it provides continuous information and assessment of anaesthesia 
helping to keep the physiological state of the patient stable during anaesthesia. A 
considerable amount of literature has been published on either the monitoring of an 
intravenous anaesthetic, such as propofol [1, 4, 33, 34, 142, 143], or monitoring inhaled 
anaesthetics such as sevoflurane and isoflurane in the hospital environment, namely in an 
urological post-anaesthesia care unit [144] and sevoflurane in an operating theatre [145].  
 Some recent studies on anaesthetics pay particular attention to the investigation of 
the elimination of volatile anaesthetics from the body following surgery. Yasuda et al. 
[12] used gas chromatography with flame ionisation detection (GC-FID) to compare the 
kinetics of sevoflurane and isoflurane in humans. One interesting relevant finding is that 
they report a fast elimination of isoflurane and sevoflurane from the body, namely within 
a day the breath concentrations had decreased by an order of magnitude. However, their 
clinical trial used seven healthy male volunteers (mean age of 23 years with a standard 
deviation of 3 years). Thus, the rapid decrease in concentration may not be a true 
reflection of what happens with sick, obese and/or older people. A more recent paper by 
Ghimenti et al. [146] reports details on a study using GC-MS of post-operative 
elimination of sevoflurane and its metabolite, hexafluroisopropanol, in exhaled breath of 
six very sick patients that had undergone a variety of surgeries. They used 
pharmacokinetic models for assessing liver function. In their investigations, mixed-
expired breath samples (multiple deep breaths) were collected in disposable Nalophan 
bags. The samples were then transferred to desorption tubes for subsequent analysis. 
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They proposed that the metabolite hexafluorisopropanol is linked to CYP2E1 metabolism 
and their variation can be used as a marker for liver function efficiency.  
 The present study investigates the elimination characteristics of post-operative 
isoflurane in alveolar exhaled breath via breath analysis. Isoflurane (1,1,1-trifluoro-2-
chloro-2-(difluoromethoxy)-ethane), C3H2ClF5O) is a commonly used inhalation 
anaesthetic drug. Prior to being able to analyse the mass spectra of the post-transplant 
breath samples, it was necessary to establish which product ions result from the reaction 
of H3O
+
 with isoflurane in the drift tube environment of a PTR-MS, divorced from the 
complex chemical environment of breath. Therefore, as part of this investigation, a 
headspace analysis of isoflurane over a range of reduced electric fields 90-140 Td is 
presented. 
 For the purpose of analysis, the branching ratios have been determined using both 
clean air and CO2 enriched clean air to mimic breath, as the buffer gases in the drift tube 
of the PTR-MS. It is important to check what happens in a CO2 enriched air because the 
presence of a high percentage of CO2 could influence the internal energies of the reagent 
ions leading to different product ion distributions. These need to be taken into account 
when analysing breath samples [28] [147]. 
 To date, there has been no reliable evidence that isoflurane can be detected in 
exhaled breath weeks after being anaesthetised. As a result, questions are raised about the 
side effects of anaesthesia, including more serious complications such as, when the 
cognitive function fully returns to a patient.  
 A longitudinal study of post-transplant breath samples provides a unique 
opportunity to investigate the presence of isoflurane in the human body over time. These 
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findings have implications on how quickly patients can safely return to a normal life. The 
results from this investigation presented in this chapter have recently been published in 
the IOPscience Journal of Breath Research [148]. 
 
6.2 Methods  
 
6.2.1 Isoflurane headspace analysis  
Isoflurane (CAS Number 26675-46-7) was purchased from Sigma Aldrich (UK). 
Isoflurane samples were prepared for analysis by adding 1µl of isoflurane into a 100 ml 
glass bottle. Figure 6.1 shows the chemical structure of isoflurane.  
 
 
Figure 6.1 Chemical structure of isoflurane 
 
 
A 100 ml glass syringe was then coupled to the top part of the bottle using a 3-way luer-
lock stopcock and 10 ml of the isoflurane headspace gas was sampled. The isoflurane 
sample was then diluted in the glass syringe with 90 ml of clean air or CO2 enriched clean 
air (4% carbon dioxide, 17% oxygen and 79% nitrogen (Scientific and Technical Gases 
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Ltd (STG, Staffordshire, UK)). The concentration of the isoflurane was sufficiently low 
that no depletion of the H3O
+
 signal was observed. 
 
6.2.2 Ethical approval 
The study was approved by the regional ethics committee of Camden and Islington (REC 
reference: 13/LO/0952).  
 
6.2.2.1 Patient selection and recruitment 
For this case study, 5 patients were recruited (3 females, 2 males) with a mean age of 50 
years (min-max 36-58 years) at the University Hospital Birmingham from the transplant 
assessment clinic. Patients were informed in detail about the procedure of the research 
and writing informed consent was obtained.  
Breath samples were collected from 5 patients who underwent liver 
transplantation and they were followed up several weeks following surgery. Table 6.1 
summarises the details of these 5 patients, with each patient being just identified by sex 
(F or M) and a number, which was used in the previous study mentioned in Chapter 4 and 
retained here for comparison [1]. Note that the number of samples and the days at which 
breath samples were taken varies because of the availability and health of the patient. 
Patients were followed from the Intensive Care Unit after their transplant, through to the 
wards until their discharge. Some patients recovered and were discharged quicker than 
others so there are fewer data points for them.  
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Table 6.1 Patient identification and details for the isoflurane study. Including sex (female 
F, male M), age, location of post-transplant breath sampling (Out-Patient Clinic (OPC) or 
Ward), and number of days after transplant when breath samples were collected.  
 
P
at
ie
n
t 
ID
 
 Age   
(year) 
Location of post-transplant 
            breath sample 
Post-transplant breath   
samples: days after 
transplant 
 
F2 
 
49 
 
OPC 
 
3, 5, 130 
F4 58 Ward 5-8, 11-15, 18, 58 
F5 53 Ward 2-6, 9-12 
M3 53 Ward 4, 7, 48 
M7 36 Ward 2, 3, 6-8, 55 
 
 
 
6.2.3 Breath sampling protocol 
In this current study breath samples were collected following the protocol detailed in 
Chapter 4 [5]. In summary, capnometer controlled sampling was used to collect the 
patient’s breath. Four glass syringes of 100 ml were taken for each patient. Within two 
hours after collection, breath samples were mass spectrometrically analyzed by PTR-MS, 
for which the syringes were maintained at a constant temperature of 40 
o
C using a heating 
bag (Infroheat, Wolverhampton). This was done to limit condensation, which could 
otherwise lead to volatile loss. The outlet from each syringe was connected directly to the 
inlet of the PTR-MS.  
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6.2.3.1 Investigation of glass syringes for the collection and storage of isoflurane breath 
samples  
The study aimed to investigate the suitability of the use of glass syringes for the storage 
of isoflurane. For that investigation, 3 glass syringes were filled with isoflurane and 
stored at room temperature for a period of time to evaluate the stability of isoflurane. 
Analysis of the samples was performed at time 0, 1 hour, two hours and 48 hours. Figure 
6.2 presents the results of the variability in concentration of isoflurane in glass syringes. It 
is important to highlight that storage condition greatly affects the decay of VOCs in 
breath. The results show that within two hours there was no significant loss of isoflurane 
in the glass syringe. Therefore, glass syringes are a convenient collection method to store 
isoflurane gas during a period of time less than two hours. 
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Figure 6.2 Isoflurane concentration (Ncps) versus storage time (hours). 
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In addition to taking breath samples from controls as described in [1], samples of air in 
the locations where the patients were seated were collected so that allowances for any 
background isoflurane could be taken into account. Hospital room air was collected every 
time breath samples were taken using glass syringes (2 syringes for every sample), which 
were analysed in the same way as the breath samples.  
Data from the isoflurane concentration in the hospital environment show that the 
maximum concentration for any of the sampling days was at 4 ppbv. There was one 
exception to this when 13 ppbv was measured for one patient, F4, who was in a small 
enclosed room with poor ventilation, and therefore the patient was almost certainly 
contaminating the air with her own breath. Interestingly, any contribution to the 
isoflurane signal from the environment is negligible compared to that in the breath. 
 
6.2.4 Analytical measurements and PTR-MS settings 
The analysis of the samples was carried out using a PTR-Quad-MS (IONICON Analytik 
GmbH). The instrument has been described in detail in Chapter 2. In brief, the instrument 
setting for this investigation was a DT voltage at 600V to provide an E/N value of 136 ±1 
Td. All the breath samples were measured at a DT pressure of 2.07 ± 0.01 mbar and 
temperature of 45 ± 1 C. For the headspace analysis the voltage across the drift-tube was 
changed from 400 V to 600 V at intervals of 20 V, E/N (96-138 Td).  
Mass spectra of the breath samples were recorded and the intensity of the mass 
spectra converted to a volume mixing ratio (VMR) by use of a standard procedure that 
relies on the use of an experimentally measured reaction rate coefficient and reagent and 
product ion counts [23]. 
 Chapter 6. Post- operative elimination of isoflurane anaesthetic 
 
133 
 
6.3 Results and Discussion 
6.3.1 Headspace analysis of isoflurane 
In this investigation, a headspace analysis of an isoflurane sample was analysed to obtain 
details on the product ions resulting from the reaction of isoflurane with H3O
+
. 
Product ions and their intensities were measured as a function of the reduced electric 
field. This study showed that for any value of the reduced electric field no protonated 
isoflurane (m/z 185) was observed. This agrees with the SIFT-MS results of Wang et al. 
who conclude that once formed the excited protonated parent spontaneously dissociates 
via various pathways [149]. However, in comparison to Wang et al. SIFT-MS (thermal 
energy) measurements, this study found substantial differences in product ions and their 
branching ratios. A possible explanation for this might be that due to the fact that 
reactions in PTR-MS are non-thermal. The results from the two studies are compared in 
table 6.2 for a reduced electric field of 138 Td. Assignments have been added by taking 
into account chlorine isotopes. For the PTR-MS studies, the product ion branching 
percentages have an error of approximately ± 20%. 
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Table 6.2 m/z values proposed product ions and branching ratio percentages resulting 
from the reaction of H3O
+
 with isoflurane using PTR-MS and SIFT-MS [149]. 
 
 
m/z 
 
Proposed 
Product Ion 
PTR-MS  
      % 
SIFT-MS [149] 
        % 
51 CHF2
+
 12 - 
67 CF2HO
+
 - 15 
67/69 CHFCl
+
 50 - 
99 CF3CH2O
+
 - 10 
117/119 CF3CHCl
+
 6 30 
119/121 CF3CFHOH2
+
 - 25 
147*/149 CF3HOCHClCH
+
 - 10 
163/165 CF3CClOCF
+
 24 - 
165/167 CF2HOCHClCF2
+
 8 10 
* In the paper by Wang et al. the ion at m/z 147 is incorrectly assigned as 
CF2HOCHClCH
+
.  
 
Another ion involving isoflurane was observed at m/z 181 which is assigned as a 
secondary (association) reaction of C3F4OCl
+
 with H2O, but its intensity was low and is 
therefore not included in the table 6.2. 
Wang et al. assigned their peak at m/z 67 to be CF2HO
+
 rather than CHFCl
+
. They 
also claim product ions which were not observed in this study at m/z 99 (CF3CH2O
+
), m/z 
119 (CF3CFHOH2
+
), and m/z 147 (CF2HOCHClCH
+
). 
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To date, previous studies in breath volatiles have highlighted the importance to take into 
account factors such as the humidity and the CO2 content for calibration purposes and 
samples storage [57, 147] to limit losses of VOCs concentrations [65] or avoiding 
systematic errors. For instance, humidity is considered a relevant factor in breath 
analysis. Humidity enhances volatiles losses depending on the chemical stability of the 
compound stored. For instance, humidity in breath can lead to solvation therefore there is 
a loss of volatiles by dilution. In Tedlar bags, volatiles losses are principally from 
diffusion through the surface of the bag [147]. On the other hand, it has been 
demonstrated that increasing CO2 can lead to enhanced water clustering to the reagent ion 
in PTR-MS. The outcome is an overestimation of the concentration of the VOCs. Keck et 
al. [28] have already demonstrated that higher CO2 concentrations in the drift tube buffer 
gas of a PTR-MS enhances the concentration ratio of the protonated water dimer to 
protonated water and changes the mass spectra of key breath gases such as methanol, 
ethanol, 1-propanol, 2-propanol, acetone and isoprene. 
For this investigation and given that the product ion branching ratios were 
obtained using normal air in the drift tube, a question remains as to whether the presence 
of higher CO2 concentrations in breath could affect these ratios through thermalisation 
effects as a result of collisions of H3O
+
 with CO2 prior to reaction with isoflurane. 
Therefore, a headspace analysis using CO2 enriched (4%) air in the drift tube was carried 
out to determine if the product ion distributions associated with isoflurane would be 
altered when analysing the breath samples.  
Table 6.3 shows the information of the product ion percentages resulting from the 
reaction of isoflurane anaesthetic gas with H3O
+
 in buffer gas containing either (a) clean 
air or (b) 4% CO2 enriched clean air as a buffer gas. The figure 6.3 summarises the results 
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of the product ion percentage branching ratios as a function of reduced electric field 
resulting from the reaction of H3O
+
 with isoflurane using (a) normal air and (b) CO2 (4%) 
enriched air as a buffer gas. The data are provided because different PTR-MS users use 
different reduced electric fields and also because of the major differences observed in the 
product ions and branching ratios compared to the only other headspace analysis by 
Wang et al. 
The results show that within experimental uncertainty, no significance difference 
in product ion percentage branching ratios is observed between normal and CO2 enriched 
air buffer gases. 
As previously stated, humidity strongly affects hydrophilic compounds in breath. 
For instance, anaesthetics with less blood gas solubility tend to equilibrate. In this study, 
an issue that was not addressed is whether the changes in humidity [149] will affect 
isoflurane concentration, but that will be investigated in future studies. 
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Figure 6.3 Product ion percentage branching ratios of isoflurane as a function of reduced 
electric field (a) normal air and (b) CO2 (4%) enriched air. 
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Table 6.3 Product ion branching percentages resulting from the reaction of isoflurane 
anaesthetic gas with H3O
+
 in buffer gas containing either (a) clean air or (b) 4% CO2. 
 (a) 
                                                Product ion and ion branching ratio (%) 
E/N (Td) 
 
CHF2
+ 
(m/z 51) 
CHFCl
+ 
(m/z 67) 
CF3CHCl
+ 
(m/z 117) 
C3F4OCl
+ 
(m/z 163) 
C3H2F4OCl
+ 
(m/z 165) 
C3F4OCl
+
H2O 
(m/z 181) 
96 3 14 2 29 44 8 
101 2 15 2 32 40 7 
106 2 18 2 36 35 7 
110 3 22 2 37 29 7 
115 4 26 3 39 23 6 
119 5 30 3 39 18 5 
124 7 34 4 37 14 3 
128 9 39 4 34 12 2 
133 10 44 5 29 9 2 
138 12 49 6 24 8 1 
 
(b) 
Product ion and ion branching ratio (%) 
     E/N (Td) 
 
CHF2
+ 
(m/z 51) 
CHFCl
+ 
(m/z 67) 
CF3CHCl
+ 
(m/z 117) 
C3F4OCl
+ 
(m/z 163) 
C3H2F4OCl
+ 
(m/z 165) 
C3F4OCl
+
H2O 
(m/z 181) 
96 3 15 2 26 45 9 
101 2 16 2 29 42 8 
106 4 22 3 31 33 7 
110 5 27 3 33 26 6 
115 8 33 3 32 19 5 
119 9 38 4 31 15 4 
124 11 42 5 28 11 3 
128 14 46 6 24 8 2 
133 16 50 7 20 7 1 
138 18 53 7 15 6 1 
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6.3.2 Isoflurane longitudinal study 
This investigation presents for the first time the results of PTR-MS analysis of temporal 
profiles of isoflurane anaesthesia in alveolar exhaled breath of 5 patients (F/M 3/2, mean 
age 50 years, min-max 36-58 years) who had undergone liver transplant surgery. 
Isoflurane concentrations in exhaled breath were calculated by using the product ions and 
their branching ratios from the reaction of H3O
+
 with isoflurane at a reduced electric field 
of 138 Td, previously obtained in the headspace study described in section 6.2.1. The 
following products ions were used; m/z 51, m/z 67 (69), m/z 117 (119), m/z 163 (165), 
and m/z 165 (167). The m/z 69 signal intensity cannot be used directly owing to the 
presence of isoprene in human breath. Thus, the total ion signal associated with CHFCl
+
 
is determined only from the m/z 67 ion intensity. The contribution of isoflurane to the 
signal intensity at m/z 69 at the beginning of the longitudinal study was found to be 
significant and varied between 12% to 99%.  
It is important to point out that since isoflurane in breath results in a spectral peak 
at m/z 69 (CHF
37
Cl
+
) there are consequences for any mass spectrometric studies which 
may monitor isoprene in the exhaled breath following a surgical procedure during which 
isoflurane is administrated.  
Figure 6.4 presents the temporal changes in isoflurane concentrations (VMR) for 
five days after liver transplant for patients, F2, F4, F5, M3 and M7. A clinically relevant 
finding to highlight is that rapid decreases in isoflurane concentrations in patient’s breath 
following surgery was not observed. 
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These results are contrary to those found by Yasuda et al. [12] who reported that the 
elimination of isoflurane from the human body was fast. Yasuda et al. showed that within 
one day the signal intensity had been observed to have dropped by about an order of 
magnitude, whereas in this investigation high concentrations of isoflurane in a patient’s 
breath were found several days after the operation. Although the Yasuda et al. study used 
healthy young male subjects (age 23 ± 3 yrs (mean ± sd)), which implied a higher 
pulmonary function. The observed temporal difference is still surprising given that the 
major elimination of isoflurane is through alveolar ventilation. Isoflurane is poorly 
metabolised (0.17%) by hepatic cytochrome P450 enzymes in the liver [150]. Only 
0.17% of the isoflurane is broken down into the products trifluoroacetic acid (TFA) and 
inorganic F
-
 by the enzymes P-450. There is no transcutaneous elimination of isoflurane.  
Previous research has established that isoflurane requires a longer time to 
equilibrate in the blood after induction in patients with high BMI (body mass index) such 
as obese patients, which implies a longer removal time. This effect is the consequence of 
a larger fat compartment in obese patients which facilitate the absorption and retention of 
isoflurane and consequently a slower release from the fat tissue [6]. 
This unexpected finding suggests a possible explanation for the differences 
observed between these results and those of Yasuda et al. by the fact that those 
discrepancies could be associated with the physical condition of the subjects/patients 
involved (BMI) and the duration of isoflurane anaesthesia exposure. 
 
 
 
 Chapter 6. Post- operative elimination of isoflurane anaesthetic 
 
141 
 
 
 
 
 
 
 
 
 
 
 
2 4 6 8 50 52 54 56 58
0
500
1000
1500
2000
Is
o
fl
u
ra
n
e 
(n
m
o
l/
m
o
l)
 
Days after transplant
M7
 
Figure 6.4 Longitudinal changes in VMR in nmol/mol for isoflurane for given days after 
surgery for patients F2, F4, F5, M3, and M7. Error bars are smaller than the symbols. 
3 4 5 128 129 130 131 132
0
200
400
600
800
1000
Is
o
fl
u
ra
n
e 
V
M
R
 (
n
m
o
l/
m
o
l)
Days after liver transplant
F2
0 2 4 6 8 40 42 44 46 48 50 52 54
0
10
20
30
40
50
60
70
80
90
Is
o
fl
u
ra
n
e 
V
M
R
 (
n
m
o
l/
m
o
l)
Days after transplant
M3
2 4 6 8 10 12 14
0
50
100
150
200
250
Is
o
fl
u
ra
n
e 
V
M
R
 (
n
m
o
l/
m
o
l)
Days after transplant
F5
0 4 8 12 16 56 60
0
200
400
600
800
Is
o
fl
u
ra
n
e 
V
M
R
 (
n
m
o
l/
m
o
l)
Days after transplant
F4
 Chapter 6. Post- operative elimination of isoflurane anaesthetic 
 
142 
 
Yasuda et al. volunteers were healthy and had a mean body mass index (BMI) of 21.7 
kg/m
2
, i.e. all were within the normal (healthy weight) range. In comparison F2, F4, F5, 
M3 and M7 had BMIs of 31.2, 32.4, 28.0, 32.5, and 35.0 kg/m
2
, respectively. 
Table 6.4 provides further additional information of the 5 patients recruited in this 
study such as, patient ID, gender, estimated isoflurane dose administrated, duration of the 
surgery and body mass index.  
Table 6.4 Patient information, body mass index, estimated isoflurane dose and duration of 
surgery. 
 
Patient ID 
 
Gender 
Estimated 
Isoflurane dose (g) 
Duration of 
Surgery (h) 
Body Mass 
Index (kg/m
2
) 
 
F2 F 68.6 5 31.2 
F4 F 90.4 7 32.4 
F5 F 87.9 5 28 
M3 M 138.3 6 32.5 
M7 M 73.8 7 35 
*M3 and F5 had desflurane administrated as maintenance agent during their operation. 
 
 
Thus, F2, F4, F5, M3 and M7 were either overweight or obese. Although isoflurane has a 
low blood/gas partition coefficient of 1.45 ± 0.12 (mean ± SD) [151], it has a high 
oil/blood partition coefficient of 97, and therefore it is proposed that for those patients a 
significant amount of the isoflurane was absorbed into fat tissue, only to be slowly 
released after surgery. It may be the case therefore that over time, isoflurane is deposited 
as a reservoir in body fat to be slowly released when the anaesthesia is stopped, and 
 Chapter 6. Post- operative elimination of isoflurane anaesthetic 
 
143 
 
thereby prolonging any effect on the neurocognitive functions and their later recovery [6, 
152].  
In addition to this, Yasuda et al. administered isoflurane for precisely 30 minutes, 
whereas in a transplant surgery patients underwent surgeries that lasted between 5 to 7 
hours. These findings may be interpreted that doses of isoflurane administrated and the 
duration is likely to prolong the elimination of the chemical from the patients. These 
findings are in agreement with another investigation which found that if isoflurane is 
administered for more than 2 hours, as would be the case for these patients, the adipose 
tissue becomes saturated and then the emergence from the anaesthetic is prolonged [153].  
It is essential to determine any factor that can be affected by race or ethnicity. 
Previous investigations have suggested that Asians compared to Europeans with the same 
BMI have 3% to 5% higher total body fat, which could have consequences in isoflurane 
elimination from the body [154]. 
BMI is a reasonable score predictor of the body fat based on the height and weight 
of individuals. Table 6.5 shows the BMI score and the interpretation of BMI score. For 
European healthy normal weight subjects, BMI ranges goes from 18.5 to 25 whereas for 
overweight goes higher than 25 BMI [155].  
Table 6.5 BMI classification and the correspondent weight status indicator. 
BMI Weight status 
<18.5 Underweight 
18.5-25 Normal 
25-30 Overweight 
>30 Obese 
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Finally, of all of the patients, patient M7 showed the fastest elimination of isoflurane even 
though he had the highest concentration in exhaled breath after surgery and was the most 
obese patient. However, the elimination time was still larger than found in the results of 
Yasuda’s study. The rapid washout, in comparison to the other patients, could be a result 
of this patient being the youngest of the group involved at 36 years old. (F2, F4, F5 and 
M3 ages were 49, 58, 71 and 53 years, respectively.) M7 also recovered from surgery 
more quickly than the other patients in the group and was discharged within one week. 
However, with such a small number of patients it was not possible to conclude whether or 
not there is any correlation with age and perhaps gender with regards to isoflurane 
elimination from fatty tissue. Further studies should be undertaken with a higher number 
of patients to investigate the washout characteristic of different anaesthesia such as 
desflurane, sevoflurane, isoflurane, halothane between subjects with different BMI, age 
and ethnicities. 
 
6.4 Conclusion and Final Remarks 
This study has successfully demonstrated the use of PTR-MS for the non- invasive 
detection of isoflurane in the breath of patients after an operation, and highlights the 
importance of product ion identification in a complex breath matrix.  
The headspace study has shown that the protonated parent ion is not observed, 
instead the resulting protonated parent ion rapidly dissociates to diagnostically useful ions 
with m/z values of 67 (69), 117 (119), m/z 163 (165) and m/z 165 (167), which are 
assigned to be CHFCl
+
, CF3CHCl
+
, C3F4OCl
+
 and C3H2F4OCl
+
, respectively. The present 
study makes several noteworthy contributions to the breath research community and 
suggests that m/z 69 cannot be used to monitor isoprene if patients have previously been 
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administrated with isoflurane anaesthesia. This investigation reports for the first time 
temporal changes in the concentrations of isoflurane in the breath of patients after major 
surgery and demonstrates that high levels of isoflurane remain in patients for several 
weeks.  
In this investigation, isoflurane elimination is much slower than previously 
reported. This research provides a framework for the exploration of the implications of 
this prolonged release. Understanding the elimination of isoflurane is crucial for an 
appropriate administration and consequently improvement of patient safety. Also this 
work is beneficial for the use as conceptual premise for future clinical trials of 
metabolism recovery in different anaesthetics, such a sevoflurane, enflurane, halothane, 
desflurane and methoxyflurane. 
Although the current study is based on a small sample of participants, it suggests 
that it could have an impact on a patient’s ability to drive and use machines after 
isoflurane anaesthesia administration, especially after a long period of exposure to the 
anaesthesia such as for long surgeries. 
Further studies need to be carried out in order to validate this investigation with a 
complete new set of patients and to estimate the average time to fully recover from the 
anaesthesia. Large controlled trials are required to assess the impact of isoflurane wash 
out in the neurocognitive function of patients focusing on current physiological factors 
such as age, ethnicity, etc.  
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7 FURTHER DISCUSSION 
 
In the final chapter the significance of the major findings from the work presented in this 
thesis are summarised. The purpose here is to highlight the outcomes and the goals 
achieved. In the final section of this chapter, possible future directions are suggested for 
breath VOCs analysis. 
 
7.1 Key Conclusions and Summary of Findings 
 
7.1.1 Applicability of PTR-MS for the detection of gas trace volatiles in breath and 
headspace analysis 
The work presented in this thesis confirms the potential of the analytical technique of 
PTR-MS as a useful tool for breath analysis to detect trace quantities of VOCs for 
medical applications. The fast response and high sensitivity allows for the quantification 
of trace volatiles and the subsequent temporal changes to be observed. In addition, it has 
been shown that PTR-MS was suitable to analyse headspace of anaesthetics. 
 
7.1.2 Breath collection 
In chapter 3, the use of a non-invasive sampling protocol for the off-line measurements of 
breath samples was demonstrated for the implementation and development of 
reproducible breath collection procedures.  
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Given the variability when measuring exhaled breath and the impact of confounding 
factors on their composition, in this investigation multiple breath samples were collected 
thereby improving the reliability of the analysis. This study showed a better-defined and 
reproducible composition of breath samples. 
The key improvement was related to breath sampling procedures, with the breath 
sampling being controlled by a capnograph allowing only the collection of end-tidal 
phase of the exhaled breath sampled in order to minimize sample dilution. In addition to 
this, and for each individual measurement, the use of multiple alveolar breath samples 
collection improved the statistics. 
 
7.1.3 Patient recruitment  
A key improvement was the use of patient’s companions as controls, thereby decreasing 
the risk of confounding factors such as exposure effects, and the recruitment of patients as 
their own controls for the second phase during the post-transplant study as described in 
detail in chapter 4. 
 
7.1.4 Inclusion of a longitudinal study design of VOCs 
The incorporation of a longitudinal design study allowed an in-depth observation of key 
VOCs and track their changes in concentration through time. For the first time this 
research was able to show wash out characteristics of VOCs in a cohort of patients after 
liver transplantation. This provided an improved accuracy to determine diagnostically 
useful VOCs.  
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Depending on the clinical study, it can be more important to measure longitudinal 
changes in VOC concentration than simply taking a breath sample at one particular time. 
The inclusion of a study to monitor changes in the key volatiles as a function of time 
unambiguously showed that the raised levels of limonene, methanol and 2-pentanone in 
the breath of patients pre-transplant are a direct result of chronic liver disease. Finally, 
this investigation highlights that breath analysis has the potential to assess liver function 
after liver transplantation.  
 
7.1.5 Breath analysis for the detection of liver disease. Comparison of pre and post- 
breath samples 
The detailed investigation focused on patients suffering from advanced liver disease. The 
study compared for the first time breath samples from pre and post- transplant patients in 
order to rule-out VOCs not resulting from the illness, but specific to liver disease. 
This was a key procedure adopted in the liver disease study. The study has gone some 
way towards enhancing the understanding of why limonene is observed at elevated 
concentrations in the breath of patients with liver disease. 
 
7.1.6 Breath analysis for the monitoring of HE 
In this investigation, it has been demonstrated that breath analysis is a useful tool for the 
detection of complications caused by chronic liver disease such as hepatic 
encephalopathy. In addition to this, the findings complement those described in chapter 4. 
The study has gone some way towards enhancing the understanding of why limonene is 
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observed at elevated concentrations in the breath of patients with liver disease. In this 
investigation, limonene in exhaled breath is higher in patients who have current 
symptoms of HE compared with patient with liver disease but no HE. For the first time, 
the time dependence of VOCs was studied as the condition changed. HE is the end 
consequence of either chronic liver disease or acute liver damage, therefore high breath 
limonene may simply be a proxy for advanced liver disease. 
Notwithstanding the relatively limited sample, this investigation offers valuable 
insights which will aid any further studies using a larger sample size for examining more 
closely the links between limonene and hepatic encephalopathy. 
 
7.1.7 Breath analysis for anaesthesia monitoring 
This study has shown that PTR-MS is ideal for the non-invasive detection of isoflurane in 
the breath of a patient after an operation. The investigation highlights the use of on-line 
monitoring mass spectrometry techniques to study longitudinal changes of anaesthesia in 
breath after surgery. The present study makes several noteworthy contributions by 
implying that in low-resolution quadrupole based PTR-MS instruments, the concentration 
of isoprene in breath after surgery is significant and confounded by the isoflurane 
concentration found in patient’s breath. This investigation strongly suggests that 
isoflurane (or any other intravenous anaesthetic) should be carefully monitored after 
anaesthesia administration depending on the technology used. These results have serious 
repercussions for breath analysis investigations which correlate isoprene to any type of 
disease or use isoprene as a biomarker. 
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In addition to this, the study provided the product ions which can be used to identify the 
presence of isoflurane in the breath. Finally, this study has thrown up many questions in 
need of further investigation. Isoflurane has been found in high concentration in breath of 
patients several days after surgery. More research is required to determine the effects and 
impact of this to ensure that cognitive function has fully returned to a patient after 
intravenous anaesthesia administration, especially after a prolonged anaesthesia 
administration during long surgeries. Further work in a larger group of participants need 
to be carried out with a range of different ages and ethnicities to better understand factors 
that affect the elimination profile of isoflurane in exhaled breath. 
The combination of these results provides support for the concept of study the 
metabolism of anaesthetics recovery, it might be possible to study different anaesthetics 
and investigate their subsequent biological effect with other drugs in humans in 
longitudinal studies. 
 
7.2 Limitations of the Study 
The investigations had a number of limitations. However, these can be overcome in any 
future work.  
 
7.2.1 Population size, ethnicity and location 
The limitation in this investigation was the low number of patients recruited, particularly 
in the follow-up study after liver transplant, the encephalopathy and isoflurane study. 
Owing to the clinical difficulties of conducting clinical research and the difficulty for 
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patient recruitment after liver transplant, only a small number of patients were involved. 
It would have been necessary to have more research personnel available to assist in the 
sampling collection and during samples measurements. A larger size study may have 
permitted more data to cross validate the results and to ensure a representative 
distribution of the affected population from liver disease. The next step towards the use of 
VOCs for liver disease detection requires larger multicentre clinical trials. Collaborative 
work between independent groups would contribute to a better understanding of liver 
disease. Although this study was limited in size, it was planned to avoid confounding 
results by using well-matched study patients. It is important to highlight that demographic 
aspects associated with liver disease may differ by ethnicity. Further investigations should 
be undertaken to understand the impact of ethnicity in liver disease. 
 
7.2.2 Project time 
It is also important to mention that clinical trials require a large amount of time to be 
completed. In this case, the time to demonstrate that the methodology was successful was 
limited. The clinical trial was limited to the time of the project funding. For instance, it 
was not possible to collect data from patients recruited for longer periods of time pre- 
transplant in order to investigate changes in key volatiles.  
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7.2.3 Off-line breath collection and sampling 
The off-line breath collection during the study was a possible limitation and the 
significance of this finding is unclear. The off-line sampling has more risk due to the 
handling of samples, which can be difficult to estimate owing the complex nature of 
breath. It is well known that the chemical stability of breath can changes due to 
condensation, evaporation and degradation effect affecting the results. This effect was 
minimised by measuring the samples within a short time period from collection and 
eliminating condensation effects by keeping warm all the samples stored. 
 
7.3 Future Directions and Further Work 
In this section recommendations for the improvement of the method, significance of the 
findings and future directions in breath analysis for the detection of liver disease are 
summarised. The work presented in this thesis demonstrates that breath VOCs analysis 
could be developed into a diagnostic procedure and used as a potential diagnostic tool for 
chronic liver disease. The results from this investigation are of direct impact and 
relevance for the diagnosis of end stage liver disease. An implication of this is that an 
exogenous compound can be used as a biomarker for chronic liver disease and that this 
compound can be used to assess liver function after liver transplantation. The findings are 
significant because of their potential to detect early stages of liver disease and hence 
reduce disease severity before the liver is irreversibly damaged.  
This thesis strongly suggest an evaluation for the diagnostic accuracy of breath 
volatiles analysis for compensated liver cirrhosis and contribute considerably to the 
development and evaluation of liver disease techniques. Larger clinical trials using breath 
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analysis methods are required to establish whether early liver disease can be detected, for 
example in patients with compensated or fatty liver.  
This study has set a pathway for the investigation and development of non-invasive 
technologies (such as a portable mass spectrometric user-friendly diagnostic point-of-care 
system) for screening, diagnosing and monitoring early stage liver disease.  
This thesis supports the idea of further investigation on key volatiles in breath to 
predict the best timing for a liver transplant or even monitor whether the patient will 
suffer liver rejection after transplantation, which cannot be foreseen immediately after 
liver transplant. More broadly, research is needed to study key volatile changes during 
liver rejection. The use of these volatiles to follow-up liver function will serve as a basis 
for future studies in breath analysis. Further research should also be conducted to 
investigate the activity of the liver function by carbon-13 breath tests using key volatiles 
as the substrate to measure the concentration of limonene and subsequent metabolites 
such as perillyl alcohol in breath avoiding background interference from the diet.  
Future large trials should take into account the impact of this investigation, and more 
work in this field would be of great help to establish a breath analysis test as a diagnostic 
procedure to detect liver disease. To conclude, it is important to mention that these 
advantages will benefit society by providing a personalized medical care improving the 
quality of life of patients and having an enormous and positive effect on savings to health 
providers.
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Appendix I Correlations between volatiles for the 31 patients and 30 controls in the 
putative marker set. Significance scores below 0.05 are highlighted in bold.  
 
  
 
Patients (N = 31) Controls (N = 30) 
                Volatiles/ m/z 
 
Kendall's 
tau-b statistic 
Significance 
Kendall's 
tau-b statistic 
Significance 
Limonene Methanol 0.127 0.158 0.057 0.656 
Limonene 2_pentanone 0.144 0.127 0.166 0.148 
Limonene 2-butanone 0.333 0.004 0.147 0.253 
Limonene Carbon disulfide 0.230 0.034 0.078 0.544 
Limonene m/z 89 0.415 0.001 0.117 0.363 
Limonene m/z 135 0.492 0.000 0.310 0.016 
Methanol 2-pentanone 0.288 0.012 -0.140 0.276 
Methanol 2-butanone 0.062 0.311 -0.101 0.432 
Methanol Carbon disulfide 0.200 0.057 0.023 0.858 
Methanol m89 0.144 0.127 0.002 0.986 
Methanol m135 0.118 0.175 0.122 0.344 
2_pentanone 2-butanone 0.127 0.158 0.087 0.498 
2_pentanone Carbon disulfide 0.028 0.413 -0.037 0.775 
2_pentanone m/z 89 0.290 0.011 0.067 0.605 
2_pentanone m/z 135 0.127 0.158 0.168 0.193 
2-butanone Carbon disulfide 0.544 0.000 0.452 0.000 
2-butanone m/z 89 0.058 0.323 0.032 0.803 
2-butanone m/z 135 0.153 0.114 0.110 0.392 
Carbon disulfide m/z 89 0.006 0.480 -0.074 0.568 
Carbon disulfide m/z 135 0.067 0.299 -0.032 0.803 
m/z 89 m/z 135 0.320 0.006 0.182 0.159 
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Appendix II Pre-transplant blood chemistry for the 12 pre-patients who underwent liver transplant.  
Blood chemistry includes values for alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate transferase (AST), albumin, total bilirubin, 
creatinine, neutrophils, platelets, potassium, prothrombin/international normalized ratio (PT/INR), and the United Kingdom Model for End-Stage Liver 
Disease (UKELD). 
 
Patient 
Identity 
ALT 
(U/L) 
ALP 
(U/L) 
AST 
(U/L) 
Albumin 
(g/L) 
Total 
Bilirubin 
(mol/L) 
Creatinine 
(mol/L) 
Neutrophils 
10
9
 
counts/mL 
Platelets 
10
9
 
counts/mL 
Potassium 
mmol/L 
 
PT/INR 
Sodium 
mmol/L 
 
UKELD 
F1 149 160 212 30 26 42 0.6 57 4 1.8 137 53 
F2 56 121 - 22 257 61 4.1 26 4.9 3.8 154 57 
F3 46 194 88 38 143 30 0.6 48 3.3 1.7 129 62 
F4 38 218 58 31 391 56 3.2 120 3.6 1.4 133 63 
M1 28 164 - 29 39 124 4.7 151 5 1.4 131 58 
M2 17 246 44 25 51 82 3.1 86 4.5 1.7 132 57 
M3 44 257 71 30 137 79 3.9 61 3.8 2 144 55 
M4 64 85 107 40 47 85 2.3 34 4.2 1.8 137 56 
M5 34 101 - 29 21 75 3.4 87 4 1.2 138 50 
M6 17 68 35 37 55 92 2.6 57 4.1 1.6 142 53 
M7 39 105 73 25 63 67 0 40 4.8 2.4 138 57 
M8 35 134 - 40 15 86 85 141 5.4 1.6 132 52 
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Appendix III Normalised count rates (area under the peak) for the 40 measured ion peaks which were included in the statistical analysis for patients, 
controls and room air. Median (lower quartile , upper quartile) and range (minimum – maximum). Count rates were normalised to 50 million counts per 
second of the areas under the ion peaks for the sum of the reagent ions m/z 19 (hydronium) and m/z 37 (the monohydrate cluster ion). 
 
  Patients (N = 31) Controls (N = 30) Room air 
m/z        Median (LQ/UQ)       Range Median (LQ/UQ)        Range     Median (LQ/UQ)     Range 
33 77200 ( 64800 / 144700) 36600 - 334700 56900 ( 45100 / 68700) 32600 - 92200 10300 ( 8800 / 14600) 5800 - 22300 
42 4300 ( 3950 / 6290) 3590 - 78060 4780 ( 3830 / 37440) 2810 - 98400 3030 ( 2800 / 5220) 1550 - 10050 
43 86200 ( 75100 / 91200) 46700 - 186300 86100 ( 63700 / 98300) 45100 - 330700 29700 ( 21300 / 34400) 10000 - 236400 
45 66400 ( 50000 / 84800) 21500 - 198200 65700 ( 39000 / 103100) 24400 - 281700 30800 ( 19800 / 40800) 8900 - 257700 
47 34500 ( 31900 / 40400) 15200 - 64100 34000 ( 26800 / 37000) 22800 - 119800 16800 ( 12200 / 18700) 8300 - 29000 
49 980 ( 720 / 1160) 320 - 3920 880 ( 720 / 1160) 310 - 1620 450 ( 220 / 630) 80 - 1310 
51 3870 ( 2830 / 5890) 720 - 12430 2480 ( 1850 / 3150) 1270 - 6000 380 ( 160 / 550) 40 - 760 
54 860 ( 580 / 1180) 290 - 2390 1050 ( 610 / 1570) 240 - 30380 260 ( 140 / 410) 40 - 610 
55 85600 ( 71100 / 120400) 37200 - 208900 72900 ( 58200 / 117500) 39100 - 1114900 5900 ( 4500 / 7300) 2100 - 81300 
57 12220 ( 10150 / 14690) 5300 - 20300 10530 ( 9670 / 12220) 6720 - 25720 4480 ( 3010 / 4960) 1970 - 9750 
58 2750 ( 2060 / 5090) 990 - 11320 2710 ( 1890 / 4590) 1030 - 92120 650 ( 480 / 1130) 270 - 8640 
59 359400 ( 268100 / 719700) 158200 - 1119800 269600 ( 219700 / 449200) 124600 - 1078500 31200 ( 20000 / 119000) 9200 - 1616500 
61 50400 ( 42100 / 57300) 13600 - 138200 49500 ( 36800 / 61100) 26200 - 121200 13000 ( 9500 / 15700) 5200 - 23600 
63 8580 ( 7370 / 10380) 3890 - 11780 7650 ( 5760 / 9320) 4760 - 13500 660 ( 510 / 1050) 220 - 1640 
65 2340 ( 1960 / 2930) 820 - 4110 1930 ( 1660 / 2390) 940 - 29660 370 ( 230 / 520) 50 - 950 
67 740 ( 590 / 940) 280 - 3330 660 ( 490 / 850) 280 - 1940 180 ( 110 / 360) 70 - 510 
68 390 ( 320 / 470) 150 - 2160 430 ( 370 / 490) 130 - 4630 140 ( 60 / 270) 20 - 630 
69 18250 ( 5800 / 25890) 2640 - 73030 11420 ( 7580 / 19410) 1890 - 43170 830 ( 550 / 970) 370 - 2800 
71 8410 ( 5530 / 11200) 2580 - 16230 6020 ( 5040 / 8130) 2230 - 13980 780 ( 660 / 1090) 340 - 2460 
72 720 ( 580 / 920) 430 - 1500 740 ( 460 / 910) 360 - 5940 230 ( 190 / 400) 40 - 890 
73 11900 ( 9600 / 17300) 7500 - 30800 8900 ( 7300 / 12500) 5800 - 25600 3300 ( 2500 / 5000) 1900 - 16800 
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                      Patients (N = 31)                      Controls (N=30)                                  Room air  
       m/z    Median (LQ/UQ)      Range Median (LQ/UQ)     Range Median (LQ/UQ)   Range 
74 870 ( 780 / 1020) 630 - 1800 780 ( 610 / 980) 450 - 2020 370 ( 270 / 540) 120 - 980 
75 4450 ( 3370 / 6830) 1490 - 13400 3060 ( 2460 / 5240) 1630 - 15240 1210 ( 890 / 1650) 390 - 4040 
77 2590 ( 1840 / 3790) 1010 - 7470 1740 ( 1330 / 2920) 830 - 8660 360 ( 230 / 510) 150 - 2260 
79 1550 ( 1240 / 1990) 420 - 3150 1300 ( 980 / 2240) 600 - 13060 410 ( 300 / 560) 150 - 830 
81 5000 ( 1700 / 14170) 800 - 61880 980 ( 830 / 1270) 540 - 2270 330 ( 260 / 450) 140 - 1880 
83 1303 ( 1019 / 1905) 530 - 3084 949 ( 787 / 1556) 520 - 2959 479 ( 426 / 571) 224 - 1084 
85 2110 ( 1070 / 3960) 650 - 5070 1800 ( 1140 / 2710) 610 - 6810 400 ( 360 / 620) 230 - 1380 
87 7630 ( 5780 / 11400) 2650 - 33000 4030 ( 3470 / 4620) 2190 - 15410 830 ( 770 / 1360) 540 - 1630 
89 1480 ( 980 / 3370) 540 - 10170 870 ( 690 / 1330) 570 - 12270 480 ( 460 / 630) 240 - 2750 
93 1890 ( 1320 / 3450) 760 - 8300 1090 ( 890 / 2050) 660 - 6350 570 ( 400 / 760) 180 - 990 
95 1810 ( 1200 / 3070) 770 - 10950 1110 ( 860 / 1580) 630 - 3730 450 ( 350 / 500) 280 - 1400 
97 630 ( 550 / 930) 300 - 2010 570 ( 470 / 790) 310 - 1760 330 ( 250 / 410) 110 - 730 
99 870 ( 750 / 1250) 450 - 5640 790 ( 630 / 980) 390 - 1550 440 ( 360 / 630) 80 - 820 
101 2940 ( 2010 / 4420) 1180 - 6370 2140 ( 1820 / 3170) 1380 - 8750 1140 ( 700 / 1640) 500 - 2510 
103 700 ( 620 / 880) 450 - 2690 690 ( 530 / 910) 300 - 3790 340 ( 230 / 430) 130 - 680 
109 610 ( 470 / 860) 190 - 4920 560 ( 480 / 750) 230 - 4570 340 ( 240 / 530) 80 - 1690 
115 610 ( 520 / 860) 410 - 2430 530 ( 460 / 650) 290 - 1520 400 ( 230 / 450) 120 - 630 
135 550 ( 490 / 1100) 270 - 2300 450 ( 310 / 570) 170 - 3750 330 ( 240 / 450) 20 - 1620 
137 3027 ( 830 / 9286) 278 - 40636 409 ( 333 / 506) 97 - 1309 243 ( 72 / 387) 43 - 855 
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Appendix IV Demographic information for the patient group. Medications are those which they were taking at the time of the pre-transplant breath sample, except 
for F5, who was only sampled post-transplant. BMI = body mass index. The weight used for the BMI calculation is the one given in the patient’s notes closest to the date 
for the pre-transplant sample. AID = Autoimmune liver disease, ALD = Alcoholic Liver Disease, CD = Cryptogenic disease, HBV = Hepatitis B virus, HCC = 
Hepatocellular cancer, HCV = Hepatitis C virus, LF = liver failure, NAFLD = Non Alcoholic Fatty Liver Disease, NASH = non-alcoholic steatohepatitis, PBC = 
Primary biliary cirrhosis, PSC = Primary sclerosing cholangitis. 
 
Study 
ID 
Sex Age BMI Diagnosis Smoker                                                                       Medications 
F1 F 27 25.8 AID yes prednisolone, tacrolimus (prograf), azathioprine, lansoprazole, ursodeoxycholic acid, sulfasalazine 
F2 F 49 31.2 LF no esomeprazole before and after transplant, hydrocortisone, flucanozole, metaclopramide, mycophenalate 
F3 F 53 26.4 PBC no ursodeoxycholic acid, paracetamol, ranitidine hydrochloride, vitamin B, thiamine, lactulose.  
F4 F 58 32.4 PSC no spironolactone, omeprazole, ciprofloxacin, thiamine, calcium carbonate 
F5 F 71 28.0 CD no carvedilol, lactulose, omeprazole 
F6 F 52 21.5 PBC no  deoxycholic acid 
F7 F 65 28.0 NASH, 
HCC 
no carvedilol, omeprazole, rifaximin, spironolactone, gabapentin, fruesamide, novomix 30 (insulin) 
F8 F 54 22.1 HCV, HCC yes clamiparin, omeprazole 
M1 M 54 33.7 ALD yes lansoprazole 
M2 M 45 21.1 ALD yes Lactulose, Lansoprazole, Mirtazapine, paracetamol, Propanolol, Adcal D-3, ciprofloxacin, Furosemide, spironolactone 
M3 M 53 32.5 ALD no Thiamine, Omeprazole, bisodol, vitamin B, amitryptiline, lactulose, topical steroid for psoriasis 
M4 M 53 28.1 ALD, 
HVC, HVB 
yes aspirin, azathioprine, coamoxiclave, cotrimoxazole, enoxaparin, entecavir, lansoprazole, Morphine Sulfate, nystatin, 
paracetamol, piperacillin/tazobactam, prednisolone, prograf (BD tacrolimus), senna, sertraline, testogel, tramadol, (cyclizine, 
lidocaine, morphine sulfate, ondansetron, paptac, tramadol as required) 
M5 M 56 27.2 ALD, 
HCV, HCC 
gave up 6 
weeks 
before 
breath 
sample 
None 
M6 M 53 33.1 CD no rifaximin,ursodeoxycholic acid, citalopram, Lactulose, carvedilol, spironolactone, buscopan, enlive plus, omeprazole, micolax 
enema, peppermint oil 
M7 M 36 35.0 CD no furosemide, amiloride, carvedilol 
M8 M 67  25.7 ALD no beclomethasone, vitamins A and D, lactulose, enoxaparin, hydrocortisone, omeprazole, paracetamol, fresnius renalyte acid 
concentrate, fresnius BiB ag, calogen extra, Build Up (sweet), ciprofloxacin, rifaxi 
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Study 
ID 
Sex Age BMI Diagnosis Smoker                                               Medications 
M9 M 55 24.0 PSC no paracetamol, codeine phosphate 
M10 M 53 42.3 ALD no lenograstim, cotrimoxazole, neomycin, vitamin B, thiamine, propanalol, lansoprazole 
M11 M 67 24.5 ALD no omeprazole, folic acid, furosamide, spironalactone, tamazepam, carvedilol 
M12 M 50 24.1 PSC no vitamin K, calcium, vitamin D 
M13 M 42 21.8 PSC no omeprazole, septrin (sulfamethoxazole), creon, questran (Cholestyramine) 
M14 M 64 35.9 ALD no propanalol, spironalactone, vitamin D (rocaltrol), omeprazole, erythromycin,  
M15 M 54 29.8 ALD no Fortimel, rifaximin, lactulose, thiamine, build up, vitamin B, lansoprazole, phosphate enema, piperacillin/tazobactan, ciprofloxacin, 
trimethoprim 
M16 M 45 31.6 ALD yes none 
M17* M 65 31.2 NAFLD, 
HCC 
no paracetamol 
M18 M 69 37.0 ALD, HCC no omeprazole, propranolol, thiamine, fluoxetine, vitamin B 
M19 M 57 27.8 HBV, HCV, 
HCC 
gave up 2 
months before 
breath sample 
metformin, omeprazole, ramipril, amitriptyline, naproxen, viagra, bendrofluazide 
M20 M 66 29.4 ALD, HCC yes furosemide, spironolactone, lactulose, vitamin B, thiamine 
M21 M 50 27.2 HBV, HCC yes tenofovir 
M22 M 71 24.5 CD, HCC no furosemide, amiloride 
M23 M 55 28.2 HCV, HCC 
 
yes 
 
metformin, insulin, paraxatone  
 
       
*Only patient M17 reported that they still drank alcohol 
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BREATHE  
This Protocol is approved by: 
 
Dr Chris Mayhew        Signature:                                                                            Date: 
 
Chief Investigator 
 
PROTOCOL SIGNATURE 
 
I have thoroughly read and reviewed the study 
protocol: BREATHE 
I have read and understood the requirement and condition of the study protocol. 
 
I am aware of my responsibilities as an Investigator under the guidelines of Good 
Clinical Practice (GCP), local regulation and the study protocol and I agree to 
conduct the study according to these guidelines and to appropriately direct and assist 
the staff under my control who will be involved in the study. 
I agree to use the study material only as specified in the protocol. 
I understand that changes to the protocol must be made in form of an amendment, which 
has to be approved by the relevant Ethics committee and the Research and Development 
department prior to its implementation. 
 
I understand that any violation of the protocol may lead to early termination of the study. 
INVESTIGATOR’S NAME  
 
…………………………………………………………………….. 
SIGNATURE                       
…………………………………………………………………….. 
DATE                                  
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STUDY SYNOPSIS 
      
Background 
 
Liver Disease incidence has increased in the UK population in recent years. Diagnosis of 
cirrhosis is difficult and usually invasive. There is no cure; patients must have a 
transplant, but, if caught early enough, some liver damage may be reversed with lifestyle 
changes. Hepatic Encephalopathy is a common side effect of liver cirrhosis and causes 
significant morbidity. Patients may suffer from acute episodes, in which they are 
extremely confused, and if not treated, may lapse into a coma. These episodes often 
arrive without warning and necessitate hospital treatment. Diagnosis of encephalopathy 
is by cognitive tests to assess the level of confusion, as well as blood ammonia. These 
tests require knowledge of the patient’s normal behaviour and have to be adjusted for 
educational level. 
 
The measurement of endogenous volatile organic compounds (VOCs) in human breath 
for thediagnosis of disease is an emerging field; the Proton-Transfer-Reaction Mass-
Spectrometer (PTR-MS) is a widely used tool for this purpose due to its high sensitivity 
and speed of analysis. Some previous studies have measured VOCs in the breath of liver 
disease patients. One conference abstract describes blood and breath measurements in 
patients with hepatic encephalopathy. 
 
No published study has examined the evolution of breath VOCs during a period in 
which a patient is receiving therapy for Hepatic Encephalopathy. 
 
Gastrointestinal Cancers (GI cancers) are common, with liver cancer often being a 
consequence of cirrhosis and hepatitis infections. Neuroendocrine tumours (NET) is a 
type of cancer commonly found in the gastrointestinal tract, including liver and pancreas. 
GI cancers are often not diagnosed until the tumour is advanced, thus reducing the 
chance of curative treatment. Paracetamol overdose is the most common poisoning event 
in the UK and leads to death by liver failure caused by the toxic effect of the metabolite 
N-acetyl-p-benzoquinoneimine (NAPQ). 
 
AIMS 
 
 
We propose to measure VOCs in the breath of patients with acute encephalopathy while 
they are receiving therapy to treat the condition. We wish to examine which VOCs are 
elevated in the breath of patients with Hepatic Encephalopathy and which change over 
time in association with the severity of symptoms. We also propose to measure VOCs in 
the breath of patients with liver cirrhosis and GI cancers and compare them to identify 
biomarkers of cirrhosis and cancer. Patients with cancer will give a sample both before 
and after tumour removal to further aid in biomarker identification. Breath samples will 
be taken from patients with paracetamol overdose to determine if the toxic metabolite 
NAPQ can be detected. 
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Entry Criteria 
 
Main inclusion criteria 
 
    Age ≥ 18 
    Admitted for treatment of hepatic encephalopathy in accordance with 
usual care 
or attending clinic for hepatic cirrhosis in accordance with usual care 
    Or attending clinic for GI cancer in accordance with usual care 
    Or admitted as an emergency for paracetamol overdose 
 
 
Recruitment 
 
Patients will be recruited from the Queen Elizabeth University Hospitals NHS 
Foundation Trust Birmingham 
 
 
ABBREVIATIONS 
 
EEG                  Electroencephalogram 
 
GC-MS             Gas Chromatography Mass Spectrometry 
 
HE                     Hepatic Encephalopathy 
 
GI                    Gastrointestinal 
 
NET                 Neuroendocrine Tumour 
 
NHS                  National Health Service 
 
PTR-MS           Proton Transfer Reaction Mass Spectrometer 
 
UK                     United Kingdom 
 
VOC                  Volatile Organic Compound 
 
NAPQ             N-acetyl-p-benzoquinoneimine 
 
NIHR                National Institutes of Health Resear 
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1. Context and Features of Disease 
 
1.1. Hepatic Encephalopathy and Liver Cirrhosis 
 
The burden of liver disease in the UK has risen sharply and poses a major public health 
issue. Deaths from chronic liver disease have increased eight fold in men aged 35-44 and 
seven fold in women over the past three decades. Liver disease already kills more people 
than diabetes and road accidents combined, but if rates of increase continue, deaths are 
predicted to double in 20 years. Hospital episode statistics for 2000/01 show over 15,000 
admissions for alcoholic liver disease alone (129,000 bed days) and almost 4000 
admissions for other conditions related to fibrosis and cirrhosis of the liver (25,000 bed 
days). The mean length of stay for patients with cirrhosis/fibrosis is 12 days serving to 
emphasise the economic cost to the NHS. 
 
Early stages of liver disease are often difficult to recognize as the liver can function 
normally even when a quite large proportion is diseased. Often patients do not present 
until the disease is quite advanced. Even then, diagnosis is difficult and symptoms are 
often general and can be mistaken for other causes. The frustration for the liver 
physician, is that, if caught early enough, much liver damage is completely reversible 
with appropriate lifestyle changes such as abstaining from alcohol. However, most 
patients do not present until the damage is too far gone because early stage liver disease 
may present like general flu-like or tiredness symptoms. Even when it is quite badly 
cirrhotic, the liver compensates and can continue to function enough to support life, 
although the patient will become increasingly ill. Cirrhosis then inevitably worsens 
until the liver can no longer support life and the organ fails completely. Before this 
outcome, the only hope of survival for the patient is a liver transplant. 
 
Liver blood tests are not very specific for liver disease and diagnosis is not 
straightforward. Conventional methods of establishing and identifying liver diseases, 
such as biopsy, can cause complications and even death, which limits their 
applicability. Biopsy is expensive and carries non-negligible risk, with approximately 1 
in 10000 patients dying as a result. Moreover, complications of liver disease such as 
encephalopathy and cancer require time and resource- intensive radiological and clinical 
techniques for detection. The use of non-invasive breath analysis to identify VOCs that 
could identify groups of patients at risk of cirrhosis or cancer is, therefore, appealing. If 
breath biomarkers of cirrhosis or cancer could be found, this may lead to earlier 
diagnosis. 
 
HE is a common side effect of liver cirrhosis. It is caused by the build up of toxins in the 
blood which are normally cleared by the liver. These toxins can cross the blood-brain 
barrier and cause neurological symptoms. Encephalopathy is graded from 1 – 4, with 4 
being the most severe. Patients with lower grade HE do not usually require hospital 
treatment and are monitored in their usual clinic visits. In general these are patients in 
the earlier stages of liver cirrhosis. Their symptoms are shortened attention span and 
difficulty with simple numerical tasks. HE is a condition characterised by variability in 
symptoms; some patients will vary between ever present minimal HE and acute, others 
can be precipitated into an acute episode from being symptom- free. As cirrhosis 
worsens, so the symptoms of HE become more apparent and begin to interfere with the 
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patient’s everyday life. Patients with grades 3 and 4 may become confused and 
disoriented, similar to symptoms of advanced dementia. These patients cannot be safely 
left on their own, as they are a danger to themselves during an acute episode and there is 
no warning when such an episode will occur. This constitutes a considerable burden on 
family/carers. 
 
Acute episodes can occur spontanteously or may be precipitated by various factors such 
as: gastrointestinal bleeding, dehydration (caused by vomiting, diarrhoea or use of 
diuretics), constipation, use of certain medications, hyponatraemia, surgical intervention 
and transjugular intra-hepatic porto-systemic shunting (TIPS). In its most severe forms 
HE can be life- threatening and may require ventilatory support. 
 
A differential diagnosis must be made for HE and other causes for the symptoms must 
be ruled out. Diagnosis of HE is by congnitive tests such as number connection, as well 
as blood ammonia and EEG studies. Cognitive tests are time consuming and have to be 
adjusted for educational ability. Blood ammonia testing is invasive and it takes time to 
receive results. A breath marker for HE would speed up diagnosis and thus lead to better 
management. 
 
HE is managed principally using diet to reduce the intake of dietary protein, which 
thus limits the production of ammonia and by use of laxatives to expel toxins. Other 
therapeutic interventions are bowel acidification and sterilisation. 
 
Another advantage of finding a VOC biomarker for HE is that it may provide insight 
into the biochemical aetiology of the condition. It is not fully understood how the 
neurological symptoms of HE are caused. 
 
 
1.2. Gastrointestinal Cancers 
 
1.2.1 Liver Cancers  
One of the complications of chronic liver disease is liver cancer, a tumour that is often 
clinically silent and frequently missed. Treatment is by transplant, ablation surgery, 
trans-arterial chemo-embolisation or oral chemotherapy with sorafenib. Patients who are 
listed for non-transplant therapy will provide samples in clinic before and after treatment. 
 
1.2.2 Neuroendocrine Cancer  
Neuroendocrine Tumours (NET) may arise in any organ where neuroendocrine cells are 
located, but they are most frequently found in the gut, pancreas and liver. Although this 
type of cancer is not one of the most common, UHB is a national centre for treatment 
and 100 patients are treated each year. Treatment is by surgery, chemotherapy or 
radionuclide therapy. Patients who are listed for tumour eradication treatment will be 
asked to give a breath sample in clinic before and after their treatment. This tumour has 
well recognise plasma biomarkers with which to compare any VOC biomarkers which 
may be discovered. 
 
Biomarkers from a non-invasive procedure such as breath analysis would potentially 
help in early recognition of GI cancers. Early treatment improves the chances of survival 
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as treatments are available but are less successful once the tumour has had time to grow 
and metastised. 
 
These cancers are typically treated within the same clinics as general liver so patients 
will be available to give samples in the same setting. 
 
1.3. Paracetamol Overdose 
Paracetamol is the most common drug taken in overdose in the UK and accounts for 120 
deaths per year on average. The cause of liver failure following paracetamol overdose is 
the build up of the hepatotoxic metabolite N-acetyl-p- benzoquinoneimine (NAPQ). At 
therapeutic doses, paracetamol is mostly converted to non-toxic metabolites via the 
Phase II metabolism by conjugation with sulphate and glucoronide. Only a small 
proportion of it is metabolized via the cytochrome P450 enzyme system to NAPQ. In 
overdose, the phase II metabolism pathways are saturated and more paracetamol is 
shunted to the cyctochrome P450 system, leading to an overproduction of NAPQ. 
Normally, NAPQ would be cleared by the liver’s natural antioxidant, glutathione. In 
overdose, glutathione cannot be produced quickly enough to cope with the oversupply of 
NAPQ, therefore, excess NAPQ directly damages the hepatocytes. Treatment depends 
on the time at which the patient presents following overdose. Treatment is mostly 
with acetylcysteine but the correct dosage must be calculated using the plasma 
paracetamol concentration and an estimate of the time of overdose. Patients may not be 
able to say exactly when they overdosed and may not even be able to identify if it was 
paracetamol which they have taken. Plasma tests take time to return from the lab, 
therefore, an instant diagnostic test for the presence of paracetamol metabolites would 
be beneficial. For those patients whose treatment is not successful, their only chance 
of survival is a liver transplant. 
 
2. VOC Analysis-Scientific Background 
 
2.1. VOC Breath Analysis - Instrumentation 
Proton Transfer Reaction Mass Spectrometry (PTR-MS) is a very sensitive chemical 
ionisation mass spectrometry technique that can be used to measure and quantify 
many trace gases. The application of PTR-MS technology to the detection of volatile 
organic compounds (VOCs) on exhaled human breath is our main area of interest. 
Breath analysis is not a new science; the measurement of exhaled fractions of 
administered compounds (both stable isotope and radioactive) is well established, a 
well-known example being the C-14 breath test for Helicobacter Pylori bacteria. 
A newer approach, which has been growing over the past two decades, is to measure 
endogenous VOCs as indicators of disease or metabolism. This field has grown so much 
in recent years that it now has its own Institute of Physics journal, the Journal of Breath 
Research, which was founded in 2008. There are hundreds of VOCs on the human 
breath, most of them products (metabolised or not) of the ambient environment, with the 
remainder produced by metabolic processes in the body, or by bacteria in the gut. These 
latter endogenously produced VOCs measured on the breath are of particular interest to 
us, as they can act as indicative markers of metabolic processes related to various 
diseases. 
The most common and best established technique used to measure the VOCs is Gas 
Chromatography Mass Spectrometry (GC-MS), which has been used extensively by 
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Michael Phillips in his pioneering work in the field. Although GC-MS is well 
established, it has numerous drawbacks; samples cannot be directly measured, they must 
first be preconcentrated, usually on Tenax tubes. This leads to time consuming trapping 
and concentration of large volumes of breath, as well as transportation to and analysis in 
specialised laboratories. This introduces a risk of errors due to issues of surface 
adsorption, contamination and permeability; this can make the breath samples unreliable. 
Furthermore, GC-MS uses electron impact to ionise molecules, which invariably leads to 
considerable fragmentation and the production of many daughter ions. This can greatly 
complicate the analysis, particularly given the highly complex chemical environment and 
low concentrations of the molecules to be detected. 
 
More recent newcomers to breath analysis include other forms of mass spectrometry 
including ion mobility mass spectrometry (IMS-MS), such as selected ion flow tube 
mass spectrometry (SIFT-MS) and solid phase micro extraction (SPME), laser 
spectroscopy and electronic noses. Numerous reviews give an overview of current 
methods and applications of endogenous VOC breath analysis. 
 
Each technique has its advantages and disadvantages, but the potential of PTR-MS to 
human breath analysis comes mainly from its superior sensitivity and real-time 
capability. This offers the opportunity to do direct real-time measurement of exhaled 
breath as well as near instantaneous analysis, without the need to pre-concentrate the 
sample. There exists now a large body of work on the application of PTR-MS to medical 
applications. 
 
2.2. VOC Breath Analysis - Liver Disease 
It has been noted that sulphur compounds are associated with liver disease and these 
have been found to be responsible for the well known odour of the breath of cirrhotics 
known as foetor hepaticus.  Other groups have measured VOCs in the breath of 
patients with liver disease. These studies used other techniques, either gas 
chromatography mass spectrometry (GC-MS) or Ion Molecule Reaction Mass 
spectrometry (IMS-MS). These studies all found some VOCs that may be indicative of 
certain liver diseases. There is some agreement between some of these studies in terms 
of which biomarkers are implicated, however, full validation studies in a different set of 
patients have not been performed. 
 
Two published studies have examined HE specifically as distinct from other liver 
diseases.  Ammonia is well known to be excreted in the breath as it passes readily from 
the blood into the alveoli in the lungs. One previous study has attempted to correlate 
breath and arterial blood ammonia in patients with HE. The results were inconclusive, 
however, the patients assesse had only minimal HE; the authors admit this limitation and 
suggest that more severe grades of HE should be assessed. Another study has measured 
breath VOCs using gas chromatography mass spectrometry in patients admitted to 
hospital for severe HE and noted a number of volatile compounds which were associated 
with symptoms of HE. This remains only a conference abstract and a full paper has not 
been published, nor has a validation study been performed. 
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2.3 Breath Analysis Cancer 
VOC breath analysis has principally focused on lung cancer although breast, and head 
and neck cancer have also been investigated. Despite large numbers of studies in lung 
cancer, inconsistent results have been reported and robust second phase clinical trials 
have not been reported to test phase one diagnostic models. No diagnostic tests have 
been developed for use in clinical settings. Previous studies have compared patients with 
other groups, as we are doing in our cirrhosis study. However, no cancer-specific 
biochemical pathways have been suggested which would account for changes in breath 
VOC. Rather, the pathways proposed are linked to oxidative stress in general, and 
may be markers of general inflammation rather than cancer. Since a great many other 
processes may lead to such oxidative stress, and may be present in the patient 
group both we do not think that comparison of groups should be used in isolation as 
way to proceed in biomarker identification for cancer. For this reason, we will use 
patients as their own controls by examining breath samples before and after treatment. In 
this way, we would hope to limit the impact of inter-individual variability which can 
confound attempts to identify biomarkers. 
 
 
3. Research Questions 
 
3.1. Hepatic Encephalopathy 
The current study seeks not only to compare breath VOCs in patient with disease with 
controls, but we also propose to investigate the time dependence of those markers as the 
severity of the condition changes. In this, we will emulate the work of Halbritter et al 
who measured breath VOCs in women being tested for gestational diabetes in response 
to a glucose challenge. They found that absolute concentrations of VOCs were not the 
best predictors of whether the women were subsequently found to have gestational 
diabetes; rather the time constant of the clearance of breath VOCs was of better 
diagnostic value. One of the most difficult problems in biomarker discovery is the 
natural variation in concentrations between individual humans, high levels of a particular 
marker may be ‘normal’ for that individual, whereas for another they may indicate 
disease. By examining the change over time in a situation where the condition varies 
from acute back to normal (or, normal for that patient), we hope not only to rule out 
confounding VOCs which may be coincidentally high but not actually related to 
encephalopathy, but also to examine how the rate of change of VOCs may be of 
diagnostic potentiIn summary, the research questions are 
 
1. Are there breath VOCs which are elevated initially in HE but which then 
reduce as the patient responds to therapy? 
2. Do concentrations of any breath VOCs relate to other diagnostic metrics such 
as blood ammonia in patients with HE? 
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3.2 Cirrhosis and GI Cancer 
The broad aim is to find VOCs in human breath which can be used as biomarkers of 
cirrhosis and GI cancer. Two approaches will be used, comparing a disease group 
(cirrhosis) with normal, and comparing patients before and after treatment to remove 
tumours (GI cancer).Cirrhosis patients will give one sample and GI cancer patients will 
give breath samples before and after surgery for tumour ablation. 
 
Samples from all patients and healthy controls will be collected in clinic. It is intended 
to ask companions of patients to act as healthy controls as they will have been breathing 
the same air in the recent past as the patient; VOCs in the air in the clinic will, 
therefore, be controlled for. Moreover, they may well share a diet and home 
environment with the patient, so long lived VOCs which may be retained in fat or other 
body compartments, may also be controlled for. 
 
There will be three groups; cirrhosis, GI cancer and healthy controls. Comparisons will 
be made between all of these groups to establish any putative biomarkers for the disease 
conditions. Further, the pre-therapy GI cancer and post-therapy GI cancer groups will be 
compared to examine any differences in VOC concentration as a consequence of the 
removal of the tumour. The difference with this comparison is that the patient will be 
acting as their own control. In theory, this should mean that there is less natural 
variability in the breath VOC composition and a difference should be more easily 
detectable. 
 
The cirrhosis and GI cancer group will act as disease controls for each other. It is 
important in breath analysis to have a disease control group, as some breath markers may 
result from general inflammation or immune system response processes. For example, 
short chain alkanes such as pentane and ethane are known to arise from oxidative stress; 
elevated pentane has been noted as elevated in conditions as diverse as sleep apnea, 
schizophrenia, asthma, lung cancer, sepsis and increased age of subject. 
 
In summary the research questions are: 
 
1. Are there breath VOC biomarkers of cirrhosis or GI cancer? 
2. Do putative breath VOC biomarkers of GI cancer change follow tumour removal. 
 
3.3. Liver Failure from Paracetamol overdose 
The aim is to determine whether the toxic metabolite NAPQ is detectable by PTR- MS. 
It is similar in chemical structure and behavior to another quinine metabolite of the 
anaesthetic agent propofol, which has been measured using PTR-MS. At this stage, 
measurements would be a simple proof of principle to establish whether any NAPQ is 
detectable in the patient’s breath. 
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4. Method and Materials 
 
4.1. Breath Sampling 
End expired air must be collected as this contains the highest proportion of alveolar air. 
The collection of mixed expired air leads to unacceptable variability in the VOC 
concentrations within and between subjects. Our own work has shown that a rebreathing 
protocol gives low levels of variability and allows for an equilibrium to be established 
between concentration of VOCs in alveolar blood and lung air. A rebreathing protocol is 
not, however, appropriate for patients in this particular clinical setting. It can be time 
consuming and difficult for patients to follow instructions. Instead, end-alveolar samples 
will be collected using a capnometer which will control the breath being collected such 
that breath will only be collected if the CO2 concentration is above a minimum threshold. 
This consists of plastic ventilation tubing with an inline capnometer. A plastic 
mouthpiece is attached to the end, and this is the only part of the apparatus that the 
patient has contact with. The sample bag is attached to the tubing. When the 
capnometer registers a CO2 level of above a specified percentage, the researcher will 
place their gloved hand over the open end of the tubing so that the patient’s breath is 
redirected into the sample bag. Patients will also be asked to exhale a full breath into a 
separate bag as this will help to identify exogenous VOCs (see ‘Confounding Variables’) 
 
For the HE in-patients, if possible, we will collect a sample before the patient has begun 
treatment; this will depend on how quickly the researchers are informed about the patient 
being admitted. Once treatment has started, one sample bag will be collected every 
half hour for the first three hours, then on an hourly basis thereafter. If the patient 
has not been discharged, breath samples will be taken on the following day on a two 
hourly basis. 
 
For cirrhosis and GI cancer patients, breath samples will be collected in clinic. For 
paracetamol overdose patients, samples will be collected at the bedside. 
 
4.2. Infection Control 
The breath sampling apparatus consists of a plastic mouthpiece connected to some 
plastic tubing with an inline medical capnometer to measure carbon dioxide, and a 
removable Tedlar bag attached to the tubing to collect the breath. The patient will only 
come into contact with the mouthpiece. A fresh mouthpiece will be used for each 
subject. Used mouthpieces will be sterilised by soaking overnight in a solution of sodium 
dichloroisocyanurate. Infection control is doubly important in this patient group as 
immune system function is compromised in advanced liver disease. 
 
4.3. Breath Gas Measurement 
Bags of breath will be taken immediately to the university and analysed on the same day. 
The sample is fed directly into the PTR-MS and the act of analysis destroys the sample, 
so samples will not be stored after analysis. The air sample (breath) to be measured is fed 
directly into the apparatus. Inside, it reacts with ionised water molecules from an internal 
water supply, such that a proton (hydrogen atom) from the ionised water attaches itself to 
the VOC. A large number of the VOCs in the breath sample will become charged by way 
of this reaction, and their charge to mass ratio is then determined by a mass 
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spectrometer. Bags containing the breath sample will be attached directly to the 
instrument and will be kept inside a heated outer bag at all times to prevent 
condensation. A full mass scan up to at least 240 m/z will be measured for each bag. 
Bags awaiting measurement will be kept in an oven to prevent condensation. 
 
4.4.Blood samples 
 
Patients in clinic routinely have blood taken as part of their disease monitoring. We 
would ask for one extra vial of blood to be stored in liquid nitrogen for possible future 
studies.of plasma VOC components. This would not involve an extra venepuncture as 
the patient will have a canula inserted anyway for their routine bloods. This would be 
done for the cirrhosis and GI cancer subjects. The samples would be stored within the 
Natinoal Institutes of Health Research (NIHR) facility at QEH. 
 
4.5. Confounding Variables 
 
It is well known that there are other sources of breath VOCs; diet, gut microbes and 
pollution being the main ones. It is not a simple matter to simply subtract these 
exogenous VOCs which are in the room air because some VOCs may be stored in 
different body compartments, eg fat tissue and released over a longer time, perhaps up 
to weeks or months.  Some of the VOCs which are emitted by gut bacteria and diet 
may also be the same ones which are associated with the disease, so it is not feasible to 
simply exclude them. Even within subjects there may be large variability in the 
concentration of breath VOCs. For example, it is well known that breath acetone levels 
vary widely depending on the time since a person last ate. There are some measures we 
can take to minimize the confounding effect of these markers: 
 
1. Smoking markers have been well characterized and there are ones which 
are well known to be associated with smoking behavior: these VOCs will be 
removed from the analysis. 
2. Patients’ companions will be asked to supply control samples; as these people 
often share a diet and environment with the patient, some VOCs associated 
with these may be controlled. 
3. A questionnaire about diet and environment will ask about known sources of 
breath VOCs such as garlic and fragrances in air freshener products, and 
what and when they have eaten on the day of sampling. 
4. One full mixed-expired breath will be collected, it has been shown that the 
ratio of VOCs in end-expired and mixed-expired air can give indications as 
to whether or not the VOC is endogenous.  This is because mixed expired 
air contains air from theupper respiratory tract which has been inhaled but 
has not taken part in gas exchange in the lungs. Comparison of mixed 
expired and end-expired air can help to identify VOCs which are in ambient 
air so that they can be excluded from the analysis. 
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5. Patients 
 
5.1. Recruitment and Consent 
For HE in-patients and paracetamol overdose a member of the care team on the ward will 
ask the patient or their relative if they wish to participate and alert the scientific research 
team to come to the hospital to take a breath sample. A member of the care team will 
obtain informed consent from all participants. The study will be explained to prospective 
participants by either a member of the care team, or a study researcher. For patients in 
clinic (cirrhosis and GI cancer), their consultant physician will explain the research to 
them and obtain consent. Subjects will be given 15 minutes to think over the study 
before consent is sought. They will be given a copy of the patient information leaflet 
and consent form if they take part. The issues of consent will be discussed further under 
‘Ethical Considerations’. 
 
The participants will be asked to fill in a questionnaire to inquire about previous 
smoking history, diet and other conditions from which they may be suffering. They will 
be taken through the questionnaire by a study researcher. The subjects will be told that 
they should terminate the procedure at any time if they feel uncomfortable. Study 
researchers will supervise the taking of breath samples. It is expected that the whole 
procedure including filling in the questionnaire and giving the breath sample will take 
approximately 10 - 15 minutes. The collection of subsequent (if any) breath samples will 
take around 2-4 minutes. 
 
5.2. Anonymisation 
 
The patient will be assigned an anonymous code by the researchers which will be 
entered on the questionnaire and against any electronic files generated from their breath 
data. Another file will be created which will relate the coded name to the participant’s 
name and hospital number. This will be kept separately from the data files. 
 
Data about patients and from the breath samples will be kept on the computers of the 
researcher in the University of Birmingham. This is on a secured server which is 
backed up to avoid data loss. No patient data will be kept on laptops, personal 
computers or flash drives. 
 
Questionnaires and consent forms will be kept in the locked offices of the researchers in 
the Molecular Physics group office in the University of Birmingham. Only researchers 
involved directly with the study will have access to any patient data. 
 
5.3. Inclusion Criteria 
 
5.3.1. Patients  
Subjects will be adults over the age of 18 of both genders. For HE, they will have a 
confirmed diagnosis of liver cirrhosis and have been admitted to hospital suffering from 
acute hepatic encephalopathy. Cirrhosis patients will have a confirmed diagnosis of 
liver cirrhosis and will be attending their usual clinic. GI cancer patients will have a 
confirmed diagnosis of GI cancer and will be either those scheduled for tumour removal 
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or those returning after tumour removal having already given a pre-tumour removal 
sample. 
 
5.3.2. Control Groups 
Control group subjects will preferably be the companion of the patient who has 
accompanied them into hospital. In cases where no companion is available or who does 
not wish to participate, a member of the ward team will act as control. 
 
5.4. Exclusion Criteria 
Any subjects who have pre-existing severe respiratory conditions such as asthma, lung 
cancer or COPD, or who are pregnant will be excluded. Controls will be excluded if they 
are suffering from liver disease or cancer of any type. 
 
6 Statistics 
 
Power calculations are not applicable at this time as we don’t know how many 
variables to expect, and what the variability on them will be. Although this is principally 
a biomarker discovery study, we will also seek to obtain more information by assessing 
VOC levels over time in response to therapy. Ideally, we would then seek to model the 
decrease in concentration and assign a time dependent parameter to the wash out curve. 
This will depend on the patient’s response to therapy and the rapidity with which VOCs 
clear from the bloodstream. 
 
As with all biomarker discovery studies, the more patients, the more power the study 
has. At present, we regard this study as a pilot, which is to identify putative markers 
which can then be validated in future work. 
 
 
6.1. Sample Sizes 
As with any biomarker discovery, the more samples the better the chances of finding 
markers which are representative of the population rather than just the current sample. 
We will seek to measure as many patients and controls as feasibly possible up to a 
maximum of 50 in each patient group (except paracetamol overdose). We will not wait 
until we reach this maximum number, however, if it is apparent that recruitment is 
insufficient within the timescale of the project. It is expected that, on average, two or 
three patients per week will be admitted for acute encephalopathy. Liver clinics see 
around 40 patients per week with cirrhosis and around 20 patients per week with GI 
cancer. For paracetamol overdose, the intention is simply to detect the metabolite, so a 
maximum of 5 patients will be recruited. Around 50 patients per year are treated at the 
QEH for paracetamol overdose. 
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7. Ethical considerations 
 
Acute encephalopathy is a very distressing illness both for the patient and their 
relatives/carers. Patients in ITU post-surgery are in a vulnerable state. Researchers 
must be sensitive to the condition of the patient and their relatives/carers. Where patients 
are being admitted for the first instance of acute HE, they and their relative/carer are 
likely to be highly anxious and will require to be treated with extra consideration. It is 
necessary to obtain breath samples from patients in the acute stages of HE because of the 
transient nature of the illness. Previous work on breath ammonia was inconclusive 
probably because only lower grades of HE were investigated. When patients are having 
an acute episode, levels of VOCs which are associated with HE are more likely to be 
elevated and, therefore, measurable. Moreover, we are deliberately attempting to 
measure a dynamic situation; biomarker research, in general, is fraught with the 
difficulty that a single measurement taken at any one time gives only a snapshot view 
of the metabolism. By taking measurements over time we hope to exclude VOCs which 
may be randomly elevated and find only those VOCs which exhibit change accordance 
with the changing condition of the patient. We can then have greater confidence that 
these VOCs are related to HE. Because confusion is a defining characteristic of acute 
HE, there is necessarily a risk that patients may not be in a fit mental state to consent at 
the outset of the study. It will be necessary for patients to have some awareness and 
ability to cooperate in order to obtain a breath sample from them, however, we would 
not automatically assume full mental capacity just because they are able to follow the 
instructions to breathe into the apparatus. It is difficult to judge to what extent an 
encephalopathic patient truly understands what is being said to them. It is, however, 
expected that once therapy is underway a patient’s mental capacity will return. We will 
check with the patient and their relative/carer and the patient’s care team to ascertain 
when the patient is deemed to have regained their mental capacity and obtain consent at 
that time. In the first instance when it is not clear if the patient can give consent or not, 
we will consult with the patient’s relative/carer to ascertain whether or not this is the 
kind of research that the patient would consent to. It is expected that the patient will have 
a companion with them when they are admitted, as they are generally unable to arrange 
for admission without assistance, such is their degree of confusion. It is possible that 
being interviewed for the questionnaire may cause the patient some stress. This is 
unlikely but it is possible. If a patient is showing signs of anxiety, then the interview 
will be stopped. 
 
8. Research benefits 
 
There is no direct benefit to the participants from taking part in this study, but they may 
gain satisfaction from knowing that they have contributed to research in this field.The  
benefits of the identification of a biomarker for HE are improved diagnosis, quicker 
diagnosis and better management. At present, a differential diagnosis must be done 
and this takes time. Ultimately, it is hoped that the identification of breath biomarkers 
would lead to the development of a home test that patients could use to monitor their 
own condition. At present, patients have to try to closely manage their intake of fluids, 
salt, protein and laxatives to prevent toxin build-up. Although a laxative, usually 
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lactulose, is a cheap and simple treatment, many people find it unpleasant to drink and it 
can lead to a distressing urgency in the need to go to the toilet. 
Patients are understandably reluctant to take too much lactulose, but too little can lead to 
HE episodes. It is difficult for patients to manage the correct dose of lactulose, while 
simultaneously managing their intake of salt, protein and fluids. It is a complex set of 
variables and can easily be thrown off balance by an infection, or something as simple 
as not drinking enough. Currently, patients have no yardstick by which to judge whether 
they are on track to prevent an episode, or whether an episode is imminent. An HE 
episode can strike suddenly; a patient may feel and behave completely normally but 
within a few hours could become mentally incapable. If they had a quick, non-
invasive test that they could do several times a day, they could monitor the change in 
levels of biomarkers. Increases in levels of VOCs may have predictive value, allowing a 
patient to increase their dose of lactulose, or give the opportunity to call someone to 
attend to them. At present, patients who are at risk of acute episodes cannot be left alone, 
which is a significant burden on carers. 
This has the potential to relieve the burden on carers and improve the quality of life for 
the sufferer. This would not only be of benefit to the patient in terms of time, distress 
and convenience, it would reduce the need for in-patient stays and, therefore, save NHS 
resources. 
Patients with complex illnesses such as liver disease and cancer endure many 
venepunctures and radiological procedures in the course of assessing their illness, often 
over many years. A non-invasive method of diagnosis would improve the patient’s 
experience and reduce distress. Treatment for paracetamol overdose must be timed 
correctly and the dose is dependent on the plasma concentration of paracetamol. The lab 
tests take time to do, so a quicker method of establishing the metabolite load would be 
beneficial. 
 
9. Resources and cost 
The research will be funded by a Daphne Jackson Fellowship (jointly funded by the 
EPSRC and the University of Birmingham) and a Marie Curie International Training 
Network grant. Consumables are sample bags and mouthpieces which will be 
bought from the Marie Curie grant. 
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Health Status Questionnaire for BreaTHE study 
 
Participant 
identification number: 
Date: 
All the information you give in this questionnaire will be treated with confidence and 
will not be divulged to any third parties 
 
Age                                         Sex : 
 
1. Are you now suffering from any of the following? 
 
a.      Severe 
asthma  
b.    COPD 
c.      Emphysema 
d.     Any other serious lung condition  
e.      Heart condition 
2.    Are you pregnant? 
If the answer to any of the above questions is yes, then you may not take part in the study. 
 
4.    Do you have any other medical condition 
5.     Do you smoke? 
 
If yes: 
How many cigarettes a day? 
For how long have you smoked?                               Years/months/weeks 
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6. Have you ever smoked in the past?  
 If yes: 
How many cigarettes a day? For how 
long did you smoke? 
 
 
 
 
 
 
 
 
 
Years/months/weeks 
 How long ago did you stop?  
Years/months/weeks 
 
7.  Have you been exposed to other people smoking in the past week? 
 
8.  Do you have an open fire, or have you recently been exposed to any other source 
of open fire? 
 
9.      Are you taking any prescribed medication other than the Pill? 
 
 
10.  Are you taking any preparations or medications that have not been 
prescribed by a GP, eg herbal remedies? 
 
11.    Are you taking any food supplements such as vitamin pills? 
 
 
12.    Have you been eating normally in recent days? 
 
 
 
13.    When did you last have something to eat or drink 
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14.    What did you last eat or drink 
15.   Have you eaten or drunk any of the following things in the past 24 hours? 
 
Garlic 
 
Coffee 
 
Alcoholic drinks 
 
16.   How many cups of coffee do you usually drink? (including decaffeinated coffee)  
Never 
 
1-3 per month 1 per day 
2 - 3 per day 
4 - 5 per day 
>5 per day 
1 per week 
5 – 6 per week 
17.   Have you used nasal decongestants or any product containing menthol in the past 
24 hours? 
18.  Do you normally eat food or drink with citrus flavour eg orange, lemon, 
grapefruit, including artificially flavoured drinks? 
19.   Have you eaten citrus fruit, or any food with citrus flavour in the past 24 hour 
20.       Have you drunk any drink with citrus flavour in the past 24 hours? 
21.   Have you been anywhere where citrus or pine scented air fresheners have been 
used in the past week? 
 
 
Your signature ………………………………………………………
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Background: The burden of liver disease in the UK has risen dramatically and there is a need for improved diagnostics.
Aims: To determine which breath volatiles are associated with the cirrhotic liver and hence diagnostically useful.
Methods: A two-stage biomarker discovery procedure was used. Alveolar breath samples of 31 patients with cirrhosis
and 30 healthy controls were mass spectrometrically analysed and compared (stage 1). 12 of these patients had their
breath analysed after liver transplant (stage 2). Five patients were followed longitudinally as in-patients in the post-
transplant period.
Results: Seven volatileswere elevated in the breath of patients versus controls. Of these,ﬁve showed statistically signif-
icant decrease post-transplant: limonene, methanol, 2-pentanone, 2-butanone and carbon disulﬁde. On an individual
basis limonene has the best diagnostic capability (the area under a receiver operating characteristic curve (AUROC) is
0.91), but this is improved by combiningmethanol, 2-pentanone and limonene (AUROC curve 0.95). Following trans-
plant, limonene shows wash-out characteristics.
Conclusions: Limonene,methanol and 2-pentanone are breathmarkers for a cirrhotic liver. This study raises the poten-
tial to investigate these volatiles as markers for early-stage liver disease. By monitoring the wash-out of limonene fol-
lowing transplant, graft liver function can be non-invasively assessed.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The publication of the 2014 Lancet Commission on liver disease has
highlighted how the burden of liver disease in the UK has risen sharply
over the past few decades and that it poses a major public health issue
(Williams et al., 2014). It is the only major cause of mortality and mor-
bidity which is on the increase in England, while at the same time de-
creasing in most other European countries, with cirrhosis accounting
for 83% of deaths (Davies, 2012). It is the third biggest cause of prema-
ture mortality, with three quarters of liver deaths due to alcohol
(Williams et al., 2014). Liver disease has a widespread effect not only
to the patient, encompassing physical and psychological morbidity
and mortality, but also incurring signiﬁcant societal costs. One of the
main difﬁculties is that often patients do not present symptoms or
signs until the disease is advanced. Even then diagnosis is difﬁcult and
the symptoms and signs are often general and can be mistaken for
other pathologies. Non-invasive diagnostic techniques currently used,
namely serum biomarkers and transient elastography (TE) are not
ideal. Serum biomarkers are not liver speciﬁc and TE results require an
expert clinician for interpretation (Castera et al., 2015).
Among the ten key recommendations in a recent Lancet report is to
strengthen the detection of early-stage liver disease, which is essential
to reduce disease progression (Williams et al., 2014). Analysis of vola-
tiles in the breath has the potential to deliver this, but only if chemical
compounds can be found that are unambiguously associated with a
diseased liver.
To date, the use of breath volatiles for medical diagnosis has met
with limited success. Confounding factors, such as volatiles present in
the environment, contamination in the sampling procedures and poor
sampling methods, have meant that there is a great deal of uncertainty
in volatile discovery (Kwak and Preti, 2011). Problems of bias and false
EBioMedicine 2 (2015) 1243–1250
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discovery in biomarker discovery research have been widely reviewed
(Broadhurst and Kell, 2006; Ransohoff, 2005).
Previous studies investigating breath volatiles in patients suffering
with liver disease have proposed a large number of possible biomarkers
(Millonig et al., 2010; Morisco et al., 2013; Sehnert et al., 2002; Solga
et al., 2006; Tangerman et al., 1983; Van den Velde et al., 2008;
Dadamio et al., 2012; Friedman et al., 1994; Hanouneh et al., 2014;
Khalid et al., 2013, 2014; Shimamoto et al., 2000; Vollnberg et al.,
2009; Verdam et al., 2013), but generally different studies report
different volatiles. Various GC–MS studies found raised levels of many
volatiles in the breath of patients with liver disease, including dimethyl
sulﬁde, acetone, 2-butanone, 2-pentanone, β-pinene, α-pinene,
and limonene (Van den Velde et al., 2008; Dadamio et al., 2012;
Friedman et al., 1994; Khalid et al., 2013). Studies using soft chemical
ionization mass spectrometric techniques have reported volatiles such
as acetaldehyde, ethanol, isoprene, benzene, methanol, 2-butanone,
2- or 3-pentanone, heptadienol, and a monoterpene (limonene)
(Morisco et al., 2013). Although the results of these studies are extreme-
ly encouraging, few volatile organic compounds (VOCs) are common to
more than two or three studies and it is not useful to have hundreds of
putative markers. Furthermore some volatiles, which have been
proposed as biomarkers for liver disease, such as isoprene, acetone
and ethanol, are not speciﬁc enough because they are possible bio-
markers for other diseases or arise from numerous normal metabolic
processes. If breath analysis is to progress to clinical utility, then
markers must be deﬁnitively associated with the disease in question.
All previous studies can be regarded as hypothesis-generating, in
that they do not follow up in a second group to conﬁrm the putative
biomarkers. We report here a two-stage breath biomarker discovery
process: breath samples from a group of patients suffering from liver
disease are ﬁrst compared to breath samples from healthy controls;
post-transplant breath samples are then compared with a sub-cohort
of these patients who went on to have a liver transplant. A set of
putative volatile markers is ﬁrst determined by comparing patients
with controls, and then pre- and post-transplant breath samples are
examined to look for intra-individual differences in these volatiles. In
this way, this study is hypothesis-led and uses patients as their own
controls, thereby reducing the risk of false discovery. Furthermore, the
use of patients' companions as controls and of room air samples
minimizes the inﬂuence of any exogenous volatiles present in the
home and hospital as confounding factors.
2. Methods
2.1. Patients, Controls and Hospital Room Air
Patients were recruited at the University Hospital Birmingham from
either the transplant assessment clinic or in wards after being admitted
with hepatic encephalopathy. 31 patients suffering from liver disease
participated in the pre-transplant measurements (F/M 8/23, mean age
55 years, min–max 27–71 years). There were a number of etiologies
and 11 patients had more than one condition: alcoholic liver disease
(N= 13), hepatocellular cancer (N= 10), cryptogenic (N= 4), hepati-
tis C (N=5), primary sclerosing cholangitis (N=4), primary biliary cir-
rhosis (N= 2), autoimmune liver disease (N= 1), hepatitis B (N= 3),
non-alcoholic steatohepatitis (N= 1), and non-alcoholic fatty liver dis-
ease (N= 1). Of these 31 patients, 12went on to have a liver transplant
(F/M4/8,mean age 48 years,min–max 27–58years). One additional pa-
tient (F, age 53 years) was recruited into the post-transplant study.
Table 1 summarises the details of the 13 patients who had a liver
transplant (12 from the pre-group), with patients being identiﬁed by
sex (F orM) and a number. In addition to pre-transplant diagnostics, de-
ﬁnitive diagnoses by histopathological examination of the explanted
liver are provided. All but one (F2) were diagnosed with cirrhosis by
standard liver function tests and biopsy. F2 was admitted suffering
with hepatic encephalopathy, and histopathology of the explanted
liver gave a diagnosis of severe hepatitis with multiacinar necrosis.
Supplementary Table 1 shows demographic information for all
patients including medications they were taking at the time of the
pre-transplant sample.
For 28 pre-transplant measurements, breath samples from the
patients' companions were taken. For the other three, two came alone
to clinic and the other's companion declined to take part. Two additional
controls were therefore recruited, one was a ward nurse and the other
was a visitor to the hospital in ITU. These controls, while not related to
the patient, had been in the same room for several hours prior to sam-
pling so that confounding factors associated with volatiles present in
the room environment were taken into consideration. In total 30 con-
trols (F:M 23:7, mean age 44 years, min–max 20–75 years) took part
in the study. The larger number of females in the control group arose
due to the tendency of men coming to the clinic accompanied with
their wives. While this means the control group is not ideally matched,
there is no consistent evidence of dependences of volatile breath
composition on sex (Kwak and Preti, 2011; Ellis and Mayhew, 2014).
In conﬁrmation of this we also found no correlation between sex and
VOCs in either our control or patient groups. We consider that inhaled
VOCs have a greater potential to confound biomarker discovery. As
themajority of the companions were living with the patients, they pro-
vided an ideal control for exposure to exogenous volatiles in the home
environment. VOCs inhaled at home, or in transit, may well still be
present in breath for hours or days after inhalation and the biological
half-life of inhaled VOCs is not well known (Beauchamp, 2011).
All study subjects were asked to complete a detailed questionnaire
which included details on their home environment, diet, smoking
status, health andmedications. Participants were asked if they had con-
sumed fruit and fruit juices and fruit ﬂavoured drinks as a normal part of
their diet, and, if so, to provide details on quantity and how long before
the breath sampling these had been consumed.
Hospital room air was collected every time breath samples were
taken so that any exogenous volatiles, such as isopropanol coming
from hand gels resulting in product ions at m/z 43 and m/z 61, could
be taken into consideration.
2.2. Breath Sampling Protocol
There is no agreed standard for the collection of breath for volatile
analysis and uncontrolled breath sampling has been shown to be
unreliable (Schubert et al., 2001; O'Hara et al., 2008). Therefore,
capnography controlled sampling was used to collect only the alveolar
phase of the breath. Subjects were in a relaxed state throughout the
measurements and were either in a seated or lying position. They
were asked to breathe normally into a gas tight respiratory system
(Intersurgical Limited) containing an in-line CO2 mainstream sensor
connected to a fast-time response capnometer (Capnogard 1265
Novametrix Medical Systems Inc.). A 100 ml glass syringe (Sigma-
Aldrich) was coupled to the tubing using a 3-way luer-lock stopcock
(BraunMedical Limited). When the alveolar plateau on the capnograph
was observed, a breath sample was manually drawn from the subject's
breath stream into the syringe. Three to four breaths samples were col-
lected for each 100 ml syringe, and four replicates of these were taken
for each subject. Glass syringes were used, because our tests showed
that they have no contaminating volatiles. Fig. 1 schematically shows
the sampling system used.
After collection, the syringes were sealed using the luer lock
ﬁtting. They were transported from hospital to laboratory (a 10 minute
outdoor walk) in an opaque storage box. Once at the laboratory, the
syringes were placed inside an incubator set at 40 °C.
All samples were mass spectrometrically analysed within 2 h of col-
lection. For themeasurements, syringeswere taken out of the incubator
and immediately placed into a purpose designed heating bag (Infroheat,
Wolverhampton) maintained at a constant temperature of 40 °C in
order to limit condensation, which could otherwise lead to volatile
1244 R. Fernández del Río et al. / EBioMedicine 2 (2015) 1243–1250
loss (Beauchamp et al., 2008). The luer stopcock was coupled to a
Swagelok ﬁtting and connected directly to the inlet of the analytical de-
vice, a proton transfer reaction mass spectrometer (PTR-MS). The inlet
ﬂow was set at 10–15 ml/min and the drift tube and inlet lines were
maintained at 45 °C. The syringes are gas tight and haveminimal friction
such that atmospheric pressure is sufﬁcient to push the plunger in
smoothly so that the breath sample is being drawn into the instrument
at a constant ﬂow.
2.3. Analytical Measurements
PTR-MS is a platform technology designed to detect low concentra-
tions of volatiles (less than parts per billion by volume). Hence it has
found use in many analytical applications ranging from drug detection
through to industrial pollution (Ellis and Mayhew, 2014; Lindinger
et al., 1998; Agarwal et al., 2011; de Gouw et al., 2011; Jurschik et al.,
2012). Details of the instrument used, a PTR-Quad-MS (IONICON
Analytik GmbH), and how it operates are described in detail in the
literature (Ellis and Mayhew, 2014; O'Hara et al., 2008; Lindinger
et al., 1998). In brief, it exploits the reactions of protonated water with
neutral volatiles (M), usually leading to a protonated parent (MH+). If
dissociative proton transfer occurs then it is not extensive in terms of
the number of resulting product ions. Operational parameters used
for this investigation were those previously reported (O'Hara et al.,
2009a,b). Namely, the drift-tube was maintained at a pressure of
2.07 ± 0.01 mbar and temperature of 45 ± 1 °C. The voltage across
the drift-tube was set at 600 V, which is sufﬁciently high to reduce
water clustering to reagent and product ions by collision induced
dissociation.
Am/z range of 20 to 200 amuwas scanned with a dwell time of 0.5 s
per atomicmass unit. Mass spectra of the breath sampleswere recorded
from the average of three cycles for each of the four syringes, for every
participant. These four spectra were averaged to provide one data set
for each subject with the uncertainty expressed as the standard error
of the mean for the four syringes.
The intensities of the product ion(s) associated with a given volatile
were converted to volumemixing ratios (VMR) in units of nmol/mol by
use of a standard procedure that relies on a calculated, compound-
speciﬁc, collisional reaction rate coefﬁcient, determined using the effec-
tive translational temperature of the reagent ions (Ellis and Mayhew,
2014).
To help identify product ions, pure samples of key volatiles were
individually measured using PTR-MS to establish the m/z values of the
product ions.
2.4. Data Analysis and Statistics
Room air contamination is a potential confounding factor in breath
analysis and has been the subject of much discussion. If the intensity of
a product ion has a signiﬁcant contribution coming from room air, then
care must be taken when using it as a biomarker. There is no simple cor-
rection which can be applied to account for inhaled volatile concentra-
tions, and it has been shown that simply subtracting the room air
concentration is too simplistic (Schubert et al., 2005; Spanel et al., 2013;
Pleil et al., 2013). For this study, a ﬁlterwas applied such that only ion sig-
nal intensities in the breath sample that were at least twice that in the
room air samples in at least half of the patients were retained for analysis.
This resulted in a set of 40 product ions for analysis. (Them/z values and
normalised counts per second are provided in Supplementary Table 2,
many of which arewell known includingm/z 33 (methanol),m/z 45 (ac-
etaldehyde),m/z 47 (ethanol),m/z 59 (acetone) andm/z 69 (isoprene).
The data sets for each volatile of interest were assessed using a
Shapiro–Wilks test and were found not to be normally distributed so
non-parametric tests were used. IBM SPSS version 22 was used for all
statistical analysis. Mann–Whitney U-tests determined which m/z
values differed between the patients and controls. A Wilcoxon signedTa
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rank test was used to determine which volatile concentrations differed
between pre- and post-transplant breath samples. To compare blood
chemistry values with breath volatiles Kendall's tau-b correlation
coefﬁcients were measured. Receiver Operating Characteristic (ROC)
curves were used to determine the diagnostic accuracy of volatiles.
3. Results
For the ﬁrst stage of our study, a Mann–Whitney U-test with a
signiﬁcance level of 95% was used to compare the 40 product ion signal
intensities used in our analysis between patients and controls. Of these,
eight showed signiﬁcant differences in intensities between patients and
controls. Their m/z values and signiﬁcance (p value in brackets) are 33
(b0.001), 73 (0.004), 77 (0.035), 81 (b0.001), 87 (b0.001), 89 (0.03),
135 (0.019) and 137 (b0.001). In the second phase, pre- and post-
transplant intensities of these eight ions were compared using a
Wilcoxon Signed Rank Test for paired samples with a signiﬁcance of
95%. This eliminated m/z 89 and 135 from the putative marker set. Of
the remaining ions, m/z 33 is assigned to be protonated methanol
(CH3OH2
+) (Lindinger et al., 1997). Based on previous GC and GC–MS
studies (Sehnert et al., 2002; Van den Velde et al., 2008; Dadamio
et al., 2012), we tentatively identify m/z 73 as protonated 2-butanone
(C4H8OH
+), m/z 77 as protonated carbon disulﬁde (CS2H
+), m/z 87 as
protonated 2-pentanone (C5H10OH
+), and m/z 81 and 137
as limonene. (m/z 81 is a fragment ion (C6H9
+) resulting from
dissociative proton transfer and m/z 137 is protonated limonene
(C10H17
+).) VMRs of these volatiles in room air, patient and control sam-
ples are shown in Fig. 2 for (a) methanol, (b) carbon disulﬁde, (c) 2-
butanone, (d) 2-pentanone, and (e) limonene (sum of the intensities
of them/z 81 andm/z 137 product ions). Themedian,mean, lower quar-
tile (LQ), and upper quartile (UQ) of the VMRs in units of nmol/mol for
each volatile are shown. It is clear from Fig. 2 that the presence of the
volatiles in room air has a negligible effect on the concentrations in
the breath samples. Furthermore, the analysis is based on comparisons
and the patients and controls should be affected similarly by the room
air contaminations.
The pre-transplant and post-transplant VMRs for methanol, carbon
disulﬁde, 2-butanone, 2-pentanone and limonene for all of our
participants who underwent liver transplants (4 females (F1–F4) and
8 males (M1–M8)) are provided in Table 2. It should be noted that
the number of days between collecting the pre-transplant and post-
transplant breath samples is variable, because it is not possible to
control when subjects are available or when a donor liver would be
found. Only for one of the patients, F2, were we able to collect a pre-
transplant breath sample just prior to surgery. However, and indepen-
dent of when the pre- and post-transplant breath samples were taken,
the results in Table 2 clearly demonstrate that the pre-transplant
concentrations of these volatiles are, for themajority of patients, higher
than the post-transplant levels for most patients. Limonene shows
the largest average decrease and also decreased in all patients post-
transplant. Post-transplant concentrations of limonene dropped to
within the normal control range (median (LQ, UQ) being 2.3 nmol/mol
(1.9, 3.0)) within a number of days for all but one of the patients, M4,
for whom limonene was found to be high even some months after
transplant.
In order to gain an insight on how the methanol, carbon disulﬁde,
2-butanone, 2-pentanone and limonene breath VMRs changed over a
period of time after transplant,ﬁve patients (F2, F4, F5,M3 andM7) par-
ticipated in a longitudinal study. The key result is that limonene VMRs
dropped gradually following transplant surgery, as illustrated in Fig. 3.
(The same data for limonene presented as normalised to the highest
intra-individual value are shown in Supplementary Fig. 1.) This concen-
tration time dependence was not observed for methanol, carbon
disulﬁde, 2-butanone and 2-pentanone. Their VMRs were found to
have dropped to within the normal range by the time of the ﬁrst post-
transplant measurement.
Taken together, the box plots (Fig. 2), the ratio of the pre- and post-
transplant VMR values and the signiﬁcance values given above imply
that ions atm/z 33, 81, 87 and 137 are the ones that are most diagnosti-
cally useful. This is conﬁrmed by ROC curve analyses. Individually,
limonene is found to provide the most predictive power (AUROC —
0.91 (standard error 0.04)). However, the best accuracy is achieved by
combining the data from methanol, 2-pentanone and limonene. The
VMRs for limonene, methanol and 2-pentanone were normalised to
the highest patient value for that volatile. These normalised fractions
were simply added with no weightings. Fig. 4 shows a ROC curve
for the combined data. The AUROC is 0.95 (standard error 0.03) and
achieves a sensitivity of 97% with a speciﬁcity of 70%.
Clinical chemistry data for the patients for whom blood data were
available were analysed for possible correlations with limonene, metha-
nol and 2-pentanone. Correlations were checked for alanine aminotrans-
ferase, alkaline phosphatase, aspartate transferase, albumin, total
bilirubin, creatinine, neutrophils, platelets, potassium, prothrombin/
international normalised ratio, and the United Kingdom Model for End-
Stage Liver Disease (UKELD). Kendall's tau-b analysis showed only one
correlation with a signiﬁcance score below 0.05. This was for methanol
with UKELDwhich had a Kendall's tau-b coefﬁcient of 0.237 (signiﬁcance
0.042). Over 33 correlations were tested and no multiple testing correc-
tion was applied so it is possible that this is a coincidental ﬁnding.
Volatile concentrations were examined for correlations with disease
etiology. Owing to the small sample size and large number of etiologies,
this was only feasible for the 13 patients with ALD versus the other 18
patients. Limonene was higher (p = 0.020) in the ALD group than the
rest, with median (LQ, UQ) of 19.7 nmol/mol (9.2, 63.9) for ALD versus
6.1 nmol/mol (2.9, 16.6) for all other etiologies.Methanol, 2-pentanone,
2-butanone and carbon disulﬁde showed no statistically signiﬁcant
difference.
Correlations between the 7 volatiles of interest in the putativemarker
set were examined both within the patient and the control group using a
Kendall's tau-b test. In the patient group, there were 8 correlations with a
signiﬁcance score of b0.05. Results for all 21 correlations are shown in
Supplementary Table 3. In the control group, only two were signiﬁcant,
limonene with m/z 135 (p = 0.016) and 2-butanone with carbon disul-
ﬁde (p b 0.001). These were also found in the patient group. Limonene
correlated signiﬁcantly with 2-butanone (p = 0.004), carbon
Fig. 1. Schematic of the breath sampling device. Breath samples are only drawn into the
glass syringe once the capnograph shows that the alveolar phase of the exhaled breath
has been reached. Typically 3–4 breaths are needed to ﬁll a syringe to 100 ml.
Fig. 2. Boxplots showing in units of nmol/mol lower quartile (LQ), median, mean and upper quartile (UQ) calculated volume mixing ratios (VMRs) for (a) methanol, (b) 2-butanone,
(c) carbon disulﬁde, (d) 2-pentanone, and (e) limonene for 31 patients with liver cirrhosis, 30 controls and room air samples. Whiskers are 1.5 times the inter-quartile range and outliers
are depicted by a star.
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disulﬁde (p = 0.034), m/z 89 (p = 0.001) and m/z 135 (p b 0.001)
but not with methanol or 2-pentanone. This suggests that the mecha-
nisms for the presence of limonene and that of methanol and 2-
pentanone are independent. 21 correlations were examined with no
multiple-testing correction applied, therefore some correlations may
be coincidental.
Correlations between the concentrations of volatiles and demo-
graphic markers such as age, BMI and sex were also checked. No
signiﬁcant correlations were found.
4. Discussion
Amajor aim of this study is to determine the viability of breath anal-
ysis as a non-invasive technique formonitoring/diagnosing liver disease
by identifying volatiles in the breath which are a consequence of the
disease. In this investigation, the monitoring of volatiles in breath
following a dramatic change in the condition of the patient, namely a
liver transplant, has provided amethod to attribute three diagnostically
useful volatiles to the cirrhotic organ itself. These are methanol,
2-pentanone, and limonene, with that of limonene being the most
signiﬁcant.
Limonene has been found in previous breath volatile studies to be
elevated in the breath of patients with cirrhosis compared with controls
(Morisco et al., 2013; Dadamio et al., 2012; Friedman et al., 1994). It has
also been observed in the breath of healthy volunteers; limonene levels
found in our control group are comparable to those previously observed
in healthy human volunteers (Mochalski et al., 2013). Limonene is not
produced in the human body. It is a common compound naturally
found in many foods and drinks; hence it would be difﬁcult to avoid
ingesting.Within the control and patient groups, we foundno association
between breath limonene and diet and no correlation between having a
self-reported large amount of fruit consumption and breath limonene
concentrations. Once in the blood stream, limonene is metabolised by
the P450 enzymes CYP2C9 and CYP2C19 to the metabolites perillyl alco-
hol, trans-carveol and trans-isopiperitenol (Miyazawa et al., 2002). It has
been found that levels of the enzyme CYP2C19 are reduced in patients
with cirrhosis and that levels inversely correlatewith severity of cirrhosis.
Moreover, of four P450 enzymes tested in patientswith liver disease,me-
tabolism by CYP2C19 was found to decrease at the earliest stage of dis-
ease (Frye et al., 2006). This is suggestive that the observed raised
concentrations of limonene in breath arise from the inability of a cirrhotic
liver to produce the appropriatemetabolic enzyme (Morisco et al., 2013).
Patient M4 is anomalous in this respect, as his breath limonene concen-
trations do not drop to the normal range post-transplant. Although his
graft liver function blood tests were found to be normal, our results sug-
gest that this patient's new liver is not producing sufﬁcient enzyme to
fully metabolise limonene.
Owing to its lipophilic properties, we propose that limonene which
is not metabolised by the liver accumulates in the fat of patients suffer-
ing from liver disease. Limonene has a blood/air partition coefﬁcient of
36 and an olive oil/blood partition coefﬁcient of 140 (Falk et al., 1990).
Assuming that the olive oil/blood partition coefﬁcient is close to a
body fat/blood partition coefﬁcient, a breath concentration of 1 part
per billion by volume (ppbv) would translate to a fat concentration of
approximately 5 parts per million by volume (ppmv). Our highest re-
corded breath VMR is 170 nmol/mol which implies a concentration in
fat of the order of 850 ppmv. A study involving women with early-
stage breast cancer taking a high oral dose of limonene (2 g/daily for
2–6 weeks before surgery) found that mean limonene concentration
in breast tissue was 41.3 ± 49.9 μg/g which is much higher than that
found in a control group (0.08 ± 0.13 μg/g) (Miller et al., 2013). Breast
tissue is primarily composed of fat (Boston et al., 2005). This supports
our hypothesis that unmetabolised limonene accumulates in fat tissue.
Following transplant, the metabolism of limonene increases, but it
takes time for the limonene to be released from the fat into the blood
stream. This, we propose, explains the observed time dependence on
limonene VMRs in the breath after transplant. A similar wash-out be-
haviour is not observed for methanol and 2-pentanone presumably
owing to their low solubilities in fat (Grifﬁn et al., 1999; Sangster, 1989).
Some medications are known to be CYP2C9 and CYP2C19
substrates and inhibitors. We therefore looked into the possibility
that medications could affect limonene concentrations. Twenty
patients were taking a CYP2C19 substrate (lansoprazole, omeprazole,
propanalol, esomeprazole), 2 were taking a CYP2C9 substrate
(naproxen, carvedilol), 6 were taking both a CYP2C9 and CYP2C19 sub-
strate and 1 was taking a CYP2C9 inhibitor (sulfamethaoxazole). Our
results show no associations of any medications which are CYP2C9
and CYP2C19 substrates or inhibitors with VMRs of breath limonene.
Moreover, nine patients who were taking enzyme substrates before
transplant were still taking them after transplant.
Of interest is the correlation between limonene and m/z 135,
because this product ion may come from perillyl alcohol (C10H16O), a
metabolite of limonene. Studies by us (unpublished) have shown that
the reaction of H3O
+ with perillyl alcohol leads to a dominant product
ion C10H15
+ resulting from dehydration of the protonated parent. Dehy-
dration following protonation is a common reaction process observed
with many alcohols (Brown et al., 2010). Morisco et al.(2013) also
noted an ion atm/z 135 from patients with cirrhosis, but they assigned
this to a terpene related compound. The fact that a correlation of m/z
135 and limonene (p b 0.001) is also signiﬁcant in the control group
lends support to our assignment, because one would expect levels of a
compound and its metabolite to be correlated in a group with well-
functioning livers. It is also of interest to note that the correlation
between limonene and m/z 89 has a very low p-value, but that m/z 89
Table 2
Calculatedmean volumemixing ratios (VMRs) for methanol, 2-butanone, carbon disulﬁde, 2-pentanone, and limonene, in units of nmol/mol for pre- and post-transplant breath samples.
The post-transplant values correspond to those for the last post-transplant sample given in Table 1. Measurement uncertainties are provided in brackets. The ratios of pre- to post-trans-
plant concentrations are also provided.
Patient Mean methanol VMRs
nmol/mol
Mean 2-butanone VMRs
nmol/mol
Mean carbon disulﬁde VMRs
nmol/mol
Mean 2-pentanone VMRs
nmol/mol
Mean limonene VMRs
nmol/mol
Pre Post Pre/post Pre Post Pre/post Pre Post Pre/post Pre Post Pre/post Pre Post Pre/post
F1 200 (6) 190 (3) 1.1 (0.04) 18 (1.2) 11 (0.2) 1.6 (0.1) 4.7 (0.4) 2.0 (0.4) 2.4 (0.5) 9.0 (0.8) 5.3 (0.6) 1.7 (0.2) 7.5 (0.6) 3.5 (0.6) 2.1 (0.4)
F2 90 (9) 230 (6) 0.4 (0.04) 16 (1.1) 15 (1.9) 1.1 (0.2) 2.4 (0.5) 20 (2.9) 0.1 (0.03) 8.3 (0.8) 7.3 (0.6) 1.1 (0.1) 60 (4.7) 1.1 (0.1) 54 (6)
F3 530 (2) 78 (5) 6.8 (0.4) 21 (1.7) 12 (2.6) 1.8 (0.4) 11 (1.3) 2.3 (0.3) 4.8 (0.8) 10 (1.2) 5.7 (0.3) 1.8 (0.2) 14 (0.7) 2.3 (0.2) 6.1 (0.6)
F4 560 (18) 71 (3) 7.9 (0.4) 19 (1.2) 12 (0.4) 1.6 (0.1) 4.7 (0.2) 2.3 (0.4) 2.0 (0.4) 25 (3.3) 6.1 (0.3) 4.1 (0.6) 11 (0.5) 2.3 (0.1) 4.8 (0.3)
M1 170 (2) 120 (15) 1.4 (0.2) 26 (1.4) 14 (1.4) 1.9 (0.2) 9.3 (0.6) 2.1 (0.4) 4.4 (0.9) 10 (0.5) 17 (2) 0.6 (0.1) 32 (0.7) 3.3 (0.5) 9.7 (1.5)
M2 430 (36) 81 (1) 5.3 (0.4) 13 (2.2) 15 (1.7) 0.9 (0.2) 3.1 (0.1) 2.4 (0.5) 1.3 (0.3) 23 (0.6) 6.2 (1.5) 3.7 (0.9) 94 (3.4) 1.6 (0.2) 59 (8)
M3 320 (32) 86 (7) 3.7 (0.5) 55 (3.1) 46 (4.2) 1.2 (0.1) 18 (2.0) 1.8 (0.2) 10 (1.6) 29 (1.0) 13 (1.2) 2.2 (0.2) 170 (1) 5.7 (0.2) 30 (1)
M4 490 (37) 93 (6) 5.3 (0.5) 38 (5.9) 23 (7.5) 1.7 (0.6) 8.5 (1.0) 2.6 (0.5) 3.3 (0.7) 38 (4.3) 9.9 (0.9) 3.8 (0.6) 110 (6) 55 (4) 2.0 (0.2)
M5 190 (3) 320 (1) 0.6 (0.01) 15 (0.5) 17 (1.3) 0.9 (0.1) 4.0 (0.4) 3.6 (0.1) 1.1 (0.1) 21 (1.3) 6.7 (0.5) 3.1 (0.3) 9.2 (0.5) 4.1 (0.2) 2.2 (0.2)
M6 230 (12) 79 (5) 2.9 (0.2) 30 (2.2) 12 (3.3) 2.5 (0.7) 13 (1.9) 2.1 (0.4) 6.2 (1.5) 13 (1.3) 5.1 (0.2) 2.5 (0.3) 120 (8) 4.8 (0.3) 25 (2)
M7 510 (21) 160 (8) 3.2 (0.2) 19 (0.7) 24 (4.2) 0.8 (0.1) 4.9 (0.9) 4.5 (0.7) 1.1 (0.3) 14 (2.6) 7.5 (0.3) 1.9 (0.4) 47 (2) 2.6 (0.1) 18 (1)
M8 180 (5) 86 (2) 2.1 (0.07) 21 (1.0) 12 (0.4) 1.8 (0.1) 6.8 (0.6) 1.9 (0.3) 3.6 (0.7) 8.8 (0.3) 13 (1.6) 0.7 (0.1) 7.7 (0.6) 3 (0.2) 2.6 (0.3)
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shows no discrimination between pre- and post-liver transplant. This is
suggestive thatm/z89 arises froman independent process related to the
patient's illness, but is not related to the cirrhosis itself.
The enhanced levels of methanol and 2-pentanone in pre-transplant
patients could come from a number of sources, including diet. Elevated
levels of methanol have been reported following consumption of alco-
hol or large quantities of fruit (Lindinger et al., 1997). It is a product of
the degradation of pectin by colonic bacteria (Siragusa et al., 1988),
and of metabolism of the sweetener aspartame (Stegink et al., 1989).
However, and in agreement with Morisco et al. (2013) we ﬁnd that
fruit consumption cannot explain the increased methanol concentra-
tions in the breath of liver patients compared to controls. Alcoholic
drinks are a source of methanol, but only one patient reported that he
had drunk alcohol within the 24 h prior to the breath sampling.
Methanol ismetabolised in humans in the liver,mainly by alcohol dehy-
drogenase (Skrzydlewska, 2003), so it is possible that thismechanism is
impaired when a liver becomes cirrhotic. Morisco et al.(2013), also
found elevated methanol in cirrhotic patients versus healthy controls.
The source of 2-pentanone in breath is unknown (King et al., 2010). It
has been found in human breath, faeces, skin and urine (de Lacy et al.,
2014), and it has been suggested that lung cells produce 2-pentanone
(Filipiak et al., 2010). 2-pentanone was suggested as a biomarker for
liver disease by three previous studies (Morisco et al., 2013; Van den
Velde et al., 2008; Vollnberg et al., 2009).
In conclusion, we have performed a two-stage study which com-
pares volatiles in the breath of pre-transplant cirrhotic patients with
controls followed by pre- and post-transplant breath samples. This has
resulted in an assignment of methanol, 2-pentanone and limonene as
markers in exhaled breath for the cirrhotic liver.We have demonstrated
that limonene can also be used for assessing liver function following
transplant by monitoring wash-out. Our study links limonene with the
diseased organ itself, rather than simply the diseased patient as a
whole. Breath volatiles have the advantage of offering non-invasive
testing, but also offer the opportunity to assess the global function of
the liver, rather than a localised test such as a biopsy. Our study raises
the possibility of a pharmacokinetic-based test for assessing liver func-
tion which could be used for diagnosing liver disease, i.e. where a
known quantity of limonene is administered and its wash-out in breath
is assessed over time. Importantly, this study provides a set of bio-
markers which can be used in future studies to assess the potential of
breath analysis for the diagnosis of early-stage liver disease.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.07.027.
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Introduction
In a recent paper we reported a study of the volatile 
biomarkers in breath associated with liver disease 
using proton transfer reaction mass spectrometry 
(PTR-MS) [1]. The results of that study strongly 
suggest that three volatiles, methanol, 2-pentanone 
and limonene, are related to a diseased liver. The risk 
of false discovery was minimised by using a two stage 
process to reduce the variable set so that we did not 
have to rely on unsupervised multivariate analysis. 
Importantly, for this present work 12 of the 31 
patients investigated in the first stage, which involved 
comparing breath samples of patients suffering with 
chronic liver disease with 30 healthy controls (usually 
partners of the ill patients), had their breath analysed 
post liver transplant. Of these 12 patients, 5 were 
followed longitudinally as in-patients during the post-
transplant period for a number of weeks. For all 12 
patients, a number of ions were observed in the proton 
transfer reaction mass spectra of the post-transplant 
breath samples, which were not present in the pre-
transplant breath samples. We considered that these 
result from a reaction of H3O
+ with the anaesthetic, 
isoflurane, (C3H2ClF5O) used during surgery. In 
agreement with this, one of the ions that we observe 
at m/z 165, has been assigned to be +CF HOCHClCF2 2  
from a Selected Ion Flow Tube-MS (SIFT-MS) analysis 
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Abstract
Isoflurane (1-chloro-2,2,2-trifluoroethyl difluoromethyl ether), C3H2ClF5O, is a commonly used 
inhalation anaesthetic. Using a proton transfer reaction mass spectrometer (PTR-MS) we have 
detected isoflurane in the breath of patients several weeks following major surgery. That isoflurane 
is detected in the breath of patients so long after being anaesthetised raises questions about when 
cognitive function has fully returned to a patient. Temporal profiles of isoflurane concentrations in 
breath are presented for five patients (F/M 3/2, mean age 50 years, min–max 36–58 years) who had 
undergone liver transplant surgery. In addition, results from a headspace analysis of isoflurane are 
presented so that the product ions resulting from the reactions of H3O
+ with isoflurane in PTR-
MS could be easily identified in the absence of the complex chemical environment of breath. Six 
product ions were identified. In order of increasing m/z (using the 35Cl isotope where appropriate) 
these are +CHF2  (m/z 51), CHFCl
+ (m/z 67), CF3CHCl
+ (m/z 117), C3F4OCl
+ (m/z 163), 
C3H2F4OCl
+ (m/z 165), and C3F4OCl
+ H2O (m/z 183). No protonated parent was detected. For the 
headspace study both clean air and CO2 enriched clean air (4% CO2) were used as buffer gases in 
the drift tube of the PTR-MS. The CO2 enriched air was used to determine if exhaled breath would 
affect the product ion branching ratios. Importantly no significant differences were observed, and 
therefore for isoflurane the product ion distributions determined in a normal air mixture can be 
used for breath analysis. Given that PTR-MS can be operated under different reduced electric fields 
(E/N), the dependence of the product ion branching percentages for isoflurane on E/N (96–138 Td) 
are reported.
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of the headspace of isoflurane with H3O
+ as the 
reagent ion [2].
Given our longitudinal measurements, which pro-
vide mass spectra of post-transplant breath samples 
for several weeks after the operation, we had a unique 
opportunity to investigate how long isoflurane remains 
in the body of unhealthy patients following major sur-
gery. This may have consequences in terms of the intel-
lectual function of patients by providing details on how 
quickly patients can safely return to a normal life.
Other PTR-MS studies have either concentrated on 
monitoring an intravenous anaesthetic, propofol, dur-
ing surgery [3–8] or for monitoring sevoflurane and 
isoflurane in the hospital environment, namely in an 
urological post-anaesthesia care unit [9] and for sevo-
flurane in an operating theatre [10].
There have been several other studies investigating 
the elimination of volatile anaesthetics from the body 
following surgery. Yasuda et al [11] used gas chroma-
tography with flame ionisation detection (GC-FID) to 
compare the kinetics of sevoflurane and isoflurane in 
humans. Of relevance to our study they report a fast 
elimination of isoflurane from the body, namely within 
a day the breath concentrations had decreased by an 
order of magnitude. However, their work used seven 
healthy male volunteers (mean age of 23 years with a 
standard deviation of 3 years). Therefore, the rapid 
decrease in concentration may not be a true reflection 
of what happens with sick, obese and/or older people. A 
more recent paper by Ghimenti et al [12] reports details 
on a study using GC-MS of post-operative elimina-
tion of sevoflurane and its metabolite, hexafluroiso-
propanol, in exhaled breath of six very sick patients 
that had undergone a variety of surgeries. They used 
pharmokinetic models for assessing liver function. 
In their investigations mixed-expired breath samples 
(multiple deep breaths) were collected in disposable 
Nalophan bags. The samples were then transferred 
to desorption tubes for subsequent analysis. Here we 
report the first PTR-MS longitudinal study investigat-
ing isoflurane in the breath of patients following sur-
gery. Prior to being able to analyse the mass spectra of 
the post-transplant breath samples, it was necessary to 
establish which product ions result from the reaction of 
H3O
+ with isoflurane in the drift tube environment of a 
PTR-MS, divorced from the complex chemical environ-
ment of breath. Therefore, as part of this study we pre-
sent a headspace analysis of isoflurane at the reduced 
electric field of 136 Td used in our previous liver study. 
Given that the product ions found in this study differ 
from those by Wang et al [2], we also present the prod-
uct ion branching ratios over an extended reduced elec-
tric field from approximately 90 Td through to 140 Td. 
These have been determined using both clean air and 
CO2 enriched clean air, to mimic breath, as the buffer 
gases in the drift tube of our PTR-MS. The use of CO2 
enriched air is important because the presence of a high 
percentage of CO2 could influence the proton transfer 
reaction leading to different product ion distributions, 
which need to be taken into account when analysing 
breath samples [13, 14].
Experimental details and methods
Headspace analysis
Isoflurane (CAS Number 26675-46-7) was purchased 
from Sigma Aldrich (UK).
Isoflurane samples were prepared for analysis by 
adding 1 µl of isoflurane into a 100 ml glass bottle. A 
100 ml glass syringe was then coupled to the top part of 
the bottle using a 3-way luer-lock stopcock and 10 ml of 
the isoflurane headspace gas was sampled. The isoflu-
rane sample was then diluted in the glass syringe with 
90 ml of clean air or CO2 enriched clean air (4% carbon 
dioxide, 17% oxygen and 79% nitrogen (Scientific and 
Technical Gases Ltd (STG, Staffordshire, UK)). The 
concentration of the isoflurane was sufficiently low that 
no depletion of the H3O
+ signal was observed.
Patients
Patients were recruited at the University Hospital 
Birmingham from the transplant assessment clinic. 
Of the 31 patients who consented to take part in the 
clinical trial, 12 went on to have liver transplant. Of 
these we were able to follow five patients for several 
weeks following surgery (F/M 3/2, mean age 50 years, 
min–max 36–58 years). Table 1 summarises the 
details of these five patients, with each patient being 
just identified by sex (F or M) and a number, which 
was used in our previous study and retained here for 
comparison [1]. Note that the number of samples 
and days at which breath samples were taken varies 
because of the availability and health of the patient. 
Patients were followed from the Intensive Care Unit 
after their transplant, through to the wards until 
their discharge. Some patients recovered and were 
discharged quicker than others so there are fewer data 
points for them.
In addition to taking breath samples from controls 
as described in [1], samples of air in the locations where 
the patients were in, were collected so that allowances 
for any background isoflurane could be taken into 
account.
Hospital room air was collected every time breath 
samples were taken using glass syringes (2 syringes for 
every sample), which were analysed in the same way as 
the breath samples. Our data relating to isoflurane con-
centrations in the hospital environment show that the 
maximum concentration for any of the sampling days 
was at 4 ppbv. There was one exception to this when 
13 ppbv was measured for one patient, F4, who was in a 
small enclosed room with poor ventilation, and there-
fore the patient was almost certainly contaminating the 
air with her own breath. Thus any contribution to the 
isoflurane signal from the environment is negligible 
compared to that in the breath.
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Breath sampling protocol
A detailed description of the breath sampling protocol 
used can be found in our earlier paper dealing with 
volatiles associated with liver disease [1]. In brief, 
capnography controlled sampling was used to 
collect only the alveolar phase of the breath. Subjects 
were seated and in a relaxed state and were asked to 
breathe normally into a gas tight respiratory system 
(Intersurgical Limited) containing an in-line CO2 
mainstream sensor connected to a fast-time response 
capnometer (Capnogard 1265 Novametrix Medical 
Systems Inc.). A 100 ml glass syringe (Sigma-Aldrich) 
was coupled to the tubing using a 3-way luer-lock 
stopcock (Braun Medical Limited). When the alveolar 
plateau on the capnograph was observed, the breath 
sample was manually drawn from the subject’s breath 
stream into the syringe. Three to four breaths samples 
were collected into each 100 ml syringe, and four 
replicates of these were taken for each subject. Glass 
syringes were used, because our tests showed that they 
minimize surface adsorption. We avoided the use of 
bags owing to potential problems associated with losses 
and ageing effects [15].
Within two hours after collection, breath samples 
were mass spectrometrically analyzed by PTR-MS, 
for which the syringes were maintained at a constant 
temperature of 40 °C using a heating bag (Infroheat, 
Wolverhampton). This was done to limit condensa-
tion, which could otherwise lead to volatile loss [16]. 
The outlet from each syringe was connected directly 
to the inlet of the PTR-MS. Within two hours we have 
found that there is no significant loss of isoflurane in 
the syringe.
Analytical measurements
PTR-MS is a technology designed to detect low 
concentrations of volatiles (less than parts per billion 
by volume). Hence it has found use in many analytical 
applications ranging from drug detection through to 
industrial pollution [17]. Details of the instrument used, 
a first generation PTR-Quad-MS (IONICON Analytik 
GmbH), and how it operates are described in detail in 
the literature [17, 18]. In brief, it exploits the reactions 
of protonated water with neutral volatiles (M), often 
leading to a protonated parent (MH+). If dissociative 
proton transfer occurs then it is not extensive in terms 
of the number of resulting product ions. The drift tube 
was maintained at 2.07  ±  0.01 mbar and temperature 
of 45  ±  1 °C. For the breath analysis the drift-tube 
voltage was set at the standard recommended value of 
600 V. For the headspace analysis the voltage across the 
drift-tube was changed from 400 V to 600 V at intervals 
of 20 V, E/N (96–138 Td).
Mass spectra of the breath samples were recorded 
and the areas under the spectral peaks converted to a 
volume mixing ratio (VMR) by use of a standard pro-
cedure that relies on the use of an experimentally meas-
ured reaction rate coefficient and reagent and product 
ion counts [17].
Results and discussion
Headspace analysis of isoflurane
No protonated isoflurane (m/z 185) was observed for 
any value of the reduced electric field. This agrees with 
the results of Wang et al who conclude that once formed 
the excited protonated parent spontaneously dissociates 
via various pathways [2]. However, in comparison to 
Wang et al SIFT-MS (thermal energy) measurements, 
we find substantial differences in product ions and 
their branching ratios. In our measurements we 
have observed primary product ions at m/z 51, m/z 
67, m/z 117, m/z 163, and m/z 165. By taking into 
account isotopic abundance we have assigned these 
to be +CHF2 , CHFCl
+, CF3CHCl
+, C3F4OCl
+, and 
C3H2F4OCl
+, respectively. Another ion involving 
isoflurane is observed at m/z 181 which is assigned as 
a secondary (association) reaction of C3F4OCl
+ with 
H2O. The product ion percentage branching ratios at 
a commonly used reduced electric field of 138 Td are 
presented in table 2 and compared to the measurements 
of Wang et al.
Wang et al observed no m/z 51 ions. This almost cer-
tainly results from the differences in collisional ener-
gies and possibly the internal energy of the H3O
+ ions, 
both of which are considered to be at thermal energies 
in SIFT-MS systems. Certainly we only observe a signifi-
cant branching ratio for this ion at 138 Td. The supple-
mentary information (stacks.iop.org/JBR/10/046006/
mmedia) provides details on the product ion branch-
ing ratios as a function of reduced electric field. This 
is provided because different PTR-MS users use dif-
ferent reduced electric fields and also because of the 
major differences observed in the product ions and 
branching ratios compared to the only other headspace 
analysis by Wang et al also observed product ions at m/z 
Table 1. Liver transplant patient details, including sex (female F, male M), age, location of post-transplant breath sampling  
(Out-Patient Clinic (OPC) or Ward), and number of days after transplant when breath samples were collected.
Patient ID Age (year)
Location of post-transplant  
breath sample
Post-transplant breath samples: 
days after transplant
F2 49 OPC 3, 5, 130
F4 58 Ward 5–8, 11–15, 18, 58
F5 53 Ward 2–6, 9–12
M3 53 Ward 4, 7, 48
M7 36 Ward 2, 3, 6–8, 55
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67, but assign it to be CF2HO
+ rather than CHFCl+, 
m/z 99 (assigned to be CF3CH2O
+), which we did not 
observe, m/z 117 (CF3CHCl
+, in agreement with our 
assignment), m/z 119 ( +CF CFHOH3 2 ), which we do not 
observe other than the 37Cl isotope of CF3CHCl
+, m/z 
147 (CF2HOCHClCH
+), which we do not observe, and 
m/z 165 (C3H2F4OCl
+).
Given that the product ion branching ratios were 
obtained using normal air in the drift tube, a question 
remains as to whether the presence of higher CO2 con-
centrations in breath could affect these ratios through 
thermalisation effects as a result of collisions of H3O
+ 
with CO2 prior to reaction with isoflurane. This is an 
important issue for breath analysis using PTR-MS. Keck 
et al [14] have already demonstrated that higher CO2 
concentrations in the drift tube buffer gas of a PTR-
MS enhances the concentration ratio of the protonated 
water dimer to protonated water and changes the mass 
spectra of key breath gases such as methanol, ethanol, 
1-propanol, 2-propanol, acetone and isoprene. We 
therefore undertook a headspace analysis using CO2 
enriched (4%) air in the drift tube to determine if the 
product ion distributions associated with isoflurane 
would be altered when analysing the breath samples. We 
find that within experimental uncertainty no signifi-
cance difference in product ion percentage branching 
ratios is observed between normal and CO2 enriched air 
buffer gases (see supplementary information). There is 
still a question of changes in humidity [2], but that will 
be the subject of another study.
Longitudinal measurements of isoflurane in breath 
samples post liver transplant
By using the product ions and their branching ratios 
determined in the headspace analysis we can determine 
the isoflurane concentrations in breath by adding the 
intensities of all product ions that result from the 
reaction of H3O
+ with isoflurane at a reduced electric 
field of 138 Td, namely m/z 51, m/z 67 (69), m/z 117 
(119), m/z 163 (165), and m/z 165 (167). It should be 
noted that the m/z 69 signal intensity cannot be used 
directly owing to the presence of isoprene in human 
breath. Therefore the total ion signal associated with 
CHFCl+ is determined only from the m/z 67 ion 
intensity. However, it is important to point out that since 
isoflurane in breath results in a spectral peak at m/z 69 
(CHF37Cl+) there are consequences for any PTR-MS 
studies which monitor isoprene in the breath following 
a surgical procedure during which isoflurane is used. 
The contribution of isoflurane to the signal intensity at 
m/z 69 was found to be significant and varied between 
12% to 99% at the beginning of our longitudinal study, 
being dependant on the concentration found in a 
patient’s breath.
Figure 1 shows the temporal changes in isoflurane 
concentrations for the five patients: F2, F4, F5, M3 
and M7. The important observation is that we did not 
observe rapid decreases in isoflurane concentrations 
following surgery. This is different from the results of 
Yasuda et al who found that the elimination of isoflu-
rane from the human body was fast [10], i.e. within 
one day the signal intensity had been observed to have 
dropped by about an order of magnitude, whereas in 
our study we still found high concentrations of iso-
flurane in the breath several days after the operation. 
Although the Yasuda et al study used healthy young 
male subjects (age 23  ±  3 years (mean  ±  sd)), the 
observed temporal difference is still surprising given 
that the major elimination of isoflurane is through 
breath. Isoflurane is poorly metabolised (0.17%) by 
hepatic cytochrome P450 enzymes in the liver [19].
A possible explanation for the observed difference 
between our results and those of Yasuda et al could 
be associated with the physical condition of the sub-
jects/patients involved and the duration of isoflurane 
administration. Yasuda et al volunteers were healthy 
and had a mean body mass index (BMI) of 21.7 kg m−2, 
i.e. all were within the normal (healthy weight) range. 
In comparision F2, F4, F5, M3 and M7 had BMIs of 
31.2, 32.4, 28.0, 32.5, and 35.0 kg m−2, respectively. 
Thus our patients were either overweight or obese. 
Furthermore, Yasuda et al administered isoflurane for 
precisely 30 min, whereas our patients underwent sur-
geries that lasted between 5 to 7 h. Although isoflurane 
has a low blood/gas partition coefficient of 1.45  ±  0.12 
(mean  ±  SD) [20], it has a high oil/blood partition 
coefficient of 97, and therefore we propose that for 
our patients a significant amount of the isoflurane was 
absorbed into fat tissue, only to be slowly released after 
surgery. In support of this argument, it has been found 
that if isoflurane is administered for more than 2 h, as 
would be the case for our patients, the adipose tissue 
becomes saturated and then the emergence from the 
anaesthetic is prolonged [21].
Finally, we comment that of all our patients, patient 
M7 showed the fastest elimination of isoflurane even 
though he had the highest concentration in exhaled 
Table 2. m/z values (dominant ion peak), proposed product ions 
and branching ratio percentages resulting from the reaction of 
H3O
+ with isoflurane using PTR-MS (reduced electric field of  
138 Td) and SIFT-MS [2]. 
m/z
Proposed  
product ion % PTR-MS % SIFT-MS [2]
51 CHF2
+ 12 —
67 CF2HO
+ — 15
67 CHFCl+ 50 —
99 CF3CH2O
+ — 10
117 CF3CHCl
+ 6 30
119 CF CFHOH3 2
+ — 25
147a CF3HOCHClCH
+ — 10
163 CF3CClOCF
+ 24 —
165 CF HOCHClCF2 2
+ 8 10
a In the paper by Wang et al the ion at m/z 147 is incorrectly given 
as CF2HOCHClCH
+.
Note: The percentages have taken into account the 37Cl isotope for 
the chlorine containing ions. For the PTR-MS studies the product 
ion branching percentages have an error of approximately  ±20%.
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breath after surgery and was the most obese patient. 
However, the elimination was still much less than found 
in the study of Yasuda’s study. The rapid washout, in 
comparison to the other patients, could be a result of 
this patient being the youngest of the group involved at 
36 years old. (F2, F4, F5 and M3 ages were 49, 58, 53 and 
53 years, respectively.) M7 also recovered from surgery 
more quickly than the other patients in this group and 
was discharged within one week. However, with such a 
small number of patients we cannot state whether or 
not there is any correlation with age and perhaps gender 
with regards to isoflurane elimination from fatty tissue. 
More detailed studies are therefore required.
Conclusions
An aim of this study was to determine which product 
ions result from the reaction of H3O
+ with isoflurane 
in order to monitor isoflurane in the breath. No 
protonated parent was observed, instead the protonated 
parent rapidly fragments to diagnostically useful ions 
with m/z values of 67 (69), 117 (119), 163 (165) and 165 
(167), which are assigned to be CHFCl+, CF3CHCl
+, 
C3F4OCl
+ and C3H2F4OCl
+ respectively. Using 
these ions, the wash out characteristics of isoflurane 
following liver transplant have shown that a patient will 
still have high levels of isoflurane in their blood even 
several days after the operation. This could have an 
impact on a patient’s ability to drive and use machines 
after isoflurane anesthesia administration, especially 
after a long operation, when isoflurane will be stored 
in fat tissue.
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Figure 1. Longitudinal changes in volume mixing ratios 
(VMR) in nmol/mol for isoflurane for given days after liver 
transplant for patients F2, F4, F5, M3, and M7. Error bars are 
not shown as they are smaller than the data points.
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Abbreviations
ALD Alcoholic liver disease
GC Gas chromatography
HE Hepatic encephalopathy
HCC Hepatocellular cancer
ITU Intensive treatment unit
LQ Lower quartile
MS Mass spectrometry
MHE Minimal hepatic encephalopathy
OHE Overt hepatic encephalopathy
OPU Out-patient clinic
ppbv Parts per billion by volume
PTR-MS Proton transfer reaction mass spectrometry
UKELD United Kingdom model for End-stage Liver 
Disease
UQ Upper quartile
VOC Volatile organic compounds
VMR Volume mixing ratio
1. Introduction
Volatile organic compounds (VOCs) are produced 
in the body as a result of various metabolic processes 
and endogenous VOC analysis in the breath has been 
proposed as a potential diagnostic tool in human 
disease. Breath analysis has attracted clinical and 
scientific attention as a potential means for delivering 
non-invasive, real-time rapid screening and diagnosis 
of complex diseases. Recent overviews of the field 
are provided in a book published in 2014 [1] and in 
numerous review papers [2–6].
Breath VOCs have been measured in patients with 
liver disease in a number of studies [7–21] and several 
VOCs have been suggested as biomarkers for cirrho-
sis. In particular, sulphur compounds have been sug-
gested as being associated with liver disease and are 
responsible for the characteristic odour of patient’s 
breath called Foetor Hepaticus [19, 22]. Previous work 
Limonene in exhaled breath is elevated in hepatic encephalopathy
M E O’Hara1,5, R Fernández del Río1, A Holt2, P Pemberton3, T Shah2, T Whitehouse3 and C A Mayhew1,4
1 School of Physics and Astronomy, University of Birmingham, Birmingham B15 2TT, UK
2 Department of Hepatology, University Hospital Birmingham NHS Trust, Birmingham B15 2TH, UK
3 Critical Care and Anaesthesia, University Hospital Birmingham NHS Trust, Birmingham B15 2TH, UK
4 Institut für Atemgasanalytik, Leopold-Franzens-Universitaet Innsbruck, Rathausplatz 4, 6850 Dornbirn, Austria
5 Author to whom any correspondence should be addressed.
E-mail: m.e.ohara@bham.ac.uk, r.fernandezdelrio@bham.ac.uk, c.mayhew@bham.ac.uk, Andrew.holt@uhb.nhs.uk,  
Tahir.Shah@bham.ac.uk, pembo@doctors.org and Tony.Whitehouse@uhb.nhs.uk
Keywords: breath analysis, cirrhosis, limonene, hepatic encephalopathy, PTR-MS, volatile organic compound
Abstract
Breath samples were taken from 31 patients with liver disease and 30 controls in a clinical setting 
and proton transfer reaction quadrupole mass spectrometry (PTR-Quad-MS) used to measure the 
concentration of volatile organic compounds (VOCs). All patients had cirrhosis of various etiologies, 
with some also suffering from hepatocellular cancer (HCC) and/or hepatic encephalopathy (HE). 
Breath limonene was higher in patients with No-HCC than with HCC, median (lower/upper 
quartile) 14.2 (7.2/60.1) versus 3.6 (2.0/13.7) and 1.5 (1.1/2.3) nmol mol−1 in controls. This may 
reflect disease severity, as those with No-HCC had significantly higher UKELD (United Kingdom 
model for End stage Liver Disease) scores. Patients with HE were categorized as having HE symptoms 
presently, having a history but no current symptoms and having neither history nor current 
symptoms. Breath limonene in these groups was median (lower/upper quartile) 46.0 (14.0/103),  
4.2 (2.6/6.4) and 7.2 (2.0/19.1) nmol mol−1, respectively. The higher concentration of limonene 
in those with current symptoms of HE than with a history but no current symptoms cannot be 
explained by disease severity as their UKELD scores were not significantly different. Longitudinal 
data from two patients admitted to hospital with HE show a large intra-subject variation in breath 
limonene, median (range) 18 (10–44) and 42 (32–58) nmol mol−1.
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has included patients with various etiologies, different 
sampling methods and different analytical methods. It 
is, therefore, difficult to compare results. There is some 
agreement as to which potential biomarkers are associ-
ated with liver disease, but not all studies find the same 
volatile markers. As previously reported [7], these issues 
were addressed by conducting a two phase biomarker 
discovery study. Limonene, methanol and 2-pentanone 
were identified as biomarkers of liver cirrhosis. These 
VOCs not only discriminated cases from controls but 
were also significantly different before and after liver 
transplantation in a sub-group of patients who had 
received a transplant.
Pilot data [23] was obtained by our group prior 
to the published study from patients in out-patient 
clinic. Twelve had cirrhosis or fibrosis, four had neu-
roendocrine disease with liver tumours and five 
had well-functioning graft livers following previous 
liver transplants due to Hepatitis C virus. This study 
found that a monoterpene, which was assumed to be 
limonene, had elevated concentrations in the breath 
of patients with cirrhosis, and in particular, those with 
hepatic encephalopathy (HE). Limonene in the breath 
of patients with liver cirrhosis has been observed in 
two other studies using GC-MS [9, 10] and tenta-
tively identified in a proto n transfer reaction—time of 
flight-mass spectrometric (PTR-TOF-MS) study [13]. 
Limonene is a monoterpene of dietary origin, typically 
found in citrus fruits but also naturally occurring in 
many vegetables. There is no evidence to suggest that 
it can be produced in the human body. It is used in the 
food and drink industry to give a citrus flavor and in 
perfumes and air fresheners. As such, it is a ubiquitous 
exogenous compound and it would be difficult to avoid 
in the diet in general. Limonene is metabolized in the 
liver by the P450 enzymes CYP2C9 and CYP2C19 [24] 
to the metabolites perillyl alcohol, trans-carveol and 
trans-isopiperitenol. It has been noted that levels of the 
enzyme CYP2C19 are reduced in patients with cirrhosis 
and, that levels inversely correlate with severity of cir-
rhosis [25]. This presents the possibility that elevated 
levels of limonene in the body may be associated with 
liver disease owing to a reduced ability of the liver to 
produce the appropriate metabolic enzymes, as has 
already been noted [13].
The present work will discuss these results further in 
respect to HE, a co-morbidity of advanced liver cirrho-
sis. Comparisons of cirrhosis with and without hepa-
tocellular cancer (HCC) and HE will be shown. Results 
of longitudinal data on patients with HE to examine 
intra-individual variation in these three VOCs of inter-
est will also be shown.
HE is a spectrum of neuropsychiatric abnormal-
ity associated with liver dysfunction. Symptoms vary 
in severity depending on the stage of the illness and 
include confusion, lethargy, sleep disturbance, person-
ality change and cognitive impairment. In its extreme 
form, it can lead to coma and even death [26]. Overt 
HE (OHE) can be diagnosed clinically, usually using 
a scoring system such as the West-Haven criteria, and 
can be episodic or persistent. HE can affect the patient’s 
mental functioning intermittently [27], so it is possible 
for them to pass a neurological test on the day of the 
examination, while still suffering from symptoms at 
other times.
Minimal HE (MHE) is difficult to diagnose and 
requires specialized testing. It is possible for patients to 
be suffering from undiagnosed MHE [28]. There is no 
gold standard for the diagnosis of HE and many scor-
ing systems have been criticized for lack of objectivity 
[28]. Current recommendations [29] include using the 
clinical HE staging scale (CHESS) [30], the HE scor-
ing algorightm (HESA) [31] or modified orientation 
log (MOD) to refine the West-Haven criteria but their 
widespread use has yet to be adopted.
Estimates of the incidence of MHE range from 20% 
to 84% of cirrhotic patients, depending on which test-
ing methods are used [27]. HE not only degrades qual-
ity of life, but it means a poorer prognosis for the patient 
[32]. HE is thought to be caused by the action of neuro-
toxic substances including ammonia and manganese, 
which are usually metabolised by the liver, persisting in 
elevated concentrations. These toxins can then cause 
glutamine induced changes in astrocytes that lead to the 
clinical manifestations of HE [33, 34]. Usual treatment 
is through the use of laxatives and antibiotics which act 
to prevent the accumulation of toxins. In the advanced 
stages, patients must be admitted to hospital for man-
agement of episodes of OHE.
Breath analysis for HE has been investigated pre-
viously in two other pilot studies which used GC-MS 
in patients with cirrhosis [20, 35], but neither of these 
reported limonene as a marker for HE. One pilot study 
investigated HE using an e-nose [36], but this technique 
is unable to specify exactly which VOCs are responsible 
for the discrimination so it is not possible to determine 
whether it is based on limonene.
2. Methods
2.1. Patients, controls and hospital room air
Patients were recruited at the University Hospital 
Birmingham from either the transplant assessment 
clinic or in wards after being admitted with HE. The 
regional ethics committee of Camden and Islington, 
London approved this study (REC reference: 13/
LO/0952). Written informed consent was obtained 
from each volunteer.
Thirty-one patients suffering from liver disease 
participated in the pre-transplant measurements (F/M 
8/23, mean age 55 years, min–max 27–71 years). There 
were a number of etiologies and 11 patients had more 
than one condition. Full details of the patients and their 
diagnoses are given in our earlier publication which 
reported volatiles associated with liver cirrhosis.
For the longitudinal data, two patients were 
recruited having been admitted as in-patients suffer-
ing from HE. Patient M1 was a 54 years old male with a 
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primary diagnosis of alcoholic liver disease (ALD). He 
gave four breath samples during an admission for HE 
before his liver transplant, then three further samples 
after transplant. Patient M15 was also a 54 years old 
male with a primary diagnosis of ALD. He gave breath 
samples on seven different days during an admission 
for HE. He did not receive a transplant so gave no post-
transplant samples.
For 28 pre-transplant measurements, breath sam-
ples from the patients’ companions were taken. For the 
other three, two came alone to clinic and the other’s 
companion declined to take part. Two additional con-
trols were therefore recruited, one was a ward nurse 
and the other was a visitor to the hospital in ITU. These 
controls, while not related to the patient, had been in 
the same room for several hours prior to sampling so 
that confounding factors associated with any volatiles 
present in the room environment could be taken into 
consideration. In total 30 controls (F:M 23:7, mean age 
44 years, min–max 20–75 years) took part in the study. 
The larger number of females in the control group arose 
because the majority of patients were men and often 
attended the clinic with their wives. While this means the 
control group is not ideally matched, there is no consist-
ent evidence of dependences of volatile breath composi-
tion on sex [1, 37]. In confirmation of this, no correlation 
was found between sex and VOCs in either our control 
or patient groups. It was considered that inhaled VOCs 
have a greater potential to confound biomarker discov-
ery. As the majority of the companions were living with 
the patients, they provided an ideal control for exposure 
of exogenous volatiles in the home environment. VOCs 
inhaled at home, or in transit, may well still be present in 
breath for hours or days after inhalation; the biological 
half-life of inhaled VOCs are not well known and in any 
case may be patient-specific [38].
All study subjects were asked to complete a detailed 
questionnaire which included details on their home 
environment, diet, smoking status, health and medi-
cations. Participants were asked if they had consumed 
fruit, fruit juices and fruit-flavoured drinks as a nor-
mal part of their diet, and, if so, to provide details on 
quanti ty and how long before the breath sampling these 
had been consumed.
Hospital room air was collected every time breath 
samples were taken so that any exogenous volatiles, 
such as isopropanol coming from hand gels, resulting 
in product ions at m/z 43 and m/z 61, could be taken 
into consideration. There are fewer room air samples 
than patient-control pairs because the same room was 
used for consecutive patient-control pairs on the same 
day in some cases.
Diagnosis of HCC was based on previous invest-
igations including radiology and histology. For analy-
sis of HCC, the groupings are HCC (N  =  10): those 
with at least one hepatocellular tumour, and No-HCC 
(N  =  21): those with no hepatocellular tumours. HE 
status was assessed both from clinical diagnosis using 
the West Haven criteria and also from questioning of the 
patient and the relative with whom they were attend-
ing clinic. Patients and relatives were questioned as to 
whether the patient was suffering from any symptoms 
of HE at the present time and were classed as having HE 
at the present time if they answered yes. Some patients 
and relatives reported having had HE in the past, some-
times following a trigger such as an infection, but that 
the patient had recovered and was not symptomatic 
on the day of the breath sample. These patients were 
classed as having a history but not currently suffering. 
The final group of patients had never had HE and did 
not have symptoms on the day of sampling according 
to their medical records and their own and their com-
panions’ assessment of their mental function. These 
patients are classed as ‘No-HE’. For analysis of HE, the 
grouping are: 1. HE-now: suffering symptoms of HE 
on the day the breath samples were taken (N  =  11); 
2. History-HE: had suffered from HE in the past but 
were not suffering symptoms on the day of sampling 
(N  =  7), and 3. No-HE: those who were not suffering 
symptoms on the day of sampling, nor had any history 
of HE (N  =  11). All patients were ambulatory and were 
seen in clinic, apart from four who had been admitted 
to hospital for HE, one of whom had acute liver failure. 
Only one patient (ID code M15) had HE above grade 
2. In the No-HE and History-HE groups, no patients 
were taking medication for HE. One patient in each of 
these two groups was taking lactulose, but in each case 
this was for constipation, not for symptoms of HE. Of 
the 11 HE-now patients, eight were taking medication 
for HE: three were on lactulose and rifaximin, one on 
rifaximin only and four on lactulose only.
2.2. Breath sampling protocol
There is no agreed standard for the collection of breath 
for volatile analysis, and uncontrolled breath sampling 
has been shown to be unreliable [39, 40]. Therefore, 
capnography controlled sampling was used to collect 
only the alveolar phase of the breath. Subjects were in 
a relaxed state throughout the measurements and were 
either in a seated or recumbent position. They were 
asked to breathe normally into a gas tight respiratory 
system (Intersurgical Limited) containing an in-line 
CO2 mainstream sensor connected to a fast-time 
response capnometer (Capnogard 1265 Novametrix 
Medical Systems Inc.). A 100 ml glass syringe (Sigma-
Aldrich) was coupled to the tubing using a 3-way luer-
lock stopcock (Braun Medical Limited). When the 
alveolar plateau on the capnograph was observed, a 
breath sample was manually drawn from the subject’s 
breath stream into the syringe. Three to four alveolar 
breath samples were collected for each 100 ml syringe, 
and four replicates of these were taken for each subject. 
Glass syringes were used, because our tests showed 
that they have no contaminating volatiles. Figure 1 
schematically shows the sampling system used.
After collection, the syringes were sealed using the 
luer lock fitting. They were transported from hospital 
to laboratory (a 10 min outdoor walk) in an opaque 
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 storage box. Once at the laboratory, the syringes were 
placed inside an incubator set at 40 °C.
All samples were mass spectrometrically analyzed 
within 2 h of collection. For the measurements, syringes 
were taken out of the incubator and immediately 
placed into a purpose designed heating bag (Infroheat, 
 Wolverhampton) maintained at a constant temper-
ature of 40 °C in order to limit condensation, which 
could otherwise lead to volatile loss [40]. The luer stop-
cock was coupled to a Swagelok fitting and connected 
directly to the inlet of the analytical device, a proton 
transfer reaction mass spectrometer (PTR-MS). The 
inlet flow was set at 10–15 ml min−1 and the drift tube 
and inlet lines were maintained at 45 °C. The syringes 
are gas tight and have minimal friction such that atmos-
pheric pressure is sufficient to push the plunger in 
smoothly so that the breath sample is being drawn into 
the instrument at a constant flow.
2.3. Analytical measurements
PTR-MS is a platform technology designed to detect 
low concentrations of volatiles (less than parts per 
billion by volume). Hence it has found use in many 
analytical applications ranging from drug detection 
through to industrial pollution [1, 41–44]. Details of 
the instrument used, a PTR-Quad-MS (IONICON 
Analytik GmbH), and how it operates are described in 
detail in the literature [1, 40, 41]. In brief, it exploits 
the reactions of protonated water with neutral 
volatiles (M), usually leading to a protonated parent 
(MH+). If dissociative proton transfer occurs then it 
is not extensive in terms of the number of resulting 
product ions. Operational parameters used for this 
investigation were those previously reported [45, 46]. 
Namely, the drift-tube was maintained at a pressure of 
2.07  ±  0.01 mbar and temperature of 45  ±  1 °C. The 
voltage across the drift-tube was set at 600 V, which is 
sufficiently high to reduce water clustering to reagent 
and product ions by collision induced dissociation.
A m/z range of 20–200 amu was scanned with a 
dwell time of 0.5 s per atomic mass unit. Mass spectra 
of the breath samples were recorded from the average 
of three cycles for each of the four syringes, for every 
participant. These four spectra were averaged to pro-
vide one data set for each subject with the uncertainty 
expressed as the standard error of the mean for the four 
syringes.
The intensities of the product ion(s) associated 
with a given volatile were converted from nor malized 
counts per second (cps) to volume mixing ratios 
(VMR) in units of nmol mol−1. Normalisation was to 
50 million cps of the sum of the area under the peak 
of the H3O
+ and the (H3O
+) · (H2O) ions. Conver-
sion to VMR was by use of a standard procedure that 
relies on a calculated, compound-specific, collisional 
reaction rate coefficient, determined using the effec-
tive translational temperature of the reagent ions [1]. It 
should be noted that PTR-Quad-MS has a mass resolu-
tion of approximately 1 amu so it is possible that other 
compounds or fragments could contribute to observed 
peaks.
To help identify product ions, pure samples of key 
volatiles were individually measured using PTR-MS to 
establish the m/z values of the product ions.
2.3.1. Statistical analyses
The data sets for each volatile of interest were assessed 
using a Shapiro–Wilks test and were found not to be 
normally distributed so non-parametric tests were 
used. IBM SPSS version 22 was used for all statistical 
analysis. Mann–Whitney U-tests determined which 
m/z values differed between the patients and controls in 
the original study, and to assess whether concentrations 
of volatiles were significantly different between HCC 
with non-HCC patients. A Kruskal–Wallis one way 
analysis of variance was used to compare the HE-now, 
History-HE and No-HE groups. All tests were done 
using a significance level of 0.95.
Figure 1. Schematic of the breath sampling device. Breath samples are only drawn into the glass syringe once the capnograph shows 
that the alveolar phase of the exhaled breath has been reached. Typically 3–4 breaths are needed to fill a 100 ml syringe.
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3. Results and discussion
3.1. Case control study
As previously reported [7], differences between patients 
and controls were found for four mass spectral peaks: 
m/z 33, m/z 81, m/z 87 and m/z 137. Peaks at m/z 81 and 
m/z 137 result from limonene; the protonated parent is 
at 137 and m/z 81 is a fragment ion (C6H9) [47, 48]. The 
area under the peaks for both m/z 81 and m/z 137 were 
summed and used to determine the concentration of 
limonene in the breath samples. PTR-MS is unable to 
differentiate isomers, and there is a possibility that other 
monoterpenes could have contributed to these peaks. 
However, previous work in humans has indicated that 
limonene is the most abundant monoterpene in human 
breath and blood [49]. GC-MS confirmation was 
performed with one of the breath samples to confirm 
the presence of limonene by colleagues at the Max 
Planck Institute in Mainz, Germany. The methodology 
has been previously reported [50, 51]. Limonene has 
also been shown to be elevated in the breath of patients 
with liver disease in other studies [10, 13].
The patient group has been further subdivided into 
those with and without hepatocellular cancer (HCC 
and No-HCC, respectively. Box plots of limonene, 
methanol (m/z 33) and 2-pentanone (m/z 87) for 
patients with and without HCC, controls and room air 
are shown in figure 2. Figures for mean, (lower quar-
tile (LQ)/upper quartile (UQ)) are given in the figure. 
There is a difference between patients with and without 
HCC only for limonene, with a Mann–Whitney U score 
of significance p  =  0.015.
Figure 3 shows comparisons for the groups 
No-HE, History-HE, HE-now, controls and room air. 
Compariso n of the three patient groups revealed that 
only one VOC, limonene, was able to successfully differ-
entiate the groups with a Kruskall–Wallis score of sig-
nificance p  =  0.001. Figure 3 shows a clear difference 
between HE-now and History-HE. For No-HE, there 
is overlap with the HE-now group, but this is highly 
skewed by just three patients.
It was conjectured that the difference in means 
between breath limonene in the No-HCC versus HCC 
groups may be a reflection of severity of cirrhosis. Often 
patients are considered for transplant on the basis of the 
presence of a hepatocellular tumour while the rest of the 
liver is still compensating adequately. This conjecture is 
supported by analysis of the UKELD (United Kingdom 
model for End-stage Liver Disease) score for the groups. 
UKELD is a scoring algorithm which combines a selec-
tion of clinical chemistry values and gives a prediction 
of 1 year mortality [52]. It is used to select patients for 
Figure 2. Boxplots showing in units of nmol mol−1 lower quartile (LQ), median (Med), and upper quartile (UQ) calculated volume 
mixing ratios (VMRs) for (a) limonene, (b) methanol and (c) 2-pentanone for 21 patients with liver cirrhosis without HCC  
(No-HCC), 10 patients with cirrhosis and HCC (HCC), 30 controls and room air. Whiskers are 1.5 times the inter-quartile range 
and outliers are depicted by a star.
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transplant in the United Kingdom and patients are 
usually considered for transplant when their UKELD 
score is  >49, unless there is an additional indication 
for transplant such as HCC. The mean (range) of the 
UKELD score for the No-HCC and HCC groups is 54 
(48–63) and 49 (43–56), respectively. These are signifi-
cantly different (Mann–Whitney p  =  0.002). A similar 
analysis was done for the HE classifications to deter-
mine whether patients in the HE-now group had more 
severe disease. UKELD scores for the three groups were 
49 (43–57) for No-HE, 53 (46–63) for History-HE and 
55 (51–62) for HE-now. There is no significant differ-
ence between the UKELD scores for the History-HE and 
HE-now groups (Mann–Whitney p  =  0.21), but there 
is a significant difference between the No-HE groups 
and the HE-now groups (Mann–Whitney p  =  0.001). 
It is perhaps not surprising that the group which has 
never experienced HE has a lower UKELD score than 
the group which was suffering symptoms at the time 
of sampling. However, the large difference in limonene 
between the History-HE group and the HE-now group 
cannot be explained by a difference in severity as judged 
by UKELD score. Overall, as previously reported [7], 
there is no correlation between the concentration of 
breath limonene and UKELD score. A prospective 
observational multicentre study of 1348 patients in 
29 liver units in eight European countries was recently 
undertaken to investigate risk factors for the develop-
ment of HE and assess survival in patients with liver 
cirrhosis [53]. This found that previous HE was the most 
important risk factor for the development of HE, with 
a poor relationship between traditional precipitating 
factors such as bacterial infections, active alcoholism 
or gastrointestinal haemorrhage. Our present study 
has found that limonene is able to distinguish between 
 History-HE and HE-now groups, which presents the pos-
sibility of a screening or monitoring tool to enable target-
ing of prophylactic therapies in at-risk populations.
As previously reported [7], there was no association 
between self-reported consumption of fruit/fruit juice 
Figure 3. Boxplots showing in units of nmol mol−1 lower quartile (LQ), median (Med) and upper quartile (UQ) calculated volume 
mixing ratios (VMRs) for (a) limonene, (b) methanol and (c) 2-pentanone for 11 patients without HE (No HE), 8 patients who 
have a history of HE but are not showing symptoms on the day of sampling (History HE), 12 patients who were suffering symptoms 
of HE on the day of sampling (HE-now), 30 controls and room air. Whiskers are 1.5 times the inter-quartile range and outliers are 
depicted by a star.
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and elevated breath limonene. Studies by us (unpub-
lished) have shown that in normal healthy people, con-
sumption of pure, concentrated orange juice is followed 
by a small increase in breath limonene which returns 
to baseline within half an hour. There is nothing in the 
diet or previous 24 h diet of the patients which would 
explain elevated breath limonene.
Khalid et al suggested isothiocyanato-cyclohexane 
as indicating the presence of HE, and methyl vinyl 
ketone as indicating absence of HE within a group of 
alcoholic cirrhotics [35]. They used a presence/absence 
analysis in which absolute concentrations were not 
measured; rather only the presence or absence of a com-
pound above three times the signal to noise ratio was 
compared across groups. Using this analysis, our previ-
ous results would not have shown a difference between 
cases and controls because limonene was also observed 
in controls, albeit at very low concentrations. Limonene 
has also been found in the blood and in the emissions 
from skin of healthy volunteers, and can be consid-
ered a normal volatile emission from healthy humans 
[54, 55]. A previous study using GC-MS to examine 
the normal volatile constituents of human breath 
reported limonene in the venous blood and breath of 
all 28  subjects [49]. The mean (range) concentration 
in breath was 1.46 ppbv (0.27–7.42), which is similar 
to our findings.
To our knowledge, Vollnberg et al [20] remains, 
until now, a conference abstract rather than a full paper 
so insufficient details are known to make a compariso n, 
but they noted acetoin (3-hydroxybutanone) and 
2-pentanone as having predictive utility for HE [20]. 
The present study has found 2-pentanone as predic-
tive for the presence of cirrhosis versus controls, but 
did not find a difference between those with and with-
out HE. Participants had been asked to indicate when 
they last had something to eat or drink, but there was 
no  association with time since last meal and concentra-
tion of 2-pentanone. Acetoin would give a prot onated 
parent peak at m/z 89. In our initial case-control com-
parison, m/z 89 was significantly different between 
patients and controls. It did not, however, show a dif-
ference between patients pre- and post-transplant so it 
was discounted as being a useful diagnostic volatile for 
liver cirrhosis. Figure 4 shows the box plot for group-
ings of HE status for m/z 89. Only normalized counts 
per second are shown as we are not confident about 
assigning an identity to this peak. The HE-now group 
is significantly different from the other groups, but the 
variation in room air is large and it overlaps with all 
other groups. An examination of the 12 patients who 
had a transplant shows that the concentration of m/z 89 
in patients with and without HE is not significantly dif-
ferent. It is important to bear in mind that isomeric and 
isobaric compounds cannot be distinguished in our 
system and a signal from acetoin may be confounded 
by the presence of another volatile which produced a 
product ion at the same m/z.
3.2. Longitudinal study
Two patients (ID codes M1 and M15) who had been 
admitted suffering with HE were followed over the 
course of their stay in hospital. Only M15 had high 
grade HE, and had very low mental capacity. M1 
received a liver transplant during the course of the study 
so his results show four pre-transplant samples and 
three post-transplant. Figure 5 shows concentrations 
of limonene, methanol and 2-pentanone in breath and 
room air over the course of the measurement period. 
For M1, study days 1, 2, 3 and 4 correspond to 47, 44, 42 
and 40 d prior to transplant, respectively. Study days 5, 6 
and 7 correspond to 28, 29 and 33 d after transplant. All 
measurements were taken in wards, except for study day 
7 which was taken in the out-patient clinic. For M15, 
Figure 4. Boxplots showing normalized counts per second lower quartile (LQ), median (Med) and upper quartile (UQ) calculated 
volume mixing ratios (VMRs) for m/z 89 for 11 patients without HE (No-HE), 8 patients who have a history of HE but are not 
showing symptoms on the day of sampling (history HCC), 12 patients who were suffering symptoms of HE on the day of sampling 
(HE-now), 30 controls and room air. Whiskers are 1.5 times the inter-quartile range and outliers are depicted by a star. Note that only 
18 room air samples are used as one sample gave a peak which could not be distinguished above the instrumental noise.
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if study day 1 is taken to be on day 1, study days 1–7 
correspond to days 1, 2, 6, 7, 8, 9 and 15. The patient was 
discharged on day 15.
The main thing to note is the high degree of 
 variability from day to day. Despite this, there is still a 
measureable drop in breath limonene and methanol 
following transplant for M1. There is what appears to be 
an anomalous result for 2-pentanone for M1 on study 
day 6, which is, at present, unexplained as it was also 
not present in the room air. A corresponding peak in 
the mass spectrum at m/z 89 suggests that it may have 
been a chlorinated compound. It is possible that the 
patient inhaled an environmental contaminant at high 
 concentration some time before the breath test and it 
was still washing out.
The variability for M15 is more pronounced than 
for M1. This patient had grade 3 or 4 HE for the first 6 d 
of the study. On study day 7 his acute HE had resolved 
sufficiently to be discharged later that day, although it 
is likely that he was still suffering from minimal HE as 
he had a recent history of repeated hospital admissions. 
There were difficulties in obtaining samples from this 
patient on some days of the study as his mental inca-
pacity was such that he was unable at times to comply 
with instructions to breathe into the apparatus. It was, 
therefore, very difficult to obtain reliable end-tidal 
Figure 5. Scatter plots showing in units of nmol mol−1 lower quartile (LQ), median (Med) and upper quartile (UQ) calculated 
volume mixing ratios (VMRs) for (a) limonene, (b) methanol and (c) 2-pentanone for patients M15 (left hand panel) and M1 
(right hand panel). Breath concentrations are shown in black triangles and room air in red triangles. For M1, study days 1–4 are 
pre-transplant and days 5–7 are post-transplant. For patient M15, all days are pre-transplant as he did not receive a transplant. The 
dashed horizontal line indicates the median of the concentration for healthy controls for each particular volatile. ∗The mean is given 
for M1 2-pentanone as it does not include the outlying point.
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samples and it is possible that some of his samples were 
contaminated with dead-space air. From this limited 
evidence, it does not appear that breath limonene can 
predict daily variations in symptoms of HE for an indi-
vidual patient.
4. Conclusions
Limonene, methanol and 2-pentanone have previously 
been shown to be elevated in the breath of cirrhotic 
patients compared with controls and in patients 
pre-transplant compared with the same patients 
after transplant [7]. Limonene, but not methanol or 
2-pentanone is able to discriminate patients currently 
suffering symptoms of HE from patients with no 
current symptoms. Patients with HCC had lower levels 
of limonene than those without HCC but this may be a 
reflection of the fact that patients with HCC are usually 
considered for transplant at an earlier stage of liver 
decompensation. This is supported by the fact that the 
UKELD scores for patients with HCC were significantly 
lower than patients without HCC.
It is possible that breath limonene is higher in more 
severe liver disease, and because HE is a complication 
of advanced disease, high breath limonene may simply 
be a proxy for advanced disease. However, there was no 
correlation between limonene and any clinical chem-
istry value. Nor was there a scorrelation with UKELD 
score. This leaves the possibility that limonene is itself a 
causative agent in HE. Limonene is highly lipophilic; this, 
together with its low molecular mass, make it possible 
for it to cross the blood–brain barrier. There have been 
cases of acute poisonings with tea tree oil, which is com-
posed of terpenes and terpinoids, including limonene 
at low levels. The symptoms were confusion, drowsi-
ness and coma [56]. These are strikingly similar to the 
symptoms of HE, and suggest that molecules from the 
oil crossed the blood–brain barrier to cause neurological 
symptoms. In all cases, the effects were transient and the 
patients recovered within a matter of hours. While this 
was not pure limonene, terpinoid oils are composed of 
similar units and it is not known what biochemical reac-
tions will occur if limonene is resident in the human body 
for long periods. While limonene has not been shown to 
be acutely toxic in humans [57], information is lacking 
about chronic exposure. If a cirrhosis patient lives with 
a high blood concentration of limonene for months or 
even years, it is not known how this will affect their health.
It has been shown that limonene concentrates in 
human breast tissue in women given a large daily dose 
of limonene for 2 weeks before undergoing surgery for 
breast cancer [58]. Breast tissue is composed mainly 
of fat [59] so this lends weight to our previously stated 
hypothesis [7] that limonene, being highly lipophilic, 
accumulates in the fat tissue of patients with liver dis-
ease. The wash-out curves for patients who gave breath 
samples on consecutive days in the 3 weeks after liver 
transplant presented in our previous paper [7] support 
this hypothesis. The brain has a high fat content, so it 
would be expected that limonene would partition into 
it should it cross the blood–brain barrier.
The main limitation of this study is the small sample 
size. The practical difficulty of requiring a patient with 
severe HE to comply with instructions would have to 
be addressed in future studies. The evidence presented 
here suggests that breath limonene is an exogenous 
compound which may serve as an indicator of an ele-
vated risk of HE in patients with cirrhosis of the liver. 
The hypothesis that limonene is itself in the causative 
pathway of HE remains to be explored.
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